{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "ExecuteTime": {
     "end_time": "2018-02-16T12:06:43.973737Z",
     "start_time": "2018-02-16T12:06:41.100969Z"
    },
    "collapsed": false,
    "inputHidden": false,
    "outputHidden": false
   },
   "outputs": [],
   "source": [
    "import sqlite3\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import time\n",
    "import pickle\n",
    "from nltk.tokenize import RegexpTokenizer\n",
    "from nltk.stem.porter import PorterStemmer\n",
    "from nltk.tokenize.moses import MosesDetokenizer\n",
    "\n",
    "from stop_words import get_stop_words\n",
    "from collections import defaultdict\n",
    "import gensim\n",
    "from gensim import corpora, models, similarities\n",
    "from gensim.models.doc2vec import TaggedDocument,TaggedLineDocument\n",
    "from gensim.models import Doc2Vec\n",
    "import gensim.models.doc2vec\n",
    "\n",
    "\n",
    "\n",
    "# #from gensim.test.test_doc2vec import ConcatenatedDoc2Vec\n",
    "# from collections import OrderedDict\n",
    "# import multiprocessing\n",
    "# from IPython.display import Image\n",
    "# import requests\n",
    "# from random import randint \n",
    "# from sklearn.manifold import TSNE\n",
    "# from sklearn.cluster import AffinityPropagation\n",
    "# #import matplotlib.pyplot as plt\n",
    "# #%matplotlib inline"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Full Body Model Training"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "conn = sqlite3.connect(\"/volume/testDB.db\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "df = pd.read_sql('SELECT doi,abstract,body from PLOS_ALL', conn)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>doi</th>\n",
       "      <th>abstract</th>\n",
       "      <th>body</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10.1371/journal.pone.0143437</td>\n",
       "      <td>Bone scintigraphies are widely applied for det...</td>\n",
       "      <td>Pulmonary and prostate cancers are the most co...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>10.1371/journal.pone.0096769</td>\n",
       "      <td>Cystic fibrosis   common autosomal recessive d...</td>\n",
       "      <td>Voice disorders, or dysphonias, can be caused ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>10.1371/journal.pone.0177044</td>\n",
       "      <td>Alzheimer’ disease   neurodegenerative syndrom...</td>\n",
       "      <td>1. Dementia is typically defined as a clinical...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>10.1371/journal.pone.0033200</td>\n",
       "      <td>PurposeXeroderma pigmentosum group  (XPD) code...</td>\n",
       "      <td>Non-small cell lung cancer (NSCLC) accounts fo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>10.1371/journal.pone.0001814</td>\n",
       "      <td>Class  MHC molecules display peptides  the cel...</td>\n",
       "      <td>The endosomal route is considered to be the de...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                            doi  \\\n",
       "0  10.1371/journal.pone.0143437   \n",
       "1  10.1371/journal.pone.0096769   \n",
       "2  10.1371/journal.pone.0177044   \n",
       "3  10.1371/journal.pone.0033200   \n",
       "4  10.1371/journal.pone.0001814   \n",
       "\n",
       "                                            abstract  \\\n",
       "0  Bone scintigraphies are widely applied for det...   \n",
       "1  Cystic fibrosis   common autosomal recessive d...   \n",
       "2  Alzheimer’ disease   neurodegenerative syndrom...   \n",
       "3  PurposeXeroderma pigmentosum group  (XPD) code...   \n",
       "4  Class  MHC molecules display peptides  the cel...   \n",
       "\n",
       "                                                body  \n",
       "0  Pulmonary and prostate cancers are the most co...  \n",
       "1  Voice disorders, or dysphonias, can be caused ...  \n",
       "2  1. Dementia is typically defined as a clinical...  \n",
       "3  Non-small cell lung cancer (NSCLC) accounts fo...  \n",
       "4  The endosomal route is considered to be the de...  "
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "ab_tok = pd.read_pickle('/volume/abtokens.pkl')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "texts = ab_tok.tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "tdf = pd.read_sql('SELECT * FROM PLOS_all_tok', conn)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>level_0</th>\n",
       "      <th>index</th>\n",
       "      <th>doi</th>\n",
       "      <th>bod_toks</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>10.1371/journal.pone.0143437</td>\n",
       "      <td>['pulmonari', 'prostat', 'cancer', 'common', '...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>10.1371/journal.pone.0096769</td>\n",
       "      <td>['voic', 'disord', 'dysphonia', 'can', 'caus',...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "      <td>10.1371/journal.pone.0177044</td>\n",
       "      <td>['dementia', 'typic', 'defin', 'clinic', 'synd...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "      <td>10.1371/journal.pone.0033200</td>\n",
       "      <td>['non', 'small', 'cell', 'lung', 'cancer', 'ns...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "      <td>10.1371/journal.pone.0001814</td>\n",
       "      <td>['endosom', 'rout', 'consid', 'default', 'path...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   level_0  index                           doi  \\\n",
       "0        0      0  10.1371/journal.pone.0143437   \n",
       "1        1      1  10.1371/journal.pone.0096769   \n",
       "2        2      2  10.1371/journal.pone.0177044   \n",
       "3        3      3  10.1371/journal.pone.0033200   \n",
       "4        4      4  10.1371/journal.pone.0001814   \n",
       "\n",
       "                                            bod_toks  \n",
       "0  ['pulmonari', 'prostat', 'cancer', 'common', '...  \n",
       "1  ['voic', 'disord', 'dysphonia', 'can', 'caus',...  \n",
       "2  ['dementia', 'typic', 'defin', 'clinic', 'synd...  \n",
       "3  ['non', 'small', 'cell', 'lung', 'cancer', 'ns...  \n",
       "4  ['endosom', 'rout', 'consid', 'default', 'path...  "
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tdf.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "bodtexts = tdf['bod_toks'].tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "tok = bodtexts[1].split(', ')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "tnew = []\n",
    "for line in tok:\n",
    "    l = line.replace(\"'\",\"\")\n",
    "    l = l.strip('[]')\n",
    "    tnew.append(l)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0\n",
      "20000\n",
      "40000\n",
      "60000\n",
      "80000\n",
      "100000\n",
      "120000\n",
      "140000\n",
      "160000\n",
      "180000\n",
      "200000\n"
     ]
    }
   ],
   "source": [
    "bods = []\n",
    "\n",
    "for i in range(0,len(bodtexts)):\n",
    "    det = bodtexts[i].replace(',','')\n",
    "    det = det.replace(\"'\",\"\")\n",
    "    det = det.strip('[]')\n",
    "    bods.append(det)\n",
    "    if i % 20000 == 0:\n",
    "        print(i)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "bods[1]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### toklen"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "tok_len = []\n",
    "\n",
    "for i in range(0,len(bods)):\n",
    "    tok_len.append(len(bods[i].split()))\n",
    "    if i % 10000 == 0:\n",
    "        print(i)\n",
    "df = pd.DataFrame(tok_len)\n",
    "df.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.columns = ['toklen']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "toklen    449\n",
       "dtype: int64"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['toklen'] > 10000].count() "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>toklen</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>449.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>11786.195991</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>2063.130425</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>10001.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>10523.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>11114.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>12338.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>27798.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             toklen\n",
       "count    449.000000\n",
       "mean   11786.195991\n",
       "std     2063.130425\n",
       "min    10001.000000\n",
       "25%    10523.000000\n",
       "50%    11114.000000\n",
       "75%    12338.000000\n",
       "max    27798.000000"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['toklen'] > 10000].describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "frequency = defaultdict(int)\n",
    "for text in texts:\n",
    "    for token in text:\n",
    "        frequency[token] += 1\n",
    "texts = [[token for token in text if frequency[token] > 1]\n",
    "         for text in texts]\n",
    "dictionary = corpora.Dictionary(texts)\n",
    "corpus = [dictionary.doc2bow(text) for text in texts]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "corpora.MmCorpus.serialize('/volume/models/corpus.mm', corpus)\n",
    "dictionary.save('/volume/models/dictionary.dict')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "tfidf = models.TfidfModel(corpus, normalize=True)\n",
    "tfidf.save('/volume/model.tfidf')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "start_time = time.time()\n",
    "lsi = models.LsiModel(corpus, id2word=dictionary, num_topics=200)\n",
    "lsi.save('/volume/models/model.lsi')\n",
    "print(\"--- %s seconds ---\" % (time.time() - start_time))\n",
    "#corpus_lsi = lsi[corpus_tfidf]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "start_time = time.time()\n",
    "lda = models.LdaModel(corpus, id2word=dictionary, num_topics=200)\n",
    "lda.save('/volume/models/model.lda')\n",
    "print(\"--- %s seconds ---\" % (time.time() - start_time))\n",
    "#corpus_lda = lda[corpus_tfidf]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "corpus_tfidf = tfidf[corpus]\n",
    "corpus_lsi = lsi[corpus_tfidf]\n",
    "corpus_lda = lda[corpus_tfidf]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "index = similarities.MatrixSimilarity(lsi[corpus])\n",
    "index.save('/volume/models/similarity.index')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "file = open('/volume/processed_body_docs.txt', 'w')\n",
    "\n",
    "for i in range(0,len(bods)):\n",
    "    detok_str = bods[i]\n",
    "    file.write(\"%s\\n\" % detok_str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "documents = []\n",
    "with open('/volume/processed_body_docs.txt') as f:\n",
    "    for line in f:\n",
    "        documents.append(TaggedLineDocument(line))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "gensim.models.doc2vec.TaggedLineDocument"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "type(documents[1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "# detok for abstracts \n",
    "\n",
    "detokenizer = MosesDetokenizer()\n",
    "file = open('/volume/processed_docs.txt', 'w')\n",
    "\n",
    "for i in range(0,len(texts)):\n",
    "    detok_str = detokenizer.detokenize(texts[i], return_str=True)\n",
    "    file.write(\"%s\\n\" % detok_str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "bods_sm = bods[0:10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "10"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(bods_sm)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "don't know how to handle uri ['pulmonari prostat cancer common malign tumor often develop bone metastas tumor cell spread bone mainli hematogen metastasi howev mechan underli bone metastasi pulmonari prostat cancer differ specif pulmonari cancer cell metastas bone mainli pulmonari vein wherea prostat cancer cell spread bone mainli via vertebr venou system differ rout metastasi can produc differ distribut featur bone metastas although studi morgan et al dodd et al support viewpoint bone scintigraphi import techniqu detect bone metastas evalu stage malign tumor prognosi patient well assess tumor respons therapi effect therapeut schedul tool can use scan entir skeleton patient therebi allow bone lesion display entireti thu bone scintigraphi use studi distribut featur bone metastas analyz relationship pathway tumor spread distribut metastat lesion numer studi bone metastas pulmonari prostat cancer compar statist analys mani studi shown predilect site bone metastas pulmonari prostat cancer similar includ vertebra pelvi rib howev littl data differ distribut bone metastas pulmonari prostat cancer understand differ will help differenti diagnosi cancer classifi patient accord total number bone metastas use lesion base analysi investig chang distribut metastat bone lesion case differ number lesion compar distribut featur bone metastas pulmonari prostat cancer found distribut characterist bone metastas differ cancer type materi methods1 clinic patientsthi retrospect studi data extract pictur archiv commun system pac januari april zhongnan hospit wuhan univers hubei china bone scintigraphi perform patient pulmonari cancer men women age median age male patient prostat cancer age median age definit diagnosi use patholog techniqu made patient patient result whole bodi bone scan perform diagnosi confirm patholog select studi need follow bone scan use diagnost refer clinic studi limit specif diseas stage approv ethic committe zhongnan hospit data analyz anonym consent waiv imag methodbon scintigraphi perform use singl head gamma camera low energi high resolut collim e cam siemen hoffman estat il usa patient instruct drink ml water within h intraven inject mbq 99mtc methylen diphosphon 99mtc mdp empti urin bone scintigraphi planar bone scan includ anterior posterior project perform approxim h inject imag reagent accord follow condit patient supin postur matrix zoom movement veloc examin bed cm min necessari addit local planar bone imag singl photon emiss comput tomographi spect scan perform imag interpret analysi findingsanalys planar bone scintigraphi spect bone scan made consensu read two nuclear medicin physician x ray comput tomographi ct magnet reson imag mri made consensu read nuclear medicin physician radiologist accord diagnost method even sapir et al use follow criteria diagnos bone metastasi bone lesion increas uptak 99mtc mdp consid bone metastas vertebr lesion involv posterior aspect vertebr bodi pedicl extens involv vertebra rib lesion appear elong tumor lamellar bone lesion present multipl site scrambl arrang focal bone lesion increas uptak 99mtc mdp regard malign exclud benign bone diseas fractur bone lesion decreas uptak 99mtc mdp categor bone metastas postradiotherapi chang metal influenc benign bone diseas bone cyst exclud bone lesion abnorm uptak 99mtc mdp deem malign simultan confirm bone metastas x ray ct mri compar result bone scan perform differ time new bone lesion consid malign diagnos benign bone scan show flare phenomenon bone metastasi note bone scintigraphi find follow circumst abnorm radiotrac uptak detect indetermin decreas radioact local bone bone lesion show increas uptak 99mtc mdp around joint bone lesion abnorm radiotrac uptak character benign condit bone fractur bone cyst hyperosteogeni osteophyt bone bridg degen osteoarthropathi inflamm group bone metastasesaccord method wilson calhoun fraction whole bone five region thorac bone includ rib sternum collarbon bladebon vertebra includ cervic spine thorac spine lumbar spine pelvi includ sacrococcyx ilium ischium pubi skull includ bone cerebr cranium facial cranium extrem includ humeru femur radioulna tibiofibula studi relationship distribut bone metastas total number lesion metastas bone compar differ distribut bone metastas pulmonari prostat cancer divid patient three group accord total number bone metastas bone metastas moder bone metastas extens bone metastas statist analysisdata analyz spss statist softwar version spss inc chicago il usa chi squar test perform compar differ proport bone metastas differ group pulmonari prostat cancer p valu less consid statist signific results1 total distribut bone metastasesof patient malign tumor bone metastas lesion bone metastasi detect incid bone metastasi prostat cancer significantli higher pulmonari cancer χ2 p bone metastas pulmonari prostat cancer mainli distribut vertebra pelvi thorac bone result tabl show distribut metastat lesion pelvi e g sacrococcyx ilium ischium pubi s1 tabl patient prostat cancer slightli greater patient pulmonari cancer χ2 p wherea distribut metastat lesion thorac bone mainli rib bladebon s1 tabl patient pulmonari cancer slightli higher prostat cancer patient χ2 p gener signific differ pulmonari prostat cancer regard differ bone region tabl journal pone t001tabl 1comparison total distribut bone metastas n pulmonari prostat cancer skeletonpulmonari cancer n prostat cancer n χ2p valuen n vertebrae63327 146pelvis49621 000thorac bones90639 002skull813 584extremities1637 902note n lesion number bone metastas chi squar test likelihood ratio perform compar differ proport bone metastas pulmonari prostat cancer comparison bone metastas pulmonari prostat cancer patient bone metastasest summar distribut metastat bone lesion patient bone metastas proport prostat cancer metastasi vertebr column two fold pulmonari cancer χ2 p lumbar vertebra account larg part differ s2 tabl proport thorac bone metastas pulmonari cancer approxim four fold prostat cancer χ2 p mainli due differ number metastas rib bladebon s2 tabl differ proport bone metastas pelvi skull extrem pulmonari prostat cancer signific p data show significantli differ distribut metastat lesion vertebra thorac bone patient pulmonari prostat cancer bone metastas compar moder extens metastas journal pone t002tabl 2comparison bone metastas pulmonari prostat cancer patient bone metastas n skeletonpulmonari cancer n prostat cancer n χ2p valuen n vertebrae7128 000pelvis4719 398thorac bones9739 000skull62 extremities2510 208note n lesion number bone metastas chi squar test likelihood ratio perform compar differ proport bone metastas pulmonari prostat cancer comparison bone metastas pulmonari prostat cancer patient moder bone metastasesth distribut bone metastas pulmonari prostat cancer patient moder bone metastas list tabl proport vertebr metastas prostat cancer greater pulmonari cancer χ2 p proport thorac bone metastas pulmonari cancer prostat cancer χ2 p howev increas proport patient moder bone metastas lower patient bone metastas furthermor distribut prostat cancer metastas pelvi significantli pulmonari cancer χ2 p journal pone t003tabl 3comparison bone metastas pulmonari prostat cancer patient moder bone metastas n skeletonpulmonari cancer n prostat cancer n χ2p valuen n vertebrae14329 010pelvis8818 000thorac bones19440 000skull173 787extremities377 911note n lesion number bone metastas chi squar test likelihood ratio perform compar differ proport bone metastas pulmonari prostat cancer comparison bone metastas pulmonari prostat cancer patient extens bone metastasesth distribut metastat bone lesion patient extens bone metastas shown tabl proport vertebr metastas prostat cancer slightli lower pulmonari cancer χ2 p differ thorac bone lesion pulmonari prostat cancer signific χ2 p contrast result patient moder bone metastas distribut bone metastas pelvi prostat cancer slightli pulmonari cancer χ2 p howev distribut metastat lesion skull extrem significantli differ pulmonari prostat cancer thu distribut bone metastas pulmonari prostat cancer similar patient extens bone metastas journal pone t004tabl 4comparison bone metastas pulmonari prostat cancer patient extens bone metastas n skeletonpulmonari cancer n prostat cancer n χ2p valuen n vertebrae41926 015pelvis36123 001thorac bones61539 275skull583 571extremities1016 363note n lesion number bone metastas chi squar test likelihood ratio perform compar differ proport bone metastas pulmonari prostat cancer comparison bone metastasi distribut differ lesionsin pulmonari cancer distribut metastat lesion pelvi patient extens bone metastas slightli patient moder bone metastas χ2 p fig distribut bone metastas vertebra χ2 p thorac bone χ2 p skull χ2 p extrem χ2 p significantli differ overal distribut differ bone pulmonari cancer similar differ lesion journal pone g001fig 1comparison pelvi metastas pulmonari prostat cancer total number bone metastas increas distribut pelvi pulmonari cancer present smaller differ χ2 p prostat cancer present signific differ χ2 p prostat cancer distribut bone metastas pelvi χ2 p skull χ2 p extrem χ2 p significantli differ howev distribut consider differ vertebra χ2 p thorac bone χ2 p increas total number bone metastas decreas tendenc metastas vertebr column fig increas tendenc spread thorac bone fig therefor significantli differ distribut metastas vertebra thorac bone prostat cancer littl differ distribut pulmonari cancer journal pone g002fig 2comparison vertebr metastas pulmonari prostat cancer result show increas bone metastas distribut vertebr metastas prostat cancer present quickli decreas tendenc χ2 p pulmonari cancer present signific differ χ2 p journal pone g003fig 3comparison thorac bone metastas pulmonari prostat cancer result show increas bone metastas distribut thorac bone metastas prostat cancer present gradual increas tendenc χ2 p pulmonari cancer present signific differ χ2 p comparison bone metastas vertebra pelvisin patient bone metastas greater distribut metastas vertebra pelvi prostat cancer pulmonari cancer χ2 p prostat cancer metastas vertebra pelvi frequent pulmonari cancer earli stage bone metastas seldom metastas bone except vertebra pelvi especi sternum collarbon bladebon bone upper extrem s1 tabl vertebra pelvi progress carcinomat metastasi rare prostat cancer spread bone howev pulmonari cancer can metastas bone rib s1 s2 fig femur s2 fig patient moder bone metastas distribut prostat cancer metastas pulmonari cancer χ2 p howev patient extens bone metastas signific differ distribut metastas pulmonari prostat cancer χ2 p condit cancer cell frequent metastas multifari bone bone metastas pulmonari s3 fig prostat cancer s4 fig also mainli distribut vertebra pelvi prostat cancer differ distribut metastat lesion vertebra pelvi significantli differ χ2 p contrast pulmonari cancer χ2 p fig journal pone g004fig 4comparison vertebra pelvi metastas pulmonari prostat cancer result show increas bone metastas proport vertebra pelvi metastas prostat cancer present gradual decreas tendenc χ2 p pulmonari cancer present signific differ χ2 p comparison bone metastas lumbar thorac cervic vertebraeth distribut bone metastas lumbar thorac cervic vertebra differ prostat cancer s2 s4 tabl patient bone metastas high proport metastas lumbar vertebra gradual decreas tendenc spread lumbar thorac vertebra cervic vertebra s2 tabl patient moder extens bone metastas distribut thorac vertebra lumbar vertebra s3 s4 tabl result indic prostat cancer frequent metastas lumbar vertebra earli stage thorac cervic vertebra howev pulmonari cancer frequent metastas thorac vertebra s3 s4 tabl discussionboth pulmonari prostat cancer great avid bone frequent lead pain untreat consequ patient advanc stage diseas frequent bone metastas result show high distribut metastat lesion vertebra pelvi thorac bone pulmonari prostat cancer demonstr bone predilect site bone metastas cancer result accord studi pulmonari prostat cancer notwithstand small differ distribut bone metastas pelvi thorac bone pulmonari prostat cancer result show total distribut metastat lesion differ region bone similar two cancer type tabl consist data morgan et al although spread pathway differ pulmonari prostat cancer data explain relationship differ metastat pathway distribut bone metastas howev understand relationship import will allow detect primari cancer lesion accord featur metastat lesion will allow differenti benign bone lesion metastat bone involv base characterist known primari tumor clearli total distribut featur bone metastas pulmonari prostat cancer aid detect primari tumor lesion differenti benign malign lesion batson thought prostat cancer cell metastas earli stage pelvi vertebra vertebr venou system bubendorf et al analyz metastat pattern prostat cancer autopsi studi patient result strongli support metastat pattern vertebr vein howev result morgan et al dodd et al show differ distribut bone metastas prostat pulmonari cancer nonprostat cancer signific thu support concept vertebr vein uniqu substanti role dissemin prostat cancer similar morgan et al dodd et al result total distribut bone metastas pulmonari prostat cancer also support role metastasi vertebr vein nevertheless result strongli support role batson s vertebr venou plexu metastat pattern prostat cancer studi patient moder bone metastas overwhelm major bone metastas prostat cancer distribut vertebra pelvi similar distribut featur prostat cancer batson venou plexu pulmonari prostat cancer differ distribut featur bone metastas distribut bone metastas prostat cancer unstabl correl total number bone metastas chang number metastas increas promin chang occur vertebra thorac bone proport vertebra thorac bone metastas patient prostat cancer invers correl total number bone metastas indic distribut bone metastas prostat cancer character preferenti metastasi vertebra thorac bone specif earli stage prostat cancer metastas occur lumbar vertebra follow thorac cervic vertebra featur variabl distribut bone metastas patient prostat cancer interpret carcinomatosi theori batson vertebr vein studi proport vertebr metastas prostat cancer gradual decreas increas total number bone metastas decreas result decreas actual number vertebr metastas rather due rel slow increas speed vertebr metastas mani metastat lesion occupi vertebra limit capac contrast prostat cancer distribut bone metastas pulmonari cancer significantli chang increas total number bone metastas addit proport metastat lesion bone region larg similar differ lesion distribut featur bone metastas pulmonari cancer may explain metastat pattern pulmonari vein pulmonari cancer cell spread bone differ region approxim changeless proport pulmonari vein therefor distribut bone metastas pulmonari cancer character random stabil proport metastat lesion pulmonari prostat cancer differ featur distribut bone metastas simpli result differ spread pathway earli distribut bone metastas present great differ pulmonari prostat cancer result show earli stage prostat cancer cell frequent encroach vertebra especi lumbar vertebra frequent metastas thorac bone pulmonari cancer cell frequent encroach vertebra also metastas thorac bone differ earli distribut bone metastas pulmonari prostat cancer use differenti benign malign bone diseas detect primari tumor patient extens bone metastas despit fact small differ distribut bone metastas pulmonari prostat cancer boni distribut two tumor still similar overal similar manifest one hand despit differ pathway tumor cell dissemin final predilect site bone metastas pulmonari prostat cancer ident vertebra pelvi thorac bone hand distribut bone metastas reflect differ dissemin pathway time therefor differ distribut bone metastas pulmonari prostat cancer result differ spread pathway present patient extens bone metastas occur earli bone metastas conclusionsa common malign tumor pulmonari prostat cancer frequent dissemin bone studi show distribut featur bone metastas pulmonari prostat cancer differ distribut bone metastas prostat cancer correl total number bone metastas differ featur differ lesion howev distribut bone metastas pulmonari cancer stabl differ lesion prostat cancer character earli dissemin vertebra metastasi thorac bone wherea pulmonari cancer character random spread differ bone rel stabl proport differ featur distribut mainli present earli bone metastas extens bone metastas result confirm distribut bone metastas pulmonari prostat cancer correl differ pattern hematogen dissemin pulmonari vein vertebr vein system separ play import role dissemin pulmonari prostat cancer earli stage bone metastas support informations1 figbon scintigraphi result year old male patient pulmonari squamou cell carcinoma bone scintigraphi pneumonectomi figur show metastat boni lesion whole bodi b bone scintigraphi 8th month pneumonectomi figur show injur rib white arrow due surgic procedur present increas uptak c bone scintigraphi 22nd month pneumonectomi figur show radioact uptak injur rib lower 22nd month white arrow 8th month two rib metastas green arrow detect tif click addit data file s2 figbon scintigraphi year old male patient pulmonari adenocarcinoma figur show bone metastas distribut rib femur without vertebra pelvi metastasi tif click addit data file s3 figbon scintigraphi year old male patient bronchioloalveolar carcinoma figur show extens bone metastas distribut mainli vertebra pelvi tif click addit data file s4 figbon scintigraphi year old male patient prostat cancer figur show extens bone metastas distribut mainli vertebra pelvi tif click addit data file s1 tablecomparison total distribut bone metastas n pulmonari prostat cancer doc click addit data file s2 tablecomparison bone metastas pulmonari prostat cancer patient bone metastas n doc click addit data file s3 tablecomparison bone metastas pulmonari prostat cancer patient moder bone metastas n doc click addit data file s4 tablecomparison bone metastas pulmonari prostat cancer patient extens bone metastas n doc click addit data file', 'voic disord dysphonia can caus neurolog structur function problem affect breath phonat articul reson prosodi product sound level larynx varieti respiratori tract disord includ chronic cough laryng tension can lead reduc voic qualiti dysphonia can caus sever drawback commun significantli impair qualiti life given import vocal commun human interact subject abnorm voic pattern high risk anxieti disord depress patient voic disord score significantli lower health statu subscal measur sf form highli valid questionnair assess qualiti life cystic fibrosi cf common autosom recess disord preval approxim live birth peopl european descent diseas caus mutat cystic fibrosi transmembran regul gene encod epitheli chlorid channel dysfunct ion channel lead abnorm transport chlorid sodium across epitheli membran result product thick viscou secret variou organ includ respiratori tract respiratori dysfunct short breath chronic cough hallmark cf major caus morbid cf patient therefor current medic practic larg part cf treatment dedic mitig effect respiratori dysfunct howev potenti effect cf respiratori complic vocal capac cf patient studi detail hypothes cf patient given characterist respiratori disord also present intrins voic alter true cf patient potenti benefit voic therapi way improv qualiti life test hypothesi measur vocal paramet use object subject clinic evalu method male femal cf patient undergo convent treatment compar age sex match control methodssubject select ethic statementsubject age year divid four group male control group n femal control group n male patient cf n femal patient cf n analys cf patient n control subject n pool independ sex cf patient diagnos base standard sweat test famili histori presenc chronic pulmonari diseas pancreat insuffici previou laryngoscop examin conduct prophylact part patient clinic monitor confirm select cf patient drastic vocal cord dysfunct laryng diseas vocal cord polyp laryng carcinoma laryng paralysi cf patient control subject never receiv voic therapi patient cf receiv individu regular treatment accompani physician dietician physiotherapist psychologist time studi none cf patient sign infect medic inhalatori antibiot hyperton salin inform clinic statu subject can found tabl s1 s4 includ bodi mass index bmi fev1 common measur lung function defin volum air exhal first second forc expir normal mean valu popul low number cf patient sex limit studi due limit pool will cf patient fit necessari criteria studi approv research ethic committe joão de barro barreto univers hospit subject legal caretak sign inform consent form vocal recordingssubject ask produc sustain vowel phonat usual intens maximum voic time voic record conduct use hand held microphon pg42 lc shure alway posit six centimet subject s mouth angl ensur compar intens measur initi second record alway exclud analysi paramet measur three second time window follow period signal record sampl rate khz analyz praat softwar object vocal analysisw measur follow quantit vocal paramet fundament frequenc f0 intens jitter index f0 variabl shimmer index intens variabl harmon nois ratio hnr index glottal turbul nois hoars paramet extens valid quantit object measur vocal qualiti routin use voic care profession diagnost tool low valu vocal intens hnr high valu jitter shimmer alter f0 potenti sign dysphonia subject vocal analysisin addit object acoust variabl also conduct perceptu assess voic qualiti cf control subject use grba grade rough breathi asthenia strain scale vocal assess method evalu patient s gener grade dysphonia repres letter g four subject paramet rough r breathi b asthenia strain s variabl determin voic care profession quantifi percept patient voic zero normal one mild alter two moder alter three sever alter abovement factor reliabl method extens valid order avoid confirm bia analys ask independ practic clinic voic therapist tie research project perform grba evalu record evalu receiv record pseudo random order complet blind structur experiment protocol project s object identif diagnosi subject evalu year profession experi voic therapi grba analysi method instruct analyz record exactli perform clinic practic data analysi statisticsdiffer object subject vocal paramet evalu mann whitney test data distribut non gaussian mani variabl defin shapiro wilk normal test tabl s5 therefor data repres median valu median interquartil rang iqr statist signific level initi set p account multipl comparison within object subject categori vocal paramet bonferroni correct method appli procedur adjust signific level p analys resultsrepres recordingsvoic signal record spectrogram repres individu studi group shown figur control group record show clear featur euphon voic high period wide amplitud rang figur b1 b1 contrast signal subject cf group show remark aperiod reduc amplitud figur b2 b2 spectrogram cf patient also show high nois level loss high frequenc harmon relat control figur c2 c2 journal pone g001figur 1repres voic record spectrogram femal patient cf red healthi control blue sound record vowel phonat femal control subject a1 femal patient cf a2 note markedli reduc amplitud rang signal cf patient relat control b amplifi view record present a1 a2 note irregular voic signal cf patient relat control c spectrogram frequenc domain represent record present a1 a2 note higher level background nois low formant segreg cf patient relat healthi control journal pone g002figur 2repres voic record spectrogram male patient cf red healthi control blue sound record vowel phonat male control subject a1 male patient cf a2 note markedli reduc amplitud rang signal cf patient relat control b amplifi view record present a1 a2 note irregular voic signal cf patient relat control c spectrogram frequenc domain represent record present a1 a2 note higher level background nois low formant segreg cf patient relat healthi control cf relat chang vocal parametersanalysi object voic paramet reveal cf patient present signific decreas intens figur b p increas jitter figur c p shimmer figur d p much lower hnr figur e p relat control differ observ f0 figur p two group journal pone g003figur 3object measur vocal paramet control subject cf patient horizont line error bar repres median iqr variabl subject pool independ sex valu f0 group b valu intens group note signific reduct intens cf group c valu jitter group note signific increas jitter cf group d valu shimmer group note signific increas shimmer cf group e valu hnr group note signific reduct variabl cf group p perceptu assess voic qualiti grba scale also reveal clear sign dysphonia cf patient relat control group patient cf present overal increas r figur b p b figur c p figur d p addit cf patient show increas g relat control figur p interestingli differ observ s score cf patient healthi control figur e p median valu iqr studi variabl statist comparison group summar tabl s6 journal pone g004figur 4subject measur vocal paramet male femal control subject cf patient horizont line error bar repres median valu group subject pool independ sex valu g group note signific increas g cf group b valu r group note signific increas r cf group c valu b group note signific increas b cf group d valu group note signific increas cf group e valu s group p p import note highli unlik cf relat chang vocal paramet relat age lung function subject none object variabl affect cf patient signific correl age fev1 figur s1 s2 r2 p correl age fev1 intens jitter shimmer hnr influenc sex cf relat dysphoniaw also analyz data segreg control cf group accord sex order reveal possibl influenc sex cf relat dysphonia analys reveal male femal cf patient relat match control present signific decreas intens figur b1 b2 p male femal increas jitter figur c1 c2 male p femal p male shimmer figur d1 d2 p femal p male interestingli femal cf patient show drastic lower valu hnr figur e1 p relat control group featur observ male cf patient figur e2 p compar respect control differ cf patient control subject observ f0 sex figur a1 a2 p comparison journal pone g005figur 5object measur vocal paramet male femal control subject cf patient horizont line error bar repres median iqr variabl valu f0 femal a1 male a2 subject group b valu intens femal a1 male a2 subject group c valu jitter femal a1 male a2 subject group d valu shimmer femal a1 male a2 subject group e valu hnr femal a1 male a2 subject group note femal cf patient lower hnr relat match control p p relat subject vocal paramet analyz grba scale male femal patient cf present overal increas r figur b1 b2 p femal p male b figur c1 c2 p femal p male figur d1 d2 p femal p male compar match control howev femal cf patient show increas g relat control figur a1 p observ male subject figur a2 p differ observ s score cf patient healthi control sex figur e1 e2 p comparison median valu iqr studi variabl statist comparison cf patient control subject segreg sex summar tabl s7 journal pone g006figur 6subject measur vocal paramet male femal control subject cf patient horizont line error bar repres median valu group valu g femal a1 male a2 subject group note femal patient signific chang g relat match control b valu r femal a1 male a2 subject group c valu b femal a1 male a2 subject group d valu femal a1 male a2 subject group e valu s femal a1 male a2 subject group p p discussionour result show subject cf present significantli alter vocal paramet object subject knowledg first systemat investig voic dysfunct cf find suggest dysphonia relev manifest cf patholog object vocal paramet affect cf intens jitter shimmer hnr chang vocal intens can observ case vocal microtrauma neurolog dysfunct obstruct respiratori diseas vocal intens depend fundament subglott air pressur upper airway airflow glottal resist observ decreas intens cf patient thu explain ineffici lung function partial upper airway obstruct characterist cf physiopatholog chronic cough major symptom cf also contribut effect chang jitter shimmer typic relat irregular vocal fold vibrat also usual relat vocal harsh presenc nois vocal signal differ variabl observ dataset can due presenc thick mucou secret vocal fold cf patient can potenti interfer oscillatori motion vocal fold addit chronic cough also known caus dysfunct vocal fold movement decreas hnr caus increas variat vocal amplitud frequenc upper airway turbul produc distort vocal signal emphas sub harmon compon vocal break consequ reduc rel contribut harmon compon overal vocal signal importantli report high vocal nois low hnr characterist sign dysphonia cf patient show drastic low hnr valu can consid patholog hoars highli detriment normal voic product decreas hnr physiolog underpin chang jitter shimmer name accumul mucu chronic cough chang object vocal paramet cf patient confirm subject evalu vocal qualiti use grba scale cf patient show signific differ perceptu vocal paramet except s previou studi shown increas r b strongli relat increas shimmer agreement find three variabl higher cf patient relat control increas caus decreas airflow rate upper airway common featur mani respiratori diseas case subglott pressur rise appropri level voic product caus asthenia hoars dataset cf patient featur can relat observ decreas intens differ g repres gener degre vocal disord e subject summat perceptu paramet make g import index within grba scale significantli higher valu g cf patient indic individu chang r b combin produc notic condit dysphonia notabl find studi femal cf patient appear vocal alter relat control male cf patient data sex analyz separ femal cf patient present signific lower valu hnr higher valu g compar match control differ sex may due intrins differ structur vocal apparatu observ men women averag men thicker vocal fold larger glottal area airflow lower laryng airway resist women data show cf vocal patholog probabl due disord vocal fold oscil obstruct upper airway dysfunct can exacerb associ thinner vocal fold higher airway resist respect taken togeth gender relat structur differ like major factor make femal patient suscept cf relat dysphonia addit sever studi report healthi male voic significantli lower hnr healthi femal across differ languag age rang also case dataset record male control subject significantli lower hnr femal control subject figur e1 e2 p femal male control intrins differ might explain alreadi mention gender relat differ structur vocal apparatu social influenc author specul women better vocal train men use voic frequent percept normal appropri voic depend expect person s gender age social group deviat vocal paramet must compar match control inde healthi women might expect higher hnr men fair predict significantli larger decreas hnr observ femal cf patient might highli deleteri impact qualiti life data suggest group femal patient voic affect pathophysiolog cf degre gener percept voic presum commun function significantli affect nevertheless import point subject male cf patient group also present low valu hnr 5db even though median valu group significantli differ control addit male cf subject also present level g valu observ male control group mean even though femal cf patient might suscept deleteri effect cf vocal capac thu present dysphon symptom male individu male cf patient might also develop signific chang hnr g result open possibl cf patient may benefit voic therapi clinic intervent strategi reduc dysphonia increas life qualiti voic therapi consist seri techniqu appli mitig voic disord includ enhanc patient s awar dysphonia applic vocal health guidelin hear train muscl relax psychodynam vocal train form therapi shown effect treatment reduc dysphon symptom sever diseas includ respiratori disord capabl least partial restor qualiti life affect patient dysphon characterist observ cf patient can potenti attribut dysfunct vocal fold movement partial upper airway obstruct can caus accumul mucu chronic cough standard symptom cf respiratori patholog avail data therapi adequ cf patient therapi vocal disord hyperfunct origin shown effect patient chronic cough given chronic cough major manifest cf patholog strategi potenti appli cf patient type intervent usual base voic educ vocal hygien strategi cough suppress also appli exercis improv dysfunct vocal fold vibrat accord data probabl major featur cf relat dysphonia cours studi must conduct confirm efficaci form treatment well form voic therapi patient cf conclusionw show patient cf exhibit symptom dysphonia chang object subject vocal paramet may relev featur cf patholog morbid voic alter pronounc femal patient exhibit mark reduct hnr overal subject voic qualiti result suggest cf patient might potenti benefit voic therapi support informationfigur s1linear correl analys age object vocal paramet control cf group p valu indic slope linear regress line significantli differ zero linear correl age f0 group note rel high invers correl r2 around two variabl control cf group b linear correl age intens group c linear correl age jitter group d linear correl age shimmer group e linear correl age hnr group p ep click addit data file figur s2linear correl analys fev1 object vocal paramet cf group fev1 common measur lung function defin volum air exhal first second forc expir normal mean valu popul p valu indic slope linear regress line significantli differ zero note small correl found fev1 object vocal paramet linear correl fev1 f0 group b linear correl fev1 intens c linear correl fev1 jitter d linear correl fev1 shimmer e linear correl fev1 hnr ep click addit data file tabl s1age bodi mass index bmi subject femal control group docx click addit data file tabl s2age bodi mass index bmi subject male control group docx click addit data file tabl s3age bodi mass index bmi fev1 medic statu femal cystic fibrosi group docx click addit data file tabl s4age bodi mass index bmi fev1 medic statu male cystic fibrosi group docx click addit data file tabl s5summari mean standard error valu normal test result studi group docx click addit data file tabl s6summari median iqr valu pool data cf control subject statist comparison includ valu mann whitney u u z score z effect size r p docx click addit data file tabl s7summari median iqr valu data cf control subject segreg accord sex statist comparison includ valu mann whitney u u z score z effect size r p docx click addit data file', 'dementia typic defin clinic syndrom cognit declin suffici sever interfer social occup function umbrella term group cognit disord character progress declin cognit function interf independ carri activ daili life due brain damag diseas relat delirium depress alzheim s diseas ad common caus dementia late life account case ad neurodegen syndrom character multidimension progress consist three core dimens cognit function psychiatr symptom function symptom defin decreas abil independ perform daili life activ preval increas rapidli due age societi though incid seem declin peopl high educ level high incom countri review focus specif late onset alzheim s diseas load defin ad onset year age load preval gener slowli progress cours compar earli onset ad current imposs provid patient famili reliabl predict cours diseas substanti variabl rate declin among individu load know factor associ declin use understand slow diseas progress well individu prognosi potenti influenti factor comorbid comorbid defin addit co exist ailment patient particular index diseas case load shown comorbid preval among individu load compar demograph match control addit review indic comorbid contribut declin load howev unclear exactli comorbid affect separ facet load sinc mani studi mere report relat comorbid one dimens load despit multifacet natur syndrom order provid multidimension overview review investig whether evid associ comorbid diseas burden cognit function psychiatr symptom individu load cross section longitudin methodsth articl identifi use electron databas medlin embas psycinfo cochran updat januari comprehens search strategi develop separ four databas s1 s2 s3 s4 appendix keyword alzheim observ studi progress comorbid use subsequ combin either cognit daili function behavior disord along synonym order meet inclus criteria articl examin cognit function neuropsychiatr outcom relat comorbid individu diagnos load age onset restrict year public use order summar avail evid associ comorbid diseas burden dementia symptom longitudin cross section studi includ sinc review address somat comorbid diseas burden gener influenc individu diseas beyond scope studi protocol review regist prospero can access dio crd42015027046 databas search yield articl paper identifi mean snowbal method yield seven articl addit search grey literatur onlin databas opengrey open doar googl scholar result identif five new articl total articl origin identifi duplic exclud titl abstract articl independ screen two review l r v m l h articl exclud meet inclus criteria anoth studi exclud base full text assess perform duplic well l r v m l h discrep two review resolv third review r j f m remain articl critic apprais two independ review l r v m l h use newcastl ottawa qualiti assess cohort studi assess select particip method control confound assess outcom cross section studi adapt version scale use question regard follow left overview select process provid fig first two author review l r v m l h co author includ studi j s l first author one includ studi r j f m moreov m j s l m g m o r r j f m co author one includ studi journal pone g001fig 1prisma flow diagram resultsout studi deem elig screen examin load dimens outcom studi influenc comorbid diseas burden focu load remain articl includ review publish overview studi provid tabl diagnosi criteria use load nincd adrda nation institut neurolog commun disord stroke alzheim s diseas relat disord associ dsm diagnost statist manual mental disord comorbid diseas burden measur use cumul ill rate scale geriatr cir g charlson comorbid index cci gener medic health rate gmhr studi count comorbid base hospit record physic examin patient caregiv report although comorbid measur differ across studi studi use person approach either interview medic examin physician journal pone t001tabl 1descript select studi author year participantscohortstudi designcomorbid measurestatist analysismean age sd yr settingmeasur interv data sourcelyketso et al n 344clinic cohort cross sectionalgener medic health ratingpearson s correlations76 nabaltimor u s naindepend assess physiciantekin et al n 143clinic cohortcross sectionalcumul ill rate scale geriatricspearson s correl stepwis linear regress baselin covariates76 8lo angel u s nanadoraiswami et al n 679mix cohort cross sectionalcumul ill rate scale geriatricsgener linear model80 na13 site state u s named histori physic examinationformiga et al n 289clinic cohortcross sectionalcharlson comorbid indexlogist regress baselin covariates81 0barcelona spainnainterview patient caregiv medic recordsoosterveld et al n 213clinic cohortcross sectionalcumul ill rate scale geriatricspearson s correl linear regress baselin covariates75 site netherlandsnamed examin physicianaguero torr et al n 46popul base cohortlongitudinalpres chronic condit ye linear regress annual rate chang baselin covariates86 6stockholm sweden3 yearsinform interviewboksay et al n 40clinic cohortlongitudinalcomorbid countna69 2new york u s yearsnasolomon et al n 102clinic cohortlongitudinalcumul ill rate scale geriatricsordin logist regress categori declin base annual rate chang baselin covariates75 2bucharest romania2 yearsmed record report patient caregiversleoutsako et al n 230popul base cohortlongitudinalgener medic health ratingquadrat mix model random effect intercept time includ baselin time vari covariates85 3utah u s month time vari year time invari interview patient caregiv medic recordsm et al n 251popul base cohortlongitudinalpres chronic conditionsquadrat mix model baselin covari random effect intercept time85 5stockholm sweden3 yearsstockholm inpati registeraubert et al n 170clinic cohortlongitudinalcharlson comorbid indexlogist regress baselin covariates83 4nant france1 yearna time comorbid measur analyz progress clinic retir nurs home popul n number particip includ analysi na inform avail five studi cross section six longitudin studi maximum follow rang year overal mean age particip across studi year rang qualiti assess one studi deem low qualiti score due lack correct confound unrepres sampl adjust baselin age unclear two studi adjust educ lack unclear five studi examin cognit adjust baselin symptom interest unclear one six longitudin studi overview qualiti assess includ studi provid s5 appendix nine studi indic symptom wors least one three dimens load individu increas comorbid diseas burden two studi fail find associ follow section will address result three differ dimens load studi global cognit abilitiesfour cross section six longitudin studi examin cognit outcom overview studi includ measur scale result provid tabl eight studi use mini mental state examin mmse measur cognit one use global deterior scale gd one use composit score neuropsycholog test presenc comorbid relat decreas cognit abil seven ten studi examin cognit three cross section four longitudin studi one longitudin studi time vari comorbid burden time invari baselin comorbid associ decreas cognit abil tabl journal pone t002tabl 2descript studi global cognit abil author year cognit measurestudi designestim se resultsmeasur interv tekin et al mini mental state examinationcross sectionalnacumul ill rate scale geriatr relat cognit statusnadoraiswami et al mini mental state examinationcross sectionalr2 p 0001higher cumul ill rate scale geriatr relat lower cognit statusnaformiga et al mini mental state examinationcross sectionalmean δ p 02higher charlson comorbid index relat lower cognit statusnaoosterveld et al neuropsycholog assessmentcross sectionalr p 01higher cumul ill rate scale geriatr relat poorer cognit statusnaaguero torr et al mini mental state examinationlongitudinalb p 694the presenc chronic condit relat chang cognition3 yearsboksay et al global deterior scalelongitudinalmean δ p 05the presenc higher number comorbid relat faster declin cognition4 yearssolomon et al mini mental state examinationlongitudinalb p 02higher cumul ill rate scale geriatr relat faster declin cognition2 yearsleoutsako et al mini mental state examinationlongitudinalβ p 01lower gener medic health rate relat decreas cognit abil analyz time vari covari use time invari baselin covariate6 month time vari year time invari β p 61meli et al mini mental state examinationlongitudinalb p 17the presenc either comorbid relat cognit cross section longitudin yearsaubert et al mini mental state examinationlongitudinalor ci p 03higher charlson comorbid index relat faster declin cognition1 yearna avail se standard error ci confid interv time comorbid measur analyz progress mix model interact linear slope report studi daili functioningfour cross section three longitudin studi examin daili function studi summar tabl function impair measur use instrument activ daili live adl four studi clinic dementia rate scale cdr one studi health util index subscal one studi psychogeriatr depend rate scale pgdr one last studi five seven studi examin daili function found comorbid relat lower function abil three cross section two longitudin one longitudin studi time vari comorbid burden time invari baselin comorbid burden associ function declin longitudin studi conduct meli et al also cross section associ baselin comorbid burden baselin function statu found two smallest studi one longitudin one cross section find associ journal pone t003tabl 3descript studi daili function author year daili function measurestudi designestim se resultsmeasur interv lyketso et al psychogeriatr depend rate scalecross sectionalβ p 001lower gener medic health rate relat increas function impairmentnatekin et al instrument activ daili livingcross sectionalr p 991cumul ill rate scale geriatr relat functioningnadoraiswami et al subscal self care health util indexcross sectionalr2 p 0001higher cumul ill rate scale geriatr relat greater function impairmentnaoosterveld et al instrument activ daili livingcross sectionalr p 001higher cumul ill rate scale geriatr relat lower function statusnasolomon et al instrument activ daili livinglongitudinalor ci 6higher cumul ill rate scale geriatr tend relat increas declin function significant2 yearsleoutsako et al clinic dementia rate sum boxeslongitudinalβ p 001lower gener medic health rate relat decreas function analyz time vari covari use time invari baselin covariate6 month time vari year time invari β p 13meli et al activ daili livinglongitudinalb p 006presenc chronic condit baselin cross section relat lower baselin function statu also longitudin faster declin functioning3 yearsna avail se standard error ci confid interv time comorbid measur analyz progress mix model interact linear slope report studi neuropsychiatr symptomsa shown tabl three studi examin neuropsychiatr symptom np use neuropsychiatr inventori npi two studi cross section one longitudin two studi one cross section one longitudin found comorbid relat increas np one longitudin studi time vari comorbid burden time invari baselin comorbid burden associ np one cross section studi found associ journal pone t004tabl 4descript studi neuropsychiatr symptom author year neuropsychiatr measurestudi designestim se resultsmeasur interv tekin et al neuropsychiatr inventorycross sectionalr p 05cumul ill rate scale geriatr relat neuropsychiatr symptomsnaoosterveld et al neuropsychiatr inventorycross sectionalr p 001higher cumul ill rate scale geriatr relat neuropsychiatr symptomsnaleoutsako et al neuropsychiatr inventorylongitudinal4 p 01lower gener medic health rate relat neuropsychiatr symptom analyz time vari covari use time invari baselin covariate6 month time vari year time invari p 38na avail se standard error time comorbid measur analyz progress mix model interact linear slope report discussion4 discuss current scientif evidencealthough total evid avail review limit main find increas somat comorbid diseas burden associ increas cognit function neuropsychiatr symptom load nine studi show associ comorbid diseas burden load symptom two studi found associ primarili cross section associ found comorbid burden three dimens load prospect studi evid longitudin associ baselin comorbid burden load progress inconsist three studi examin dimens load simultan two found associ comorbid burden dimens load third studi tekin et al cross section find associ argu associ possibl obscur rel low level comorbid mean sd cir g young age mean sd year studi popul one studi evalu time vari associ found three dimens associ time vari comorbid burden seven ten studi examin cognit abil found signific associ increas comorbid diseas burden lower cognit abil three studi found associ two longitudin conduct cohort third studi tekin et al mention previous five seven studi examin daili function found decreas function statu associ comorbid diseas burden two neg studi studi tekin et al smallest studi daili function solomon et al detect non signific trend two three studi examin np found comorbid relat increas np neg studi studi tekin et al overal qualiti avail evid rate high accord newcastl ottawa qualiti assess s5 appendix except one studi result interpret caution note assess distinguish longitudin cross section studi studi review cross section report adjust confound found inconsist across studi although studi adjust age correct educ far less common worth mention qualiti assess assess studi sampl size tabl although take follow rate end studi account length studi ignor two thing clearli relat altogeth major studi review suggest comorbid contribut rapid worsen symptom load accord broader conceptu load consequ dynam interact diseas relat individu factor howev associ comorbid burden load progress reduc linear causal relat exposur higher level comorbid burden link prospect dementia outcom rather relat complex dynam will expand next paragraph observ associ timeth studi leoutsako et al studi use time invari time vari covari studi analyz comorbid diseas burden baselin time invari predictor analyz comorbid diseas burden time vari covari mean look relationship comorbid load facet correspond point time compar two analysi approach offer interest perspect analyz associ baselin medic health rate subsequ load progress signific relationship found howev upon examin rate time vari covari clear associ cognit function psychiatr progress emerg base result leoutsako et al postul associ comorbid diseas burden load progress immedi proxim one patient facet load given point time affect health time result review provid support notion sinc associ predominantli found studi analyz cross section associ near futur progress rare observ studi analyz progress distant futur exampl examin studi comorbid cognit six seven studi report associ measur cognit cross section near futur word time comorbid measur analyz symptom now refer measur interv studi shorter year tabl extent longitudin studi measur interv longer year avail evid associ baselin comorbid burden cognit progress lack possibl explan pattern comorbid statu fluctuat dilut relationship baselin comorbid diseas burden cognit progress time short associ comorbid cognit appear time vari e dynam hypothesi support previou studi specif scope vascular co morbid found associ chang comorbid measur progress cognit impair use comorbid time vari covari possibl elucid relationship progress take fluctuat comorbid statu across follow account although gener accept prove causal hardli possibl observ studi must note particularli time vari analysi sinc establish tempor relationship imposs anoth import methodolog consequ studi occurr relat time vari way level exposur possibl risk factor need establish follow up predictor inform may avail follow assess assess less rigor detail cohort studi potenti mechan effect comorbidityth potenti mechan comorbid may affect differ dimens load numer exampl comorbid often associ increas stress level shown stress experi associ increas risk dementia possibl imbal adrenocort axi studi mice show short stress simul condit may exacerb cognit deficit preclin load acceler amyloid patholog reduc synaps number anoth common featur comorbid disrupt sleep known increas risk cognit impair especi peopl load sleep depriv may contribut wors cognit function np sinc load alreadi associ delay circadian phase line find detriment influenc comorbid cognit also observ peopl parkinson s diseas prospect studi includ elderli show excess polypharmaci logic consequ increas comorbid diseas burden also associ decreas cognit capac moreov polypharmaci found contribut function declin commun dwell patient load fact comorbid diseas burden appear posit associ cognit function declin surpris given two strongli relat load fact function impair ad appear follow cognit impair tempor impair daili function turn may decreas amount leisur social activ known protect cognit declin lower level healthi behavior self care similar mechan state previou paragraph therefor drive patient neg spiral function cognit deterior relationship diseas burden daili function also observ sever larg popul base studi healthi elderli indic comorbid condit may lead function impair irrespect load diagnosi exampl condit affect mobil although number studi support associ comorbid increas np load small multipl studi differ popul support relat increas comorbid diseas burden psychiatr disord anxieti depress cognit function consequ increas comorbid diseas burden like contribut social depriv stress found signific predictor psychosi depress compar includ studiesdur critic apprais studi methodolog challeng emerg diverg sampl frame one three studi popul base seven use clinic sampl one studi sampl obtain multipl set tabl although heterogen can increas extern valid differ studi set can also potenti influenc result due differ case mix howev compar popul base non popul base studi analyz similar dimens pattern discrep found result thu associ somat comorbid progress appear independ studi set differ inclus criteria among studi also affect case mix therefor hinder compar studi studi boksay et al use stringent criteria exclud patient histori variou comorbid might hamper compar along small sampl size lack correct age educ baselin cognit statu analys four studi analyz result load separ dementia type sinc four studi report major sampl suffer load result appear accord studi includ probabl minor influenc result given high qualiti cross section studi decid includ longitudin cross section studi review provid integr overview avail studi topic although cross section studi address diseas progress time mostli line longitudin studi use measur interv year strength limitationson strength review multidimension approach unambigu patient also experi impair activ daili live behavior chang load defin cognit impair alon narrow approach load progress adopt mani studi therefor worrisom take account three dimens review provid comprehens perspect load limit review larg variat progress measur comorbid index data sourc studi design includ studi tabl hamper quantif associ comorbid diseas burden progress differ studi popul also pose problem given larg heterogen age gender stage load medic use moreov question whether measur certain dimens truli reflect construct whether comorbid measur sensit enough captur comorbid burden suffici detail therefor meta analysi perform anoth limit review none studi took onset durat comorbid account might much amount sever comorbid burden relev rather length exposur comorbid burden without inform hypothesi imposs verifi refut given dementia long period insidi onset revers causat rule even studi focus effect comorbid burden point load becam incid contrast mani studi focu singl comorbid condit review aim examin relat overal somat comorbid diseas burden load progress provid generaliz overview howev drawback use scale overal comorbid diseas burden potenti circular studi examin np caus presenc psychiatr domain comorbid measur cir g choic studi overal comorbid burden also render imposs draw conclus individu comorbid understand mechan extent singular comorbid affect cours load might enabl us slow multidimension progress provid individu prognosi howev beyond scope review conclusionit evid cognit function psychiatr declin address simultan obtain comprehens understand load progress one first observ although highli relev three studi address three dimens load simultan therefor addit multidimension longitudin studi need provid scientif basi evid base care grow number individu affect load comorbid diseas review provid evid associ somat comorbid multifacet load progress given comorbid diseas burden given time point seem associ load facet around moment long term seem like dynam relationship comorbid diseas burden load progress comorbid burden possibl modifi factor contribut load result stress import optim treatment monitor comorbid peopl load monitor progress might particularli import case somat comorbid manifest load onset given associ comorbid load progress near futur prevent accur treatment comorbid health care profession may prevent rapid progress load moreov review emphas relev take comorbid burden account investig load progress diagnosi also follow futur studi might gain knowledg consid possibl dynam interconnect comorbid diseas burden load progress mean repeatedli measur comorbid statu preclin phase load onward analyz time vari covari conclud clear associ comorbid diseas burden load progress associ reduc simpl linear caus effect relat therefor futur studi clinic practic may benefit regard comorbid modifi factor possibl fluctuat influenc load support informations1 appendixsearch strategi medlin pdf click addit data file s2 appendixsearch strategi psycinfo pdf click addit data file s3 appendixsearch strategi embas pdf click addit data file s4 appendixsearch strategi cochran pdf click addit data file s5 appendixqu assess pdf click addit data file s6 appendixprisma checklist pdf click addit data file s7 appendixreview protocol pdf click addit data file', 'non small cell lung cancer nsclc account approxim primari lung cancer patient diagnos advanc stage stage iii iv although chemotherapi involv platinum agent repres one common first line treatment patient year surviv rate remain less clinic factor patient featur age perform statu diseas extens roughli character stage remain major determin prognosi nsclc howev variabl outcom still observ patient similar clinic featur seem host inherit factor may import role determin treatment outcom nsclc highlight necess identifi genet marker optim individu therapi consid platinum agent use chemotherapi caus dna damag cell death activ cell signal pathway host cellular dna repair capac possibl influenc outcom nsclc patient chemotherapi previou studi shown suboptim dna repair capac within tumor may lead decreas remov dna lesion therefor increas sensit platinum base chemotherapi result better clinic outcom nucleotid excis repair ner major pathway repair platinum induc dna cross link mammalian cell xpd gene encod atp depend helicas mediat dna unwind initi ner sever studi shown xpd polymorph appear effect dna repair capac possibl alter function protein product common variant xpd gene found correl decreas cancer risk clinic epidemiolog evid indic xpd lys751gln polymorph significantli associ chemotherapi effect howev polymorph xpd arg156arg xpd asp711asp epidemiolog data clinic outcom nsclc patient still scarc therefor prognost import xpd polymorph remain unclear xpd asp312asn rs1799793 lys751gln rs13181 polymorph nonsynonym singl nucleotid polymorph snp result chang amino acid sequenc protein wherea arg156arg rs238406 asp711asp rs1052555 polymorph silent mutat previou studi shown variant genotyp xpd arg156arg associ increas risk seriou hematolog toxic chines han popul base observ hypothes four potenti function snp xpd codon may influenc nsclc prognosi studi use dna sampl obtain seri nsclc patient assess associ xpd polymorph surviv advanc nsclc patient treat platinum base chemotherapi materi methodspati recruit follow upth studi design subject recruit describ previous patient inoper histolog confirm stage iii iv nsclc consecut recruit march august shanghai chest hospit shanghai china elig patient studi least year old requir fulfil follow criteria presenc measur lesion eastern cooper oncolog group perform statu ecog ps eastern cooper oncolog group perform statu criteria use assess diseas affect daili life abil patient grade grade absolut neutrophil count anc cell l platelet cell l serum creatinin upper limit normal aspart aminotransferas ast alanin aminotransferas alt upper limit normal estim creatinin clearanc ml min patient exclud prior histori malign except non melanoma skin cancer carcinoma situ uterin cervix alreadi cure tumor y diseas free surviv previou chemotherapi radiotherapi surgeri activ congest heart failur cardiac arrhythmia recent mo date treatment myocardi infarct sever mental disord infecti diseas need immunotherapi written inform consent provid patient studi carri approv ethic review committe hospit treatment patient receiv evalu includ complet medic histori health examin score perform statu routin clinic biochemistri test chest radiograph comput tomographi chest abdomen data demograph clinic characterist includ age sex smoke statu tumor histolog obtain clinic medic record review oncologist smoke statu smoke less one cigarett per day less year lifetim defin non smoker otherwis consid smoker inform surviv statist collect sever sourc includ follow call social secur death index inpati outpati clinic medic record investig blind genet polymorph statu patient patient enrol studi inoper receiv first line platinum base chemotherapi chemotherapeut regimen follow navelbin mg m2 day day plu cisplatin mg m2 carboplatin auc day repeat everi week gemicitabin mg m2 day plu cisplatin mg m2 carboplatin auc day repeat everi week taxol mg m2 plu cisplatin mg m2 carboplatin auc day repeat everi week docetaxel mg m2 plu cisplatin mg m2 day repeat everi week patient given platinum base chemotherapi chemotherapi drug administ intraven treatment two six cycl patient respons treatment evalu first line cycl chemotherapi respons evalu criteria solid tumor recist guidelin version total patient advanc nsclc particip studi complet follow statist signific differ observ distribut demograph clinic featur patient includ studi data shown result final analysi limit patient snp genotypingblood sampl collect subject time recruit genom dna extract use qiaamp dna maxi kit qiagen gmbh xpd arg156arg asp312asn asp711asp polymorph determin use sequenom massarray iplex platform matrix assist laser desorpt ioniz time flight mass spectromet previous describ lys751gln identifi pcr base sequenc primer sequenc avail request overal genotyp success determin snp qualiti control sampl subject randomli select re genotyp duplic sampl genotyp concord statist analysishardi weinberg equilibrium test snp good fit x2 test pearson x2 test categor variabl student s t test continu variabl use compar demograph clinic characterist patient achiev complet respons cr partial respons pr defin respond patient stabl diseas sd progress diseas defin non respond addit analys done group patient cr pr sd defin patient clinic benefit versu pd defin patient without clinic benefit overal surviv os calcul time death date diagnosi progress free surviv pf calcul time progress death without progress date diagnosi kaplan meier method use plot pf os curv log rank test appli compar distribut group multivari cox proport hazard model use estim hazard ratio hr confid interv ci clinic variabl log rank p univari analysi enter multivari analysi due limit number homozyg variant genotyp asp312asn asp711asp lys751gln polymorph model domin model linkag disequilibrium ld analysi d r2 valu genotyp snp calcul haploview softwar http www broad mit edu person jcbarret haplo haplotyp assess perform use phase data analyz use spss version spss inc p valu two side statist signific set level evalu chanc obtain fals posit associ due multipl hypothesi test use bayesian fals discoveri probabl bfdp test calcul probabl associ moder rang prior probabl presenc associ bfdp threshold set fals non discoveri rate four time costli fals discoveri resultspati characterist clinic outcomesdemograph clinic featur patient present tabl median age rang year patient male among subject stage iiia diseas stage iiib stage iv diseas consid histopatholog type patient diagnos adenocarcinoma squamou cell carcinoma adenosquamocarcinoma carcinoma journal pone t001tabl 1clinic characterist nsclc patient patient characteristicsn total patients353median age rang gendermale246 female107 ecog ps0 tmn stageiiia34 iiib107 iv212 histolog typeadenocarcinoma213 squamou cell75 adenosquamocarcinoma12 other smoke statusnev smokers154 ever smokers199 chemotherapi regimensplatinum navelbine187 platinum gemcitabine54 platinum paclitaxel73 platinum docetaxel18 platinum combinations20 note ecog ps eastern cooper oncolog group perform statu tnm tumor node metastasi other includ mix cell neuroendocrin carcinoma undifferenti carcinoma associ polymorph clinic benefitgenotyp inform present tabl genotyp distribut accord hardi weinberg equilibrium p associ polymorph efficaci outcom respons rate clinic benefit assess use pearson x2 test univari logist regress snp signific predictor respons rate clinic benefit overal tabl journal pone t002tabl 2xpd polymorph tumor respons univari analysi clinic benefit cr pr sd n respons rate cr pr n polymorphismsno ci p ci p arg156argc c73 00reference0 00reference0 682c a154 51a a57 39asp312asng g251 00reference0 00reference0 305a g a30 48asp711aspc c258 00reference0 00reference0 339c t t t28 55lys751glna a249 00reference0 00reference0 440a c c c32 63note cr complet respons pr partial respons sd stabl diseas odd ratio comput pearson chi squar test estim use univari logist regress associ xpd polymorph haplotyp pf ostabl show pf os analysi data accord examin polymorph overal median pf month confid interv month although lys751gln polymorph show margin correl pf signific differ pf respect xpd genotyp journal pone t003tabl 3pf os accord xpd polymorph patientspolymorphismsno median pf mo ci log rank pmedian os mo ci log rank parg156argc c85 759c a194 a70 asp312asng g308 006a g a38 asp711aspc c319 006c t t t34 lys751glna a304 014a c c c43 note pf progress free surviv os overal surviv ci confid interv asp312asn asp711asp lys751gln polymorph show statist signific associ os log rank test tabl tabl fig xpd asp312asn lys751gln polymorph median surviv time patient variant genotyp month month respect shorter wild type homozygot mst month log rank p respect signific remain adjust perform statu stage treatment regimen factor significantli associ os log rank test tabl s1 cox regress model adjust p respect tabl asp711asp polymorph t carrier genotyp associ reduc surviv compar wild type c c genotyp month versu month log rank p margin signific p valu observ adjust clinic featur adjust hr ci signific differ arg156arg os observ journal pone g001figur 1kaplan meier curv overal surviv accord xpd asp312asn polymorph b xpd haplotyp journal pone t004tabl 4polymorph associ os median os multivari analysisbfdp priorpolymorphismsmo ci log rank padjust hazard ratio ci p 05asp312asng g19 refer 88a g a13 asp711aspc c19 refer 90c t t t14 lys751glna a19 refer 88a c c c15 xpd haplotypehaplotyp gca copi number refer copi number note os overal surviv hr hazard ratio ci confid interv bfdp bayesian fals discoveri probabl bold figur remain noteworthi bfdp level suggest true associ data estim multivari cox proport hazard model adjust patient characterist p univari analysi perform statu clinic stage type treatment regimen haplotyp compos order asp312asn asp711asp lys751gln gca common haplotyp pairwis linkag disequilibrium ld four snp present tabl s2 moder ld observ among asp312asn asp711asp lys751gln variant d common haplotyp gca order asp312asn asp711asp lys751gln found account studi popul surviv patient two copi gca haplotyp wild type significantli longer patient zero one copi tabl bfdp valu observ associ calcul two level prior probabl tabl prior probabl two snp asp312asn lys751gln haplotyp remain noteworthi bfdp subgroup analysi associ xpd haplotyp overal survivalth effect asp312asn haplotyp nsclc surviv evalu subgroup analysi stage histolog type chemotherapi regimen perform statu tabl obviou evid associ haplotyp os observ stage iiib patient log rank p variant haplotyp associ significantli decreas surviv mst month adjust hr ci compar wild type gca haplotyp mst month statist signific differ also observ subgroup patient ecog perform statu patient adenocarcinoma tabl moreov haplotyp distribut differ significantli among nsclc patient consid clinic factor histolog type clinic stage ps tabl s3 journal pone t005tabl 5subgroup analysi associ xpd haplotyp overal surviv haplotyp gca copi number copi number bfdp priorvariablesdeath patientsmst month death patientsmst month log rank padjust hr ci adjust p 05total340tnm stageiii b45 31iv104 ecog ps0 44chemotherapi regimensplatinum navelbine91 platinum gemcitabine25 platinum paclitaxel31 histolog typeadenocarcinoma93 73squamou cell37 note ecog ps eastern cooper oncolog group perform statu tnm tumor node metastasi mst median surviv time hr hazard ratio bfdp bayesian fals discoveri probabl bold figur remain noteworthi bfdp level suggest true associ haplotyp compos order asp312asn asp711asp lys751gln gca common haplotyp stratifi test estim multivari cox proport hazard model adjust patient characterist p univari analysi perform statu clinic stage type treatment regimen bfdp conduct stratifi analysi use prior probabl tabl observ associ remain noteworthi even prior probabl discussionthi studi evalu whether common xpd polymorph influenc clinic outcom chines nsclc patient treat platinum base chemotherapi found variant genotyp haplotyp asp312asn asp711asp lys751gln polymorph signific contribut shorter surviv time compar correspond wild type homozyg genotyp adjust clinic factor xpd haplotyp still significantli associ os effect predomin patient stage iiib diseas addit bfdp correct suggest observ associ snp main effect subgroup analysi probabl due fals discoveri xpd member nine subunit complex tfiih act ner helicas activ requir initi ner process vivo vitro studi indic variat xpd gene may influenc clinic benefit platinum base therapi polymorph xpd codon investig sever studi consensu reach genet variat codon nonsynonym polymorph result chang amino acid sequenc protein previou studi seker et al report lymphoblastoid cell carri variant genotyp codon display higher apoptot respons uv compar carri wild type genotyp besid sever studi suggest xpd gln substitut might produc signific conform chang protein lead low number chromatid aberr decreas risk suboptim dna repair result consist previou experiment epidemiolog find variant genotyp associ effici dna repair capac human tissu result decreas effect cytotox chemotherapi asp711asp polymorph common silent substitut asp711asp lys751gln polymorph strong ld d exact function asp711asp elucid yet possibl affect stabil mrna influenc rate translat convert high usag codon low usag one altern biolog plausibl correl mediat linkag disequilibrium lys751gln potenti function snp analysi signific associ found reduc surviv haplotyp analysi effect still signific adjust clinic factor adjust p cumul effect xpd haplotyp might result synergist effect snp vitro vivo studi base combin three loci help investig true biolog mechan surviv differ haplotyp appar patient stage iiib diseas highli accord studi gurubhagavatula et al one possibl explan individu stage iv diseas may accumul mani mutat cours tumor growth may drive treatment resist overwhelm genet chang may alter dna repair capac recent meta analysi point none asp312asn lys751gln alon significantli associ os nsclc patient receiv platinum base chemotherapi howev asian popul includ lys751gln polymorph one studi includ patient elig final os analysi asp312asn studi elig os analysi minor allel frequenc three polymorph consider lower asian popul european popul adequ sampl size need boost power studi therefor examin snp chines popul will also help elucid mechan interethn differ outcom patient chemotherapi statist signific differ os snp also observ patient adenocarcinoma sinc adenocarcinoma common tumor type chines popul tend show wors prognosi find meaning effect predict particular subgroup lung cancer patient howev xpd statu tumor cell need determin tumor specimen although surviv outcom differ across xpd genotyp respons therapi differ among subgroup suggest genet factor respons short term efficaci like differ os studi sever strength compar publish studi rel larg number advanc nsclc patient treat platinum base chemotherapi first line treatment enrol studi rel homogen treatment standard limit potenti confound effect patient recruit data collect carri without knowledg genet statu addit consist subgroup analysi indic find like biolog plausibl limit work includ retrospect singl center design lack dna repair gene confirm multi center prospect studi result studi interpret sinc incid egfr mutat expect particularli high east asian popul clinic trial examin xpd snp nsclc patient regard egfr mutat may help clarifi whether xpd polymorph haplotyp act predict marker chemotherapi conclus result provid evid predict role xpd asp312asn asp711asp lys751gln polymorph haplotyp nsclc prognosi among nsclc patient treat platinum base chemotherapi suggest xpd polymorph might use risk assess chemotherapi effect predict individu treatment optim support informationt s1comparison overal surviv accord clinic characterist patient doc click addit data file tabl s2linkag disequilibrium d r2 snp xpd doc click addit data file tabl s3haplotyp distribut accord clinic factor doc click addit data file', 'endosom rout consid default pathway load class ii mhc molecul mhc molecul encount intern protein serv antigen sourc insid cell acid lysosom like compart miic howev experi fix cell mhc express cell lack key compon process pathway indic mhc load can take place also directli cell surfac appli optim size peptid also larger polypeptid chain even full length protein particular immatur dendrit cell dc util pathway dc contain larg fraction empti class ii mhc molecul cell surfac may allow direct captur antigen extracellular space cell cell surfac process seem repres major antigen load pathway cell caus irregular immun respons name matur dc activ b cell ligand present cell surfac accur reflect peptid composit insid miic compart presum safeguard mechan evolv prevent accident load class ii mhc molecul mhc molecul lost ligand rapidli convert stabl inact state non recept free peptid neither recept non recept conform structur defin yet character sole kinet paramet principl convers two form revers equilibrium larg shift toward non recept conform consequ cell surfac load usual ineffici hinder induct product immun respons peptid vaccin endosom process pathway mhc load facilit hla dm chaperon stabil peptid recept state previou studi shown surprisingli also small organ compound can exhibit effect similarli hla dm mhc load enhanc mle stabil peptid recept state result acceler antigen load ligand exchang demonstr simpl organ chemic also amino acid side chain can mediat effect experi short dipeptid demonstr can provok ligand exchang peptid load target conserv p1 anchor pocket class ii mhc molecul presenc peptid mle t cell assay therefor significantli improv cell surfac load antigen present cell apc peptid antigen directli translat increas sensit antigen specif t cell respons resultsstudi synthet organ mhc ligand exchang catalyst point alreadi p1 pocket specif target site mhc load enhanc mle pocket locat bind groov close n termin side peptid ligand ligand complex pocket accommod side chain key anchor residu peptid fig 1a therefor assum mle effect may also achiev small natur like compound consist amino acid order test assumpt solubl hla dr1 molecul incub high affin peptid ligand ha306 presenc amino acid short peptid free amino acid exhibit effect data shown simpl dipeptid tyr arg yr acceler mhc load ha306 peptid dose depend way fig 1b effect observ ala arg ar dipeptid lack aromat anchor side chain indic replac tyrosin alanin complet abrog mle effect journal pone g001figur 1amino acid side chain short peptid fragment can catalyz format mhc ligand complex locat p1 h bond network class ii mhc molecul left panel top view peptid bind site class ii mhc molecul hla dr1 α1 blue ribbon β1 domain mhc molecul red ribbon depict posit p1 indic backbon peptid ligand ha306 anchor side chain fill p1 pocket shown yellow mhc residu form h bond backbon label grey right panel side view p1 pocket load tyrosin anchor side chain surfac pocket indic yellow amino acid residu form pocket indic peptid shown spacefil mode green imag base crystal structur ha306 hla dr1 pdb 1dlh b catalyt impact dipeptid side chain format antigen complex influenc short peptid complex format rate ha306 solubl hla dr1 determin load reaction carri presenc titrat amount dipeptid tyr arg yr fill circl ala arg ar open circl absenc dipeptid dash line complex format determin elisa express rel enhanc refer spontan complex format absenc catalyst amount catalyt peptid fragment mle concentr indic x axi illustr fig 1a stabil mhc ligand complex maintain h bond network form backbon peptid consider number bond form immedi vicin p1 pocket stabil dipeptid maxim number h bond acetyl amid group introduc n c termini dipeptid comput dock acetyl dipeptid amid ac yr nh2 p1 pocket hla dr1 indic much five conserv h bond can form minim peptid coordin dock enclos supplement pdb file pdb_coordin s1 compar free dipeptid yr fold increas catalyt activ observ ac yr nh2 fig 2a partial mle effect observ also ac yr yr nh2 wherea ac ar nh2 still complet inact confirm import natur peptid structur dipeptid analogu ac yr nh2 employ tyrosin replac β homotyrosin b3hi introduct amino acid increas distanc side chain addit ch2 group result total loss activ fig 2b likewis replac standard l amino acid respect d enantiom abrog catalyt activ also dipeptid ac ry nh2 compos d amino acid invers sequenc show effect indic strict stereo specif catalyst fig 2c journal pone g002figur 2structur activ relationship catalyt dipeptid role h bond catalyt activ dipeptid variou h bond bridg proxim p1 pocket stabil ligand complex compar fig 1a n termin acetyl c termin amid introduc yr dipeptid facilit util h bond network minim peptid mle catalyst influenc demonstr load reaction ha306 sol hla dr1 presenc titrat amount yr fill circl ac yr open circl yr nh2 open triangl ac yr nh2 open squar control ac ar nh2 open diamond b impact elong side chain space dipeptid deriv use side chain space elong singl ch2 group use l β homotyrosin ac b3hyr nh2 open circl instead tyrosin ac yr nh2 fill circl c influenc d amino acid complex format carri presenc titrat amount ac yr nh2 fill circl ac ry nh2 open circl ac ry nh2 open triangl ac ry nh2 open squar ac yr nh2 open diamond ac yr nh2 open triangl ac yr nh2 open hexagon d amino acid indic small letter d structur requir catalyt anchor side chain p1 pocket hla dr1 interact prefer bulki hydrophob anchor side chain compar catalyt activ known structur prefer p1 complex format ha306 hla dr1 shown ac fr nh2 fill circl ac wr nh2 fill triangl ac yr nh2 fill squar ac lr nh2 open circl ac mr nh2 open triangl ac ir nh2 open squar ac vr nh2 open diamond ac er nh2 open triangl steric requir h bond usag particular failur dipeptid lack aromat side chain support assumpt effect mediat dimorph p1 pocket pocket hla dr1 drb1 contain residu β86g result prefer aromat lower extent aliphat anchor residu determin whether prefer reflect catalyt activ peptid mle collect acetyl dipeptid amid test tyrosin residu ac yr nh2 replac one two aromat amino acid phenylalanin f tryptophan w aliphat amino acid leucin l methionin m isoleucin valin v line expect strongest increas observ dipeptid contain f y w dipeptid aliphat side chain show weaker activ fig 2d enhanc detect ac er nh2 tyrosin substitut glutam e belong residu fit p1 pocket hla dr1 mean catalyt mle activ summar tabl solubl hla dr1 drb1 catalyt rate enhanc coeffici determin mm mm mm minim peptid mle contain f y w respect compar ac fr nh2 dipeptid aliphat mle side chain exhibit l v activ similar catalyt activ also detect unmodifi tripeptid well two peptid deriv invari chain lrmk lrmklpk ii key describ facilit mhc load target alloster invari chain bind site locat outsid p1 pocket activ howev significantli higher unmodifi tripeptid combin use activ peptid mle ac fr nh2 show cooper data shown notabl effect observ n termin fragment invari chain octapeptid lrkppkpv although fragment report facilit antigen load catalyz self releas invari chain peptid ic106 clip least experiment system catalyt effect observ journal pone t001tabl 1catalyt activ short peptid load solubl hla dr1 ha306 318compound catalyt rate enhanc m rel cat activ minim peptid mle1ac fr nh26 21002ac yr nh23 0573ac wr nh23 9544ac lr nh20 08125ac mr nh20 0086ac ir nh20 0177ac vr nh20 0248ac er nh20 0209ac ar nh20 000b catalyt tripeptides10yfr0 291111ykt0 12912kyv0 15813gyv0 168c invari chain deriv peptides14lrmklpk0 211515lrmk0 15816lrkppkpv0 minim peptid mle catalyt tripeptid introduc studi catalyt activ invari chain deriv peptid report lrmk lrmklpk lrkppkpv catalyt rate enhanc coeffici k repres rel increas spontan load rate rspont presenc catalyt peptid pcat total rate rtot can calcul rtot rspont k pcat rspont rel cat activ indic rel catalyt activ peptid deriv express percentag refer catalyt rate enhanc ac fr nh2 far impact peptid mle determin load empti mhc molecul evalu influenc complex dissoci solubl class ii mhc molecul preload medium affin clip peptid fig although peptid bind hla dr1 lower affin ha306 virtual spontan decay detect left panel appli also experi carri presenc dipeptid mle situat look differ ha306 peptid ad right panel less h hla dr1 clip complex disappear ac fr nh2 present dissoci notabl absenc catalyst complex still remain intact even h incub indic dipeptid mle abl increas also rate peptid ligand presenc ac yr nh2 ac lr nh2 half life shorten h h ac ar nh2 limit effect revers acceler complex format complex dissoci therefor correl anchor prefer p1 pocket journal pone g003figur 3catalyt dipeptid trigger revers ligand exchang demonstr peptid mle can catalyz revers ligand exchang complex dissoci clip hla dr1 induc peptid mle determin absenc left panel presenc µg ml free ha306 right panel experi mm ac fr nh2 fill circl ac yr nh2 fill triangl ac lr nh2 open circl ac ar nh2 open triangl catalyst cross use percentag clip hla dr1 complex remain indic time point determin elisa order formal demonstr catalyt side chain peptid mle act p1 pocket mutant hla dr1 gener glycin residu β86 floor p1 replac either valin β86v tyrosin ß86i fig hla dr β86v repres natur dimorph altern β86g occup β86 valin produc shallow hydrophob pocket abl accommod aliphat side chain contrast β86g pocket small bulki aromat residu non natur substitut β86i shown produc mhc molecul highli recept contain p1 pocket block tyrosin residu peptid can bind bind depend p1 pocket therefor load experi therefor carri abl908 pentadecapeptid deriv abl kinas can form complex three variant höpner et al manuscript prepar fig upper panel absenc peptid mle abl908 bind equal strong wt hla dr1 β86g hla dr1 β86g v due inher increas recept mutant exhibit highest spontan rate hla dr1 β86g y also addit peptid mle result increas load reaction fig lower panel wt hla dr1 β86g enhanc abl908 load correspond result obtain ha306 aromat dipeptid show stronger enhanc aliphat ac lr nh2 peptid pattern revers hla dr1 β86g v line anchor prefer shallow p1 pocket best enhanc obtain ac lr nh2 weaker amplif detect aromat dipeptid enhanc observ hla dr1 β86g y even slight reduct detect highest dipeptid concentr use chlorophenol pcp simpl disubstitut benzen known act independ p1 still exhibit mle effect journal pone g004figur 4allel select catalyt dipeptid recombin solubl hla dr1 molecul mutat insid p1 pocket use load experi abl908 peptid abl bind wt well mutat form hla dr1 s höpner unpublish upper panel spontan load abl908 shown wt hla dr1 β86g hla dr1 β86g v hla dr1 β86g y format abl908 hla dr complex express count per minut cpm dash line indic background signal lower panel allel select effect catalyt dipeptid shown influenc hla dr load shown ac fr nh2 fill circl ac wr nh2 fill triangl ac yr nh2 fill squar ac lr nh2 open circl p chlorophenol pcp cross dash line simpl aromat mle compound act independ p1 µg ml abl908 use wt hla dr1 hla dr1 β86g v µg ml hla dr1 β86g y complex format express rel enhanc refer spontan complex format absenc catalyst load determin elisa exposur cell synthet organ mle facilit antigen load directli cell surfac mhc molecul determin whether appli also peptid mle cell express hla dr1 gfp fusion protein drb1gfp incub absenc presenc ac fr nh2 biotinyl ha306 peptid stain fluoresc label streptavidin imag cell confoc laser scan microscopi reveal strike increas amount peptid bound cell surfac presenc ac fr nh2 fig 5a almost ha306 peptid detect load carri absenc dipeptid mle addit catalyst result bright surfac stain coloc hla dr1 gfp fusion protein journal pone g005figur 5enhanc load cell surfac mhc peptid mle confoc laser scan analysi cell surfac load drb1gfp cell express gfp tag hla dr1 molecul incub biotinyl ha306 peptid absenc presenc ac fr nh2 stain streptavidin cy5 imag taken confoc laser scan microscopi scale bar repres µm b impact apc load t cell respons fibroblast transfect express either wt hla dr1 left panel mutat hla dr1 β86g v right panel incub abl908 presenc titrat amount ac fr nh2 fill circl ac wr nh2 fill triangl ac yr nh2 fill squar ac lr nh2 open circl absenc peptid mle upper panel analysi cell surfac load fac fibroblast cell incub µg ml biotinyl abl908 4h peptid load determin fac express geometr mean geo mean lower panel enhanc abl908 specif t cell respons fibroblast cell express wt hla dr1 hla dr1 β86g v incub h ng ml ng ml abl908 wash use challeng saabl1 g2 abl908 specif t cell hybridoma recogn peptid hla dr1 molecul respons express il releas dash line repres t cell respons trigger absenc mle compound detail analysi peptid load cell analyz fac fig 5b experi fibroblast cell use express endogen class ii mhc molecul transfect full length version wt hla dr1 β86g mutat hla dr1 β86g v previou experi cell incub biotinyl mhc bind peptid abl908 absenc presenc titrat amount catalyt dipeptid fig 5b upper panel quantif peptid load fac reveal similar pattern observ solubl mhc molecul compar fig fibroblast express wt hla dr1 strongest enhanc observ aromat dipeptid aliphat ac lr nh2 peptid show weakest effect similar effect also observ bone marrow deriv dendrit cell obtain hla dr1 transgen mice data shown cell express mutat β86g v molecul aliphat ac lr nh2 effect peptid mle aromat side chain thu also enhanc cell surfac load correl allel specif anchor prefer p1 importantli increas load effici translat directli improv cd4 t cell respons fig 5b lower panel cd4 t cell hybridoma specif abl epitop saabl g2 show strongest respons stimul fibroblast cell load presenc dipeptid pattern enhanc reflect catalyt effect antigen load directli correl allel specif p1 anchor prefer aromat dipeptid effici wt hla dr1 β86g aliphat ac lr nh2 show best stimul cell express mutat hla dr1 β86g v shallow p1 pocket influenc catalyt dipeptid cd4 t cell respons studi vitro t cell assay t cell apc expos free peptid antigen peptid mle experi ha306 use antigen challeng two differ hla dr restrict cd4 t cell mous t cell hybridoma evha x5 fig 6a upper panel human t cell line pd2 fig 6a lower panel cell line presenc peptid mle result drastic increas sensit t cell respons titrat peptid mle suboptim antigen dosag reveal maxim enhanc t cell respons concentr around mm left panel concentr dose respons curv ha306 antigen shift fold toward lower concentr right panel half maxim respons absenc catalyst detect concentr ng ml evha x5 ng ml pd2 ac fr nh2 lower threshold ng ml ng ml respect line previou data weaker effect determin ac lr nh2 journal pone g006figur 6amplif antigen specif t cell respons enhanc vitro t cell respons influenc catalyt peptid antigen specif cd4 t cell respons test mous t cell hybridoma evha x5 upper panel human t cell line pd2 lower panel recogn ha306 antigen context hla dr1 left panel show influenc titrat amount ac fr nh2 fill circl ac yr nh2 fill triangl ac lr nh2 open circl evha x5 pd2 presenc ng ml ha306 respect respons absenc catalyst indic dash line right panel show dose respons curv ha306 presenc mm ac fr nh2 fill circl ac lr nh2 open circl mm ac yr nh2 fill triangl absenc peptid mle cross dash line indic background b enhanc ex vivo t cell respons lymph node cell isol hla dr1tg mice prime ha306 peptid ny eso ex vivo respons determin ifn γ elispot assay challeng cell ng ml ha306 upper panel ng ml ny eso lower panel respect bar repres number spot detect absenc black bar presenc mm ac fr nh2 grey bar spot origin singl ifn γ secret cell dash line indic background signal lastli confirm peptid mle mediat enhanc can observ also primari cell lymph node cell hla dr1tg mice challeng ex vivo absenc presenc ac fr nh2 mice prime either ha306 ny eso cd4 t cell epitop deriv ny eso protein associ variou solid tumour day antigen specif ex vivo respons determin ifn γ elispot assay fig 6b line previou result catalyt dipeptid found significantli increas sensit assay concentr ng ml ha306 upper panel ng ml ny eso lower panel number spot repres singl ifn γ secret cell significantli higher ac fr nh2 ad thu short peptid exhibit mle like activ can amplifi immun respons also primari cultur contain natur cd4 t cell profession apc discussionour experiment data show short peptid fragment can influenc ligand composit class ii mhc molecul catalyt way place amino acid side chain defin pocket mhc molecul trigger ligand exchang antigen load mutat analysi indic alreadi occup pocket p1 crucial catalyt effect organ mle compound demonstr human molecul hla dr1 similar role also establish ligand exchang driven short peptid p1 present mhc class ii molecul locat within peptid bind site accommod side chain key anchor residu peptid ligand locat pocket conserv contain polymorph residu determin allel specif prefer anchor residu sinc structur requir also dictat interact catalyt side chain short peptid exhibit effect allel select way shown simpl organ compound mle mechan base stabil peptid recept conform earlier studi show alreadi substitut residu β86g tyrosin result fill p1 pocket produc mhc molecul elev recept p1 locat proxim bind site hla dm bind studi suggest hla dm interact specif flexibl empti hydrophob p1 pocket activ convers non recept molecul hla dm recent question undisput chaperon interact region proxim p1 stabil peptid recept conform recent public introduc model transit non recept state directli correl structur chang insid pocket p1 experiment evid taken observ p1 target mle compound prevent transit strict correl catalyt activ structur requir p1 introduc studi provid addit support hypothesi stabil p1 prevent transit non recept state molecular dynam md simul confirm pocket p1 inde quickli lost peptid ligand strip mhc molecul rupp et al manuscript prepar fig calcul base coordin crystal structur hla dr1 ha306 complex reveal signific transit detect near p1 pocket shift result narrow two α helic 7å fig 7a also led complet loss p1 pocket less ns p1 caviti fill side chain remov distort fig 7c d notabl collaps prevent prior md simul ac fr nh2 dock p1 pocket fig 7b journal pone g007figur 7molecular dynam md calcul empti peptid mle stabil hla dr1 coordin mhc compon crystal hla dr1 ha306 complex 1dhl use carri ns md calcul empti mhc molecul dynam empti mhc molecul floor compos β plate sheat depict magenta α helic start structur shown red α helic structur obtain ns shown blue approxim posit p1 indic dynam carri extracellular domain bind site shown α1 β1 domain b dynam peptid mle stabil mhc molecul md calcul carri fig 7a except coordin hla dr1 molecul use prior md calcul peptid mle ac fr nh2 dock p1 pocket c p1 pocket peptid load mhc complex imag show cross section hla dr1 ha306 complex surfac mhc molecul shown yellow peptid ligand red posit p1 pocket indic d loss p1 empti mhc molecul cross section shown fig 7c peptid load mhc shown empti molecul obtain ns md calcul structur p1 pocket can longer locat base model even partial occup bind site short peptid suffici stabil recept state long posit anchor side chain insid p1 pocket supplement pdb file pdb_coordin s1 p1 therefor seem function sensor peptid load occup lead stabil open conform requir accommod peptid ligand studi group alreadi shown load statu p1 play crucial role indic intracellular antigen process pathway interact hla dm seem depend load state catalyt activ report mediat βh81 conserv residu locat top p1 pocket insid cell occup state p1 seem control interact key compon process pathway cell surfac may regul transit non recept conform function trigger safeguard mechan close bind site soon ligand lost studi show small peptid fragment can pass mechan catalyt way particularli strike effect ligand exchang peptid mle abl increas load empti hla dr molecul also dissoci hla dr molecul preload lower affin ligand revers reaction effect account increas antigen load cell surfac mhc molecul translat directli improv cd4 t cell respons molecular tool mle compound may therefor find applic experiment therapeut set improv antigen load desir particular suitabl field may peptid base tumour immun intervent exposur antigen hostil proteolyt environ extend limit access recept mhc molecul surfac profession apc import cd4 t cell product tumour immun respons just begun fulli discov role induct autoimmun respons long acknowledg evid instanc strong genet link class ii mhc molecul fact experiment autoimmun diseas can often induc adopt transfer auto aggress cd4 t cell respect accident load cell self antigen peptid mle may therefor trigger unwant auto aggress respons vitro shown alreadi presenc simpl organ mle compound can enhanc encephalitogen t cell respons may also appli coliti celiac diseas intestin dendrit cell known penetr gut epithelia cell expos dendrit insid gut lumen extrem high polypeptid concentr origin diet commens debri captur solubl antigen immatur dc lymph blood hand also seem import mechan toler induct direct cell surfac load discuss altern process pathway immatur dendrit cell natur protein fragment present blood lymph act peptid mle may therefor particip process mediat direct transfer antigen onto cell surfac mhc molecul materi methodscompound reagentsth follow peptid use ic106 kmrmatpllmqalpm clip peptid ha306 pkyvkqntlklat ny eso efylampfatpm human abl kgklsrlkpappppp hopner et al unpublish n termin biotinyl introduc use two amino hexano acid spacer unit stock solut short peptid mm prepar dmso pb ultrasound sonic follow dmso concentr yr ar lrmk yfr gyv ac ar nh2 ac ry nh2 ac ry nh2 ac ry nh2 ac yr nh2 ac yr nh2 ac b3hyr nh2 ac fr nh2 ac yr nh2 ac lr nh2 ac er nh2 lpkppkpv ac wr nh2 ac vr nh2 ac mr nh2 ac ir nh2 ac ry nh2 peptid produc emc microcollect gmbh tübingen germani analyz rp hplc nm esi ms antibodi solubl hla dr1phycoerythrin pe conjug streptavidin purchas caltag α hla dr pe l243 obtain bd bioscienc unlabel α hla dr l243 α ifn γ an18 r4 6a2 purifi hybridoma supernat prot prot g column ge healthcar r4 6a2 label nh biotin accord manufactur recommend pierc solubl wt hla dr1 dra drb1 produc s2 insect cell describ mutant form hla dr1 express baculoviru express system briefli dna code extracellular domain dra dr1b separ clone transfer vector pfastbac invitrogen leucin zipper domain ad c termini α β chain describ site direct mutagenesi hla dr1 β chain carri use quickchang site direct mutagenesi kit stratagen recombin virus gener s frugiperda cell sf21 express protein cell co infect virus α β chain cellsth follow class ii express cell line use l929 fibroblast atcc transfect wt drb1 mutat hla dr1 hla drb1 β86v ebv transform b cell atcc htr drb1gfp cell produc stabli transfect cell hla dr ß chain drb1 c termin fuse egfp falk et al unpublish follow t cell use drb1 restrict ha306 specif mous hybridoma line evha x5 human cd4 t cell line pd2 abl specif t cell hybridoma saabl g2 gener fuse cd4 t cell line gener hla dr1 tg mice bw cell hopner et al unpublish peptid load solubl hla dr1 moleculesload experi solubl mhc molecul carri describ briefli nm hla dr1 incub µg ml biotinyl ha306 peptid pb ph c h amount peptid mhc complex form determin elisa α hla dr captur antibodi l243 atcc eu3 label streptavidin delfia wallac use victor 3v reader perkin elmer ligand exchang experi carri preload hla dr1 clip complex µm hla dr1 µg ml biotinyl clip h ph ethanol pb dilut incub without µg ml ha peptid presenc absenc mm dipeptid experi carri time peptid load cell surfac mhc moleculesload experi carri describ briefli hla dr express cell well incub biotinyl mhc bind peptid presenc absenc catalyt dipeptid h c dmem fc well v bottom plate fac analysi cell stain streptavidin pe analyz facscalibur instrument bd bioscienc dead cell exclud propidium iodid stain experi carri twice confoc laser scan microscopybriefli hla dr1 express cell drb1gfp per well incub µg ml biotinyl ha peptid presenc absenc mm ac fr nh2 h c dmem fc well v bottom plate cell wash incub poli l lysin sigma coat plate min c rpmi medium gibco follow min formaldehyd fixat wash cell stain streptavidin cy5 amersham mount vectashield vector lab fix cell microscopi perform zeiss lsm510meta confoc setup phase contrast plan apochromat oil object experi carri twice t cell assayst cell assay carri describ briefli hla dr express cell well incub mhc bind peptid presenc absenc catalyt dipeptid c dmem fc well round bottom plate assay antigen puls apc cell wash h t cell ad perman exposur assay t cell ad directli without prior remov peptid experi t cell hybridoma cultur supernat remov h t cell respons determin measur il releas secondari assay ctll cell atcc describ previous experi t cell line apc radiat gy 3h thymidin ad 48h incorpor determin use microbeta counter wallac experi carri twice detect ex vivo respons elispot assayhla dr1tg mice prime µg ha306 µg ny eso incomplet freud s adjuv sigma µg cpg ond biotez gmbh day lymph node cell isol incub elispot plate multiscreen ht well filter plate millipor coat α ifn γ clone an18 cell incub densiti splenocyt well indic amount ha306 ac fr nh2 peptid h c co2 rpmi fc detect carri accord manufactur s recommend use biotinyl α ifn γ detect antibodi clone r4 6a2 avidin hrp enzym conjug sigma diaminobenzidin tablet sigma spot count use immunospot reader c t l europ gmbh experi carri twice calcul catalyt rate enhanc catalyt rate enhanc coeffici determin load assay nm solubl hla dr1 µg ml ha306 titrat amount catalyt peptid mle h c ph curv fit carri hyperbola regress f x ax b x use sigmaplot version softwar systat softwar inc coeffici determin form averag start slope b independ experi dock molecular dynam calculationth benzen ring phenylalanin residu backbon ac fr nh2 dipeptid superimpos residu y308 v309 ha306 peptid ha306 hla dr1 crystal structur 1dlh follow conform search arginin side chain dipeptid find optim orient subsequ complex structur minim use tripo softwar sybyl tripo inc st loui usa gromac forc field empti mhc structur ac fr nh2 mhc complex ns molecular dynam simul gromac forc field perform rupp et al manuscript prepar simul done physiolog condit nacl k equilibr period ps use posit restraint kjmol 1nm frame store everi ps visualis trajectori arrang figur realis use vmd support informationpdb_coordin s1the text file contain calcul coordin complex ac fr nh2 hla dr1 pdb file format dock ac fr nh2 benzen ring phenylalanin residu backbon dipeptid superimpos residu y308 locat within p1 pocket v309 ha306 peptid ha hla dr1 crystal structur 1dlh subsequ complex minim use tripo gromac forc field chain hla dr1 α chain dra chain b hla dr1 β chain drb1 chain c ac fr nh2 mb txt click addit data file', 'taylorella equigenitali gram neg coccobacillu classifi alcaligenacea famili caus agent contagi equin metriti cem sexual transmit infect hors first report current detect mani countri variou hors breed notifi oie world organis anim health cem character infect mare abund mucopurul vagin discharg variabl degre vagin endometr cervic usual result temporari infertil stallion clinic sign observ asymptomat carrier mare also report cem usual transmit sexual contact asymptomat carrier stallion indirect genit contact infect mare stallion vice versa also import factor spread cem sinc infect semen indirect vener contact use contamin fomit vagin specula artifici vagina wash bucket tail bandag can dissemin infect term biochem properti t equigenitali genu fastidi growth requir depend enrich bacteriolog media microaerophil incub condit grow bacterium report independ glycolysi hexos monophosph pathway depend tricarboxyl acid tca cycl oxid phosphoryl cell energi vitro vivo morpholog studi shown t equigenitali capsul express pili vivo t equigenitali remain abl replic equin neutrophil describ invas replic abil equin derm cell invas assay date precis virul factor report t equigenitali discoveri new bacteri isol two jack mare clinic sign taylorella genu consist one speci newli identifi bacterium character slight differ coloni morpholog notabl slower growth rate diverg immunofluoresc characterist compar t equigenitali classifi follow taxonom studi new speci name taylorella asinigenitali due high degre related remain difficult differenti two taylorella speci use classic identif techniqu alreadi report t asinigenitali incorrectli identifi t equigenitali date detect t equigenitali hors lead declar cem howev question whether declar case cem follow infect t asinigenitali remain relev sinc report mare experiment infect t asinigenitali develop clinic sign metriti cervic order understand differenti two close relat taylorella speci particularli term metabol virul capac herein report first genom sequenc t asinigenitali carri compar genom analysi sequenc recent describ genom sequenc t equigenitali resultst asinigenitali t equigenitali genom properti gener featurest asinigenitali figur 1a 1c singl bp circular chromosom overal g c content contain code sequenc cdss rrna gene trna gene tabl figur 1a plasmid found identifi protein code gene averag length bp correspond protein code content gene assign predict function tabl present t asinigenitali previous describ t equigenitali genom characterist figur 1b 1d accord gc skew analysi g c g c like origin replic t asinigenitali t equigenitali chromosom replic termin site chromosom appear diametr oppos origin can consist propos figur 1a 1b direct comparison predict cdss t asinigenitali t equigenitali perform reciproc fasta use minimum cutoff amino acid similar length result reveal cdss total gene predict t asinigenitali t equigenitali respect common taylorella speci figur averag nucleotid ident gene common strain averag amino acid ident moreov identifi t asinigenitali sequenc gave hit non signific hit t equigenitali tabl s1 reciproc t equigenitali absent t asinigenitali tabl s2 journal pone g001figur 1circular represent t asinigenitali mce3 t equigenitali mce9 genom b circular represent t asinigenitali mce3 chromosom t equigenitali mce9 chromosom respect outer circl show posit bp second blue third circl red show forward cdss revers cdss respect fourth circl show rrna black trna pink fifth circl show g c content plot innermost circl show gc skew purpl indic neg valu oliv posit valu replic origin clearli detect c d scan electron micrograph t asinigenitali mce3 observ x30 t equigenitali mce9 observ x33 respect cell observ stationari growth phase major diverg observ transmiss electron microscopi analysi t asinigenitali t equigenitali coccoid shape t asinigenitali rode shape t equigenitali howev studi necessari confirm observ sinc shown t equigenitali harbor bacillari coccoid form within singl coloni journal pone g002figur 2venn diagram illustr number put protein associ t asinigenitali t asinigenitali diagram construct reciproc fasta use minimum cutoff amino acid similar sequenc surfac proport number gene journal pone t001tabl 1gener featur genom t asinigenitali mce3 t equigenitali mce9 size bp gc cdsscode code densiti averag cd length bp rrna clusterstrnasinsert elementsaplasmidt asinigenitali mce31 33800t equigenitali mce91 33800aaccord finder http www biotoul fr html e valu t asinigenitali mce3 t equigenitali mce9 respect burkholderial phylogenyburkholderial phylogeni construct base put core ortholog gene bacteri genom sequenc burkholderial order identifi use scissor implement imomi framework result phylogenom analys figur consist previous describ rrna deriv β proteobacteria phylogeni show two taylorella speci markedli distant member alcaligenacea journal pone g003figur 3phylogenom analysi repres burkholderial speci select set genom belong burkholderial order one outgroup genom rhodococcu equi tabl s3 put core ortholog gene identifi use scissor implement imomi framework similar distanc matrix built averag percentag amino acid sequenc similar provid clustalw comparison distanc averag percent similar use infer neighbor join tree mega softwar genom alignmentth artemi comparison tool act use examin conserv gene order synteni t asinigenitali t equigenitali genom figur align show vast major common gene order averag ident align portion genom bp despit global conserv synteni genom align reveal larg chromosom invers symmetr across replic axi major diverg genom region describ tabl determin invers conserv t asinigenitali t equigenitali strain construct pcr primer set base genom sequenc t asinigenitali t equigenitali tabl s3 determin long pcr analysi orient larg invert genom region t asinigenitali t equigenitali strain tabl s4 result experi reveal orient larg genom fragment specif conserv speci given chromosom invers t asinigenitali compar t equigenitali symmetr across replic axi event chang gene orient respect replic axi thu lead gc skew discontinu journal pone g004figur 4sequenc align t asinigenitali mce3 t equigenitali mce9 genom genom t asinigenitali mce3 t equigenitali mce9 compar use blastn comparison visual artemi comparison tool act red blue line connect homolog region direct revers orient respect gap indic uniqu dna gray bar repres forward revers strand blue region number arrow indic t asinigenitali mce3 specif region pink region number arrow indic t equigenitali mce9 specif region black region number arrow indic variabl region rearrang region strain specif region briefli describ tabl analyz detail addit file journal pone t002tabl 2main characterist diverg region t asinigenitali mce3 t equigenitali mce9 genom t asinigenitali mce3t equigenitali mce9region noahypothet functionblength kbp specif genehypothet functionlength kbp specif gene1region unknown function33 130region unknown function5 552crispr associ region11 45restrict modification10 694antigen o region9 05antigen o region20 5127restrict modification3 02invers rearrang region1 438invers rearrang region7 98invers rearrang region9 059region unknown function10 04yada hep_hag relat region3 133region unknown function9 235prophag region50 9646region unknown function2 4510hemagluttinin relat region25 4511abc transport relat region14 01112efflux system5 8313region unknown function4 6514type iv secret system45 65715rh relat region15 210anumb region correspond region shown figur bdetermin basi sequenc homolog strain specif gene region t asinigenitali t equigenitalisstrain specif region t asinigenitali t equigenitali determin use act softwar specif region genom manual curat strain specif region number posit shown figur summar tabl detail addit file t asinigenitali genom contain three specif region region figur tabl s2 compos cdss furthermor t asinigenitali specif cdss mainli compos hypothet protein tabl s2 randomli insert genom region compos three hypothet protein ii four hypothet protein dnaj hypothet chaperon protein respect tabl s2 region largest t asinigenitali specif region specif cdss tasi_0412 tasi_0476 distribut genom region kb figur tabl s2 region assign put prophag prophag element identifi t equigenitali genom t equigenitali genom contain six strain specif region region figur tabl s1 contain uniqu cdss anoth t equigenitali specif cdss distribut t equigenitali genom tabl s1 region encod five protein two annot hemagglutinin abl induc agglutin erythrocyt thu involv virul phylogenet relat bordetella genu region therefor classifi hemagglutinin relat region tabl region encod six hypothet protein five protein potenti involv transmembran transport includ three abc transport relat protein thu classifi abc transport relat region region contain three put efflux system transmembran rnd resist nodul cell divis protein previous determin involv virul resist antimicrobi compound region compos four hypothet protein protein contain relaxas domain pfam03432 potenti involv horizont transfer genet inform classifi region unknown function region longest t equigenitali specif region specif cdss encod type iv secret system t4ss system membran associ transport complex use variou bacteria deliv substrat molecul wide rang target cell particular involv toxin secret inject virul factor eukaryot host target cell sever mammalian pathogen describ region classifi rearrang hot spot rh relat region compos cdss includ three rh famili protein contain repeat motif potenti locat cell surfac rh like element determin involv bacteriocin product pseudomona savastanoi pv savastanoi region specif t asinigenitali t equigenitali genom six region exist strain differ gene content design variabl region speci region compos hypothet protein must therefor classifi region unknown function region detail figur compos cluster regularli interspac short palindrom repeat crispr restrict modif r m system t asinigenitali t equigenitali respect crispr r m system mediat resist infect foreign dna genet materi e g bacteriophag conjug plasmid transpos element thu inhibit horizont gene transfer t asinigenitali crispr system contain two gene similar cas1 cas3 gene tasi_0215 tasi_0216 blast e valu e figur direct repeat bp spacer sequenc bp long blast analysi one spacer sequenc appear homolog prophag sequenc one genom part intracellular pathogen rickettsia bellii tabl s5 sequenc homolog found spacer sequenc alreadi describ e coli sulfolobu sulfataricu leader sequenc found t asinigenitali crispr loci mobil element found near crispr locu correspond t asinigenitali crispr cluster locu t equigenitali genom display six gene relat type restrict modif system figur tabl s1 r m system compos gene encod restrict enzym modif methylas act defens mechan protect host bacterium invad attack non self dna interestingli although content region diverg taylorella speci locu nonetheless contain mechan defens invad attack non self dna journal pone g005figur 5compar analysi t asinigenitali mce3 crispr t equigenitali mce9 r m system associ loci t asinigenitali mce3 crispr associ locu t equigenitali mce9 r m system locu compar use blastn comparison visual act red line connect homolog region direct orient gap indic uniqu dna gray bar repres forward revers strand repeat shown dark blue ca gene appear green neighbor open read frame light blue gc content plot bp window shown top bottom figur region correspond detail view region figur region t asinigenitali t equigenitali compos gene involv lipopolysaccharid lp o antigen biosynthesi capac induc intens host immun respons lp o antigen consid potenti virul relat factor structur analysi lp produc t asinigenitali atcc t equigenitali atcc show o antigen structur speci differ chemic structur serolog characterist observ consist fact lp o antigen use specif marker identifi differenti t equigenitali t asinigenitali character chromosom region encod lp o antigen t asinigenitali t equigenitali may allow find still unknown o antigen variant foster develop specif detect assay distinguish two speci region locat edg larg invert region genom contain one put restrict modif r m system compos restrict enzym dna cytosin methyltransferas t asinigenitali three hypothet protein t equigenitali presenc r m locu edg larg invert region alreadi describ differ genom propos involv genom invers region t asinigenitali includ seven hypothet protein tripartit atp independ periplasm transport trap content region t equigenitali quit differ includ four hypothet protein outer membran receptor protein region t asinigenitali contain three hypothet protein encod gene one potenti atp depend dna helicas recg play critic role recombin dna repair region t equigenitali includ one yada like protein one hep_hag famili protein one hypothet protein protein contain yada hep_hag domain associ autotransport share protein domain architectur hemagglutinin invas shown import virul relat role act multimer surfac protein modul cell interact host environ exampl burkholderia mallei protein contain yada hep_hag domain shown gener strong antibodi respons experiment equin model glander gener speak presenc locu rearrang two genom suggest recent speciat consist close phylogenom relationship two speci shown burkholderial phylogenom tree present figur basic nutrit metabolismth t asinigenitali t equigenitali genom predict complet tca cycl figur wherea three main pathway allow convers glucos pyruv miss sinc phosphofructokinas gene glycolysi embden meyerhof parna pathway absent ii pentos phosphat pathway lack non oxid branch transaldolas iii identifi gene entner doudoroff pathway consist observ biolog gen iii microplatetm assay show three organ acid metabol carbon sourc two speci taylorella genu malat glutam α ketoglutar tabl s6 figur malat α ketoglutar intermedi tca cycl glutam de amin α ketoglutar glutam deshydrogenas figur can also incorpor tca cycl previou studi report t equigenitali respir stimul tca cycl intermedi malat citrat succin glucos fructos maltos sucros observ partial consist observ sinc metabol activ detect experi presenc citrat succin differ explain strain variabl metabolit requir specif transport system exampl differ relat experiment procedur journal pone g006figur 6propos carbon flux taylorella genu enzym particip major reaction number thu pyruv dehydrogenas tasi_0903 tequi_1387 citrat synthas tasi_1018 tequi_1584 aconitas tasi_0659 tequi_1215 isocitr dehydrogenas tasi_0396 tequi_1024 α ketoglutar dehydrogenas tasi_0983 tequi_1309 succinyl coa synthetas tasi_0746 tequi_1545 succin dehydrogenas tasi_1020 tequi_1586 fumar hydratas tasi_0400 tequi_1028 malat dehydrogenas tasi_1024 tequi_1590 malic enzym tasi_0984 tequi_1308 glutam dehydrogénas tasi_1163 tequi_0187 pyruv phosphat dikinas tasi_0871 tequi_1418 trios phosphat isomeras tasi_0409 tequi_1037 fructos bisphosph aldolas tasi_1324 tequi_0348 fructos bisphosphatas tasi_0582 tequi_1137 glucos phosphat isomeras tasi_1244 tequi_0262 transketolas tasi_1328 tequi_0352 carbon sourc identifi metabol t asinigenitali mce3 t equigenitali mce9 gen iii micopl experiment tabl s6 highlight green dot line indic gene miss analysi appear acetyl coa need suppli tca cycl mainli produc convers malat pyruv malic enzym figur follow convers pyruv acetyl coa pyruv dehydrogenas figur furthermor compound requir purin pyrimidin lipopolysaccharid biosynthesi pathway produc gluconeogenesi pathway partial pentos phosphat pathway figur assum carbon sourc metabol t equigenitali t asinigenitali combin requir glycolysi partial pentos phosphat biosynthesi pathway synthes purin pyrimidin lipopolysaccharid partli account slow growth rate t equigenitali t asinigenitali moreov although high atmospher concentr co2 sever effect cellular physiolog alter membran properti probabl modifi intracellular ph can assum t asinigenitali t equigenitali co2 requir partli due util substrat sever carboxyl reaction involv amino acid pyrimidin biosynthesi pathway gene content analysi main gener metabol pathway t asinigenitali t equigenitali reveal differ gene composit suggest slower growth rate t asinigenitali compar t equigenitali due differ gene express enzym effici substrat suppli lack metabol pathway transport systemsth uptak efflux solut mediat transport system embed plasma membran membran compon feed use cognat high affin periplasm solut bind protein scaveng specif ligand s date three solut import famili identifi abc transport atp bind cassett trap transport ttt tripartit tricarboxyl transport t asinigenitali transport system consist gene gene encod compon abc transport system encod complet abc transport system encod trap transport five encod ttt encod miscellan protein t equigenitali transport system consist gene gene encod compon abc transport system encod complet abc transport system encod trap transport five encod ttt encod miscellan protein tabl s7 three carbon sourc metabol taylorella speci glutam α ketoglutar malat constitut substrat sever transport put glutam aspart abc transport system put proton glutam symport protein put c4 dicarboxyl transport tabl s7 howev number transport suggest taylorella speci abl transport metabol carbon substrat yet identifi despit report inabl t equigenitali util sugar confirm herein taylorella speci biolog gen iii microplatetm assay tabl s6 identifi t asinigenitali t equigenitali genom sever compon phosphotransferas system pt gener involv transport phosphoryl carbohydr identifi gene encod pt enzym tasi_1132 tequi_0099 phosphocarri protein hpr tasi_1133 tequi_0100 one cytoplasm protein eiia tasi_1134 tequi_0101 one eiia like protein ptsn tasi_0239 tequi_0851 one hpr kinas phosphorylas hprk p tasi_0238 tequi_0850 context bacteria unabl use sugar presenc gene involv pt seem surpris howev lack eiib eiic homolog suggest pt dedic sugar transport phosphoryl taylorella speci rather altern rout substrat inde previou studi pt paralog protein shown involv altern phosphotransferas rout includ unusu pt depend util dihydroxyaceton establish connect carbon nitrogen metabol explain presenc gene taylorella genom respiratori capacitysequ analysi t asinigenitali t equigenitali genom reveal presenc gene synthesi nadh dehydrogenas succin dehydrogenas cytochrom c reductas complet set gene atp synthas one termin oxidas belong cbb3 type cytochrom c oxidas tabl s8 cbb3 type cytochrom c oxidas due great affin oxygen involv microaerob metabol suggest express requir success colon anox tissu consequ cbb3 type cytochrom c oxidas may import determin pathogen taylorella speci oxid stress tolerancedur taylorella genom analysi identifi speci one superoxid dismutas tasi_0915 tequi_1375 one catalas tasi_1292 tequi_0317 one glutathion reductas tasi_0256 tequi_0384 one thiol peroxidas tasi_0972 tequi_1320 one alkylhydroperoxidas protein d tasi_0501 tequi_1062 one alkyl hydroperoxid reductas protein c tasi_0502 tequi_1063 two antioxid thioredoxin tasi_0667 tasi_1027 tequi_1592 tequi_1225 two thioredoxin reductas tasi_0294 tasi_1178 tequi_0201 tequi_0906 protein repair peptid methionin sulfoxid reductas msra b tasi_1464 tequi_0502 analysi show speci share ident set gene involv oxid stress resist suggest compar capac face oxid stress moreov number gene identifi involv oxid stress resist appear taylorella speci well equip face oxid stress potenti encount host secret systemsprotein secret key virul mechan pathogen symbiot bacteria make investig secret protein effector crucial understand molecular bacterium host interact secret system requir transport protein across cell membran play role virul fit analysi taylorella genom identifi three secret system t asinigenitali four t equigenitali tabl s9 show list put secret system identifi basi comput predict t asinigenitali t equigenitali type ii secret system t2ss consid main termin branch gener secret pathway found wide rang gram neg speci respons extracellular transport hydrolyt enzym toxin protein crucial pathogenesi mani microorgan t2ss requir presenc n termin signal peptid order util sec twin arginin transloc tat pathway protein transloc cytoplasm periplasm sec depend tat depend secret protein first produc precursor contain n termin cleavabl signal sequenc transport inner membran via proteinac complex export signal peptid cleav signal peptidas matur protein releas periplasm space fold protein transloc across outer membran taylorella speci identifi complet sec tat transloc pathway tabl s9 signal peptidas spase requir n termin signal peptid cleavag secret protein tasi_0543 tequi_1105 signal peptidas spase ii requir cleavag lipoprotein signal peptid tasi tequi_0053 signalp predict secret protein allow us identifi protein total protein respect potenti harbor signal peptid thu potenti secret via t2ss t asinigenitali t equigenitali respect tabl s10 s11 potenti locat host pathogen interfac protein constitut interest subject taylorella pathogenesi studi taylorella genom identifi type iii secret system t3ss potenti encod type ivb tight adher tad pili tabl s9 consid ubiquit pili mediat host colon persist mechan shown tad pili essenti biofilm format colon pathogenesi numer genera includ haemophilu pasteurella pseudomona yersinia data consist previous report observ pili express vivo t equigenitali found gram posit gram neg bacteria well archaea t4ss use transport macromolecul protein dna across cell envelop t4ss can mediat transport monomer protein multi subunit protein toxin nucleoprotein complex t4sss use transfer protein found pathogen bacteria play import role virul exampl establish pathogen host interact transfer toxic effector protein protein complex host cell s cytoplasm t equigenitali identifi nine t4ss relat protein virb1 virb4 virb5 virb6 virb8 virb9 virb10 virb11 vird4 tabl s9 overal structur t equigenitali t4ss region seem relat cytotoxin associ gene cag pathogen island found highli virul helicobact pylori strain form syring like pilu structur inject virul factor caga effector protein host target cell lack t4ss t asinigenitali partli explain differ virul capac two taylorella speci structur analysi recent identifi type vi secret system t6ss compon suggest secret system mimic bacteriophag machineri punctur target cell membran transloc effector protein host cell repres novel mechan deliv solubl effector t6sss contribut virul develop variou pathogen often activ upon contact target cell may also foster commens mutualist relationship bacteria eukaryot mediat cooper competit interact bacteria taylorella genom analysi identifi six t6ss relat gene tabl s9 includ hcp hemolysin coregul protein vgrg valin glycin repeat might serv conduit t6ss specif solubl effector protein regulatori functionsrel gene encod transcript regul identifi t asinigenitali t equigenitali total potenti transcript regul identifi respect includ six two compon system two sigma factor tabl s12 put extracytoplasm function ecf type σ factor identifi featur like reflect adapt stabl nutrit environ fewer biosynthet function fewer adapt requir virul factorsa cem infect remain genit tract invad damag host tissu like virul associ determin t equigenitali involv factor relat attach host extracellular matrix host cell intercellular adhes rather damag tissu keep observ identifi silico sever gene potenti involv bind colon host cell base homolog known microbi virul factor autom genom wide screen virul associ motif identifi enzym caus damag host tissu hyaluronidas hemolysin gene common speci identifi potenti involv bind colon host cell identifi abovement o antigen encod gene gene encod protein contain ankyrin sel1 subtyp tetratricopeptid repeat motif tpr sel1 protein encod eukaryot domain shown import interact variou intracellular bacteri pathogen eukaryot host cell within t asinigenitali genom identifi six tpr sel1 repeat contain protein tasi_0026 tasi_0290 tasi_0331 tasi_0362 tasi_0643 tasi_0687 one ankyrin protein tasi_0860 t equigenitali genom identifi five tpr sel1 repeat contain protein tequi_0900 tequi_0945 tequi_0979 tequi_1197 tequi_1243 two ankyrin protein tequi_1429 tequi_1600 t equigenitali specif gene identifi potenti involv bind colon host cell can cite abovement hemagluttinin relat protein three put efflux system transmembran rnd protein t4ss yada hep_hag domain contain protein tabl tabl s1 also identifi among t equigenitali specif cdss randomli insert genom virul associ gene tonb depend lactoferrin transferrin receptor tequi_0057 tequi_0058 tequi_0902 tequi_0903 heat shock protein hsp60 tequi_0973 tonb depend outer membran receptor lactoferrin transferrin identifi allow iron import mammalian iron carrier lactoferrin transferrin across outer membran iron essenti microbi growth abil acquir ferric iron host directli relat virul suggest virul charact t equigenitali due better iron acquisit capac t asinigenitali hsp60 character particular legionella pneumophila multifunct chaperonin can express bacteri cell surfac act invas factor non phagocyt cell releas host cell act effector capabl alter organel traffick organ actin microfila cell signal pathway absenc protein t asinigenitali suggest cell invad capac specif t equigenitali t asinigenitali genom screen identifi t asinigenitali specif gene potenti involv virul absent t equigenitali discussionlittl known molecular level mechan taylorella pathogen neither virul mechan host resist known first compar genom analysi two member taylorella genu present reveal close relationship two speci limit size taylorella genom conserv synteni suggest quit strong select pressur good adapt ecolog nich fact main genet differ concentr rearrang loci mainli link mobil genet element e g bacteriophag rearrang hot spot r m suggest restrict adapt driven mobil element rather need adapt divers environ observ appear consist conserv metabol pathway strict nutrit requir two speci context can hypothes hors infect aris contamin contact anim display asymptomat carriag taylorella speci unidentifi environment sourc contamin inde bacteria lack catabol pathway requir surviv mani environ seem unlik taylorella speci abl propag outsid host perspect intracellular facult lifestyl t equigenitali put t asinigenitali assum slow growth rate small number metabol carbon sourc despit usual avail larg varieti carbon sourc mammalian host cell due filter nutrient suppli allow surviv expens slow growth inde order surviv long possibl within infect host cell bacteria withdraw mani basic nutrient essenti host cell metabol host will soon starv death bacteria quickli lose protect nich chromosom invers across replic axi taylorella strain gener characterist x shape symmetr dna dot plot data shown alreadi report numer bacteria seem frequent bacteri evolut although function invers often determin suggest maintain distort replichor induc insert foreign genet element gener genet shuffl creat novel gene pool can enhanc virul environment fit fact major strain specif gene locat within specif region gener associ atyp gc content figur suggest region incorpor genom recent horizont gene transfer time decay genom wide averag gc content moreov given bacteria share vivo nich may consid genit equida microbiom constitut sourc horizont transfer gene screen system mediat resist infect foreign dna genet materi show t asinigenitali genom seem effici equip defend phage integr prophag integr one crispr system one r m system t equigenitali can defend one r m system despit prophag detect t asinigenitali genom t equigenitali genom differ phage phage resist gene content confirm strain speci order determin featur repres speci level may therefor mean term phage interact impact gene transfer potenti identifi numer secret system taylorella genom complet t2ss t3ss t6sss identifi strain t4ss identifi t equigenitali genom protein secret key virul mechan pathogen bacteria crucial pathogenesi molecular bacterium host interact great interest studi system absenc t4ss t asinigenitali partli explain differ virul capac two taylorella speci two main characterist explain differ virul capac t asinigenitali t equigenitali potenti better capac t equigenitali acquir ferric iron host reveal presenc lactoferrin transferrin receptor t equigenitali absent t asinigenitali ii presenc t equigenitali alon hsp60 homolog protein can express bacteri cell surfac act invas factor moreov although virul factor gener consid associ host interact pathogen note mani can also consid fit factor non virul context adhesin exampl import colon manner nich although colon necessarili lead infect diseas can illustr asymptomat carriag t equigenitali t asinigenitali mani mare previous report given close overal similar genom sequenc futur function investig speci specif cdss appear interest particular respect inter speci differ term growth abil anim host prefer pathogen capac addit file context benefici experiment determin whether t asinigenitali like t equigenitali abl invad replic cultur cell order concentr pathogen studi gene belong one speci sequenc two relat speci share similar lifestyl provid insight biolog organ notabl refin expand knowledg phylogeni metabol virul comparison t equigenitali genom led identif sever speci depend gene studi region will help us clarifi intrins differ taylorella genu potenti host specif virul associ factor analysi suggest t equigenitali effici equip t asinigenitali term pathogen relat factor investig requir determin whether justifi declar cem caus t asinigenitali now taylorella genom sequenc annot appear necessari develop molecular genet tool includ transform taylorella order develop function studi mechan involv virul materi methodsbacteri strain cultur conditionsth t asinigenitali strain isol genit tract year old donkey jack stud farm loir et cher franc identif strain maintain french nation refer laboratori cem ans dozulé laboratori equin diseas franc t asinigenitali t equigenitali strain inocul readi use chocol agar media ae chemunex combourg franc plate incub c v v co2 air h h respect genom dna extract previous describ biolog gen iii micropl assay biolog inc http www biolog com perform accord manufactur s recommend micropl incub h c v v co2 air result analyz sequenc assemblywhol genom sequenc t asinigenitali entail combin gs flx solexa pair end sequenc technolog carri beckman coulter genom danver ma unit state genom librari contain kb insert construct read includ pair end read produc use gs flx system give fold coverag genom assembl four larg contig one potenti larg scale scaffold use mira softwar total million read averag length bp gener use illumina solexa genom analyz ii map contig use cons softwar correct error gener technolog order orient four larg contig confirm pcr assembl singl sequenc protein similar kegg protein databas use kegg ortholog pathway assign annotationannot result merg result obtain rast rapid annot use subsystem technolog server trnascan se rnammer follow manual curat overal subsystem categori distribut t asinigenitali t equigenitali genom similar figur s1 crispr loci detect crisprfind secret protein identifi effect analysi http effector org t asinigenitali genom sequenc deposit embl genbank databas access cp003059 access number genom sequenc use compar analys list tabl s13 analysi occurr t asinigenitali t equigenitali larg genom invers pcrthe orient larg chromosom invert region t asinigenitali t equigenitali chromosom depict figur examin la pcr method takara otsu japan use site specif primer pair tabl s3 t asinigenitali strain inclus t equigenitali strain inclus tabl s4 briefli pcr perform follow c min one cycl c sec c min cycl c min one cycl amplifi fragment separ use agaros gel electrophoresi visual ethidium bromid stain electron microscopytaylorella cultur rins pb ph fix glutaraldehyd cacodyl buffer m ph overnight c fixat cell sediment thermanox coverslip coat poli l lysin cell rins cacodyl buffer m ph presenc m sucros post fix hour osmium tetroxyd cacodyl buffer m ph presenc m sucros c protect light cell rins cacodyl buffer m ph presenc m sucros cell dehydr progress bath ethanol critic point dri cpd leica microsystem cell sputter platinum observ jeol 6400f scan electron microscop jeol ltd tokyo japan support informationfigur s1subsystem distribut cdss t asinigenitali mce3 t equigenitali mce9 rast subsystem base annot success categor predict code sequenc t asinigenitali mce3 subsystem t equigenitali mce9 subsystem overal subsystem categori distribut t asinigenitali mce3 t equigenitali mce9 similar variat includ rna metabol cell wall capsul amino acid deriv docx click addit data file tabl s1t equigenitali mce9 specif cdss gene homolog t asinigenitali mce3 reciproc fasta use minimum cutoff amino acid similar sequenc xlsx click addit data file tabl s2t asinigenitali mce3 specif cdss gene homolog t equigenitali mce9 reciproc fasta use minimum cutoff amino acid similar sequenc xlsx click addit data file tabl s3primer use orient analysi larg genom invers region taylorella strain docx click addit data file tabl s4taylorella strain use studi larg genom invers docx click addit data file tabl s5characterist crispr loci found t asinigenitali mce3 sequenc similar crispr spacer spacer similar determin blastn ncbi nucleotid collect descript origin blast e valu indic similar found databas xlsx click addit data file tabl s6result biolog gen iii microplatetm growth assay t asinigenitali mce3 t equigenitali mce9 xlsx click addit data file tabl s7list predict transport system t asinigenitali mce3 t equigenitali mce9 xlsx click addit data file tabl s8list gene potenti involv t asinigenitali mce3 t equigenitali mce9 respiratori capac xlsx click addit data file tabl s9predict gene composit secret system t asinigenitali mce3 t equigenitali mce9 xlsx click addit data file tabl s10t asinigenitali mce3 secret protein accord signalp predict xlsx click addit data file tabl s11t equigenitali mce9 secret protein accord signalp predict xlsx click addit data file tabl s12put transcript regul two compon signal transduct system identifi taylorella speci xlsx click addit data file tabl s13genbank access number taxon number genom use phylogenet analysi docx click addit data file', 'sulin like growth factor ii igf ii import regul growth metabol human anim adult human almost igf bound insulin like growth factor bind protein igfbp addit modul igf bioavail exert biolog effect adult human igf circul mainli ternari complex bound igfbp igfbp acid labil subunit igfal ternari complex prolong half life igf thu major determin igf concentr igf system well describ cat indic import differ cat human understand igf system cat improv clinic diagnos benefici abl measur igf ii igfbp felin medicin igf mainli analyz diagnosi growth hormon disord also research igf ii igfbp routin analyz clinic practic knowledg commerci valid assay cat larg variabl human igf immunoassay report colleg american pathologist cap profici test program igf demonstr interlaboratori variabl cv septemb march mass spectrometri base method demonstr better reproduc cv one studi demonstr larg variabl measur felin igf four non cat specif immunoassay appli human immunoassay analysi sampl speci might caus problem includ weak reactiv unwant cross reactiv assay therefor need thoroughli valid use measur igf immunoassay difficult due interfer igfbp may caus fals high fals low valu depend assay target mass spectrometri base method attract altern immunoassay approach restrict select speci time consum expens work produc affin reagent circumv concept target select peptid precursor quantif base fragment peptid target ms usual perform tripl quadrupol refer select reaction monitor multipl reaction monitor srm mrm time consum difficult part srm mrm method develop find good precursor product ion pair late altern approach refer parallel reaction monitor prm develop quadrupol orbitrap mass spectromet prm analysi transit target precursor measur select fragment quantif done post acquisit combin high select quadrupol ms high resolut orbitrap ms make good method target proteom complex matric serum plasma commonli use strategi absolut quantif srm mrm experi includ synthet heavi isotop label refer peptid studi recent launch product name qprest use intern standard qprest amino acid long sequenc segment human protein heavi isotop label 15n 13c lysin arginin develop within human protein atla project qprest digest togeth sampl give potenti advantag incomplet unspecif digest corrupt result can issu use synthet isotop label peptid similar reagent market call qconcat construct qconcat artifici protein consist tryptic peptid sever protein sequenc variant qconcat avail includ reagent natur flank sequenc qprest produc alreadi exist librari well valid construct cover human protein code gene human sever quantit mass spectrometri base method set determin igf ii igfbp public srm mrm top approach recent also shown mass spectrometri base method decreas interlaboratori varianc compar affin base method regard speci mass spectrometri base quantif studi publish igf hors plasma serum best author knowledg mass spectrometri base quantif studi publish felin igf ii igfbp aim studi therefor set quantit target mass spectrometri method igf ii igfbp igfbp felin sera demonstr prm base strategi enabl accur quantif four target protein addit qprest origin develop repres human protein shown use intern standard also applic concern felin protein materi methodschem reagentsacetonitril acn aceton formic acid fa purchas merck darmstadt germani ammonium bicarbon nh4hco3 urea dithiothreitol dtt iodoacetamid iaa obtain sigma aldrich st loui mo usa tryptic digest trypsin sequenc grade modifi promega madison wi usa use ultrapur water prepar milli q water purif system millipor bedford ma usa felin serum sampl gel fraction felin serumapprov blood sampl cat given swedish ethic committe c301 swedish board agricultur blood sampl centrifug minut room temperatur serum frozen c use serum one cat separ size exclus chromatographi superdex column ge healthcar littl chalfont u k acid condit separ igf igfbp protocol publish mohan baylink follow except sampl incub m acet acid contain m nacl minut load onto column short ml serum dilut ml acet acid nacl solut incub minut room temperatur filter remov particl whatman rezist μm ge healthcar volum ml sampl load onto column elut ml min fraction collect everi second minut dri speedvac system commerci avail igf elisa mediagnost reutlingen hous igf ii assay use immunoreact measur fraction three gel fraction fraction ii iii select analysi mass spectrometri total seven felin sera sampl includ studi g sampl chosen repres cat potenti differ level target protein three sampl collect healthi cat c three sampl cat diabet mellitu d f sampl f collect insulin treatment cat e final sampl cat diabet mellitu diagnos acromegali includ sampl g sampl g fraction protein standardsto abl match tryptic peptid qprest felin sequenc emboss needl use sequenc align human felin amino acid aa sequenc see fig qprest contain peptid match felin igf ii qprest22489 igfbp qprest23429 igfbp qprest23781 qprest23782 isotop puriti peptid puriti obtain atla antibodi stockholm sweden igf two peptid gpetlcgaelvdalqfvcgdr lemycaplkpak synthes heavi label 15n 13c lysin arginin isotop puriti peptid puriti purchas new england peptid refer neptun peptid gardner ma usa human recombin igf igf ii protein purchas immunolog biochem testsystem binzwangen germani human control serum specifi concentr igf control ks2 valid mediagnost igf e20 elisa purchas mediagnost reutlingen germani journal pone g001fig 1homolog studi four select cat protein human analogu human felin amino acid sequenc qprest sequenc underscor human sequenc igfbp two avail qprest igf ii igfbp one tryptic peptid qprest match peptid found felin sequenc market bold ital green peptid use quantif red one evalu use igf tryptic peptid qprest match felin peptid blue peptid synthet neptun peptid use quantif red peptid evalu use shorter matur protein mark igf igf ii similar score emboss needl present sequenc solut tryptic digestionth protein content felin sera measur bradford protein assay bio rad laboratori hercul ca usa aliquot correspond approxim μg total protein taken solut digest volum adjust m nh4hco3 ph total volum μl qprest igfbp spike final concentr fmol μl respect qprest igf ii spike fmol μl sampl sonic minut μl mm dtt ad sampl kept c min reduc protein irrevers carbamidomethyl cystein μl mm iaa ad follow min incub room temperatur dark digest trypsin w w ad sampl incub night c heavi label synthet peptid spike final concentr fmol μl tryptic digest sampl divid aliquot correspond μg protein aliquot desalt ziptip c18 column merck millipor aliquot dri speedvac system re dissolv μl fa tip activ x μl acn equilibr x μl fa sampl coupl matrix repeat cycl μl sampl load tip wash x μl fa final sampl elut μl acn fa cycl aspir dispens desalt sampl dri speedvac system analysi nanolc ltq orbitrap mass spectrometri peptid aliquot re dissolv μl fa milli q water protocol adjust gel fraction felin serum sampl amount dtt iaa reduc μl ziptip c18 column step exclud sinc pre purif sampl obtain size exclus chromatographi step human control serum prepar twice exactli way felin sera sampl two differ analyst shotgun nanolc ltq orbitrap ms ms analysisonlin nano lc separ obtain easi nlc ii system thermofish volum μl sampl load onto pre column easi column cm inner diamet μm μm c18 a1 thermofish scientif maximum pressur bar peptid elut onto easi column cm inner diamet μm μm c18 a2 thermofish scientif use separ flow rate nl min use mobil phase milli q water fa b acn fa set separ min step gradient b b min follow min wash step b use easi nlc ii system connect via nano flex ion sourc ltq orbitrap velo pro etd mass spectromet thermofish scientif spray voltag set kv instrument oper data depend mode automat switch high resolut mass spectrum low resolut ltq system control ltq tune plustun xcalibur survey scan perform m z resolut m z abund ion peak cid fragment full scan cycl screen done charg state dynam exclus set second mass window precursor ion select set m z ms ms normal collis energi activ time ms activ q use fragment scan low pressur cell ion trap detect secondari electron multipli nanolc q exact plu prm analysisth prm analys perform q exact plu orbitrap mass spectromet thermofish scientif easi nlc system thermofish scientif use peptid separ column ion sourc analog use easi nlc ii system shotgun set flow rate nl min use mobil phase milli q water fa b acn fa use separ four μl tryptic digest felin serum sampl inject min step gradient b b min b b min follow min wash step b use system control q exact plu tune xcalibur prm method combin two scan event start full scan event follow target ms ms doubli tripli charg precursor ion schedul inclus list min retent time window full scan event employ m z mass select orbitrap resolut m z automat gain control agc target valu maximum fill time ms target ms ms run orbitrap resolut m z agc target valu maximum fill time ms target peptid isol use m z unit window fragment perform normal collis energi nce ev repeat charg state regard signal intens chosen select peptid total nine peptid correspond heavi peptid compris inclus list differ two charg state obviou kept analysi felin sera tabl journal pone t001tabl 1target peptid includ prm method bold underscor peptid use final quantif c termin arginin r lysin k heavi label cystein carbamidomethyl fragment select quantif given fragment singli charg igf m z th chargesequencepositionrt min fragments769 gpetlcgaelvdalqfvcgdr light 5y4 y5 y6 y7 y10 b9773 gpetlcgaelvdalqfvcgdr heavi lemycaplkpak light lemycaplkpak heavi lemycaplkpak light lemycaplkpak heavi lem ycaplkpak light lem ycaplkpak heavi 6igf ii m z th chargesequencert min giveeccfr light 8y3 y4 y5 y6 y7 b3590 giveeccfr heavi 8igfbp 3rt min m z th chargesequence506 eteygpcr light 0y2 y4 y5511 eteygpcr heavi 0igfbp m z th chargesequencert min gvclnek light gvclnek heavi eheepttsemaeetyspk light eheepttsemaeetyspk heavi fvggaentahpr light fvggaentahpr heavi fvggaentahpr light 1y2 y7 y10422 fvggaentahpr heavi qeseqgpcr light qeseqgpcr heavi hmeaslqelk light hmeaslqelk heavi hmeaslqelk light hmeaslqelk heavi 7data analysisprotein identif shotgun run perform use proteom discover version thermofisch scientif search perform use sequest ht includ percol search done felin refer proteom without isoform taxonomi download www uniprot org paramet search set fix modif carbamidomethyl c variabl modif deamid n q oxid m precursor mass toler ppm fragment mass toler da maximum two miss cleavag site s n threshold set search result valid use percol fals discoveri rate fdr use minimum two uniqu peptid per protein use identif data analysi quantif prm run skylin softwar use quantif base sum area curv auc three six fragment select peptid ratio sampl peptid fragment heavi isotop peptid fragment sampl measur three time mean standard deviat determin concentr calcul determin linear limit detect limit quantificationqprest longer neptun peptid use spike experi determin linear limit detect lod limit quantif loq target protein appli optim prm method qprest digest thereaft spike digest cat sera final concentr fmol μl neptun peptid spike sampl without prior treatment final concentr fmol μl respect sampl analyz three replic run lod loq calcul base linear regress follow formula lod 3sa b loq 10sa b sa standard deviat y intercept b slope standard dilut curv skylin softwar appli extract auc fragment built tool data analysi microsoft excel use perform linear regress statist evalu resultssampl screen intern standard selectionth aim studi set target mass spectrometri method quantif igf igf ii igfbp igfbp felin sera sinc felin protein standard avail gel fraction perform concentr target protein remov interf abund protein target protein classifi uncharacter protein uniprot databas therefor import valid sequenc prior peptid select guidanc result elisa run target igf ii three gel fraction select mass spectrometri analysi shotgun analysi ltq orbitrap velo pro etd mass spectromet result number detect protein four target protein among identifi one see tabl support inform s1a s1c tabl detect sequenc coverag igf igf ii igfbp respect thu result confirm part uncharacter sequenc show number peptid potenti use quantif journal pone t002tabl 2result shotgun analys gel fraction cat sera sampl fraction ifract iifract iiitot number detect proteins755027igf ipresentpresentpresentigf iinot presentpresentpresentigfbp 3presentnot presentnot presentigfbp 5presentnot presentnot presentan addit object studi explor human deriv qprest s use intern standard quantif cat protein align human canon sequenc use felin sequenc reveal sequenc matur form igf aa ident human sequenc matur form igf ii aa differ aa human sequenc first gap felin igfbp sequenc consid similar felin human protein moreov demonstr three four target protein match tryptic peptid least one qprest fig igf ii igfbp one felin tryptic peptid per protein match sequenc five match tryptic peptid origin two qprest s identifi igfbp therefor conclud qprest s use intern standard quantif three protein igf match qprest avail even though matur human felin igf protein ident therefor type intern standard requir quantif igf synthet heavi isotop label peptid neptun select method optimizationgiven sequenc similar recombin human igf igf ii protein use method optim prm method q exact plu orbitrap ms minut lc gradient appli ensur good separ tryptic peptid sever paramet includ agc maximum inject time resolut isol window nce optim final set method can found experiment section inclus list doubli tripli charg peptid base tryptic qprest peptid neptun peptid set includ prm method tabl care evalu one peptid per protein select quantif see tabl peptid igf provid six ms ms fragment use quantif overal better perform igf observ methionin oxid occur peptid igf tabl result differ run igf ii peptid also produc six reproduc fragment igfbp peptid produc one domin fragment total three fragment use quantif igfbp challeng protein quantifi sinc lowest concentr peptid igfbp select quantif base spectrum reproduc signal intens optim method evalu linear limit detect lod limit quantif loq spike experi tryptic digest cat serum perform heavi label peptid e qprest s neptun peptid ad known amount normal toward correspond nativ peptid linear regress normal signal four intern standard peptid result correl coeffici igf igf ii igfbp igfbp respect fig lod loq attomol μl pm level establish sampl matrix e tryptic digest cat serum see tabl detect limit also recalcul correspond concentr nativ serum assum tryptic digest protein sampl matrix complet calcul shown support inform s1 file journal pone g002fig 2intern standard dilut seri qprest neptun peptid spike cat serum analyz prm method differ concentr ratio synthet nativ peptid plot spike concentr journal pone t003tabl 3lod loq valu quantifi peptid dilut felin serum correspond valu nativ serum igf iigf iiigfbp 3igfbp 5dilut serumn serumdilut serumn serumdilut serumn serumdilut serumn serumlod fmol μl 1528loq fmol μl 5193quantif felin serafin concentr igf igf ii igfbp igfbp determin felin serum sampl get indic repeat method one sampl analyz three replic two differ prepar six measur gave accept rel standard deviat valu igf igf ii igfbp igfbp respect concentr four target protein determin three replic run shown seven cat sera sampl fig raw data calcul given support inform s2 file observ igf ii concentr higher igf concentr non acromegal cat serum cat suffer acromegali contain significantli higher level igf igfbp igfbp serum healthi diabet cat igf ii elev cat journal pone g003fig 3quantifi concentr four target protein seven sampl felin sera averag concentr standard deviat given n sampl b g n sampl sampl c sampl healthi cat d e collect cat diabet mellitu insulin treatment sampl f collect cat sampl e insulin treatment sampl g collect cat acromegali discussionin studi prm method set quantif four felin growth relat hormon igf ii igfbp previous establish method measur felin igf ii igfbp igfbp knowledg present method first one develop quantifi four protein cat serum one advantag ms base method immunoassay target protein measur within experiment run reduc variat due methodolog amount serum need analysi can great advantag cat small anim four target protein classifi uncharacter protein uniprot databas howev shotgun analysi confirm part sequenc reveal potenti target peptid studi first one investig applic qprest quantif protein non human sampl felin serum advantag use qpreststm protein standard includ qconcat digest togeth target protein compens incomplet cleavag addit protein express e coli therefor rel cheap produc purchas digest sever peptid avail quantif even though qprest human origin high similar cat human target protein confirm fig support use reagent felin studi repeat result obtain three target protein quantifi use qprest howev limit quantifi non human protein demonstr studi gener fewer tryptic peptid can select quantif sole one tryptic fragment avail two protein igf ii igfbp qprest still consid good option sinc produc alreadi exist librari well valid construct built sequenc known low sequenc similar protein human proteom studi demonstr natur flank sequenc improv perform qconcat synthet peptid tryptic peptid deriv qprest flank nativ human sequenc felin human sequenc similar proxim cleavag site fig advantag mani valid ms base method reli quantif one singl tryptic peptid surprisingli match qprest found igf despit fact matur human felin igf protein ident explan qprest produc toward sequenc e domain pro igf part matur igf sampl studi select aim analyz serum healthi cat well cat igf routin measur clinic practic e diabet acromegal cat protein concentr determin categori sampl prm method deliv detect limit attomol μl pm level sampl matrix analysi igf igf ii igfbp gave concentr calcul loq investig cat serum sampl lowest concentr determin igfbp five seven sampl lod protein sampl acromegal cat sampl g gave valu calcul loq thu exact quantiti protein determin significantli higher concentr measur serum acromegal cat peptid use quantif igfbp elut earli gradient might therefor set affect void volum gold standard method analysi igf cat refer materi avail henc difficult state true concentr explor accuraci prm approach human control serum use igf elisa specifi igf concentr ng ml analyz sinc present method optim igf peptid common human cat protein method well applic analysi human sampl analysi result valu within given rang support inform s3 file recent approach base cleavabl report peptid recalibr therebi determin exact concentr peptid standard suggest worth mention initi amount qprest determin similar method e normal toward well defin tag standard present studi sera six differ cat analyz make difficult draw conclus clinic use nevertheless cat acromegali expect higher igf healthi cat healthi human igf ii concentr higher igf also observ non acromegal cat present studi acromegal cat igf ii elev compar healthi cat remain three protein show high concentr human igf ii less gh depend igf concentr acromegal peopl shown increas decreas regul growth relat protein cat yet explor may facilit use ms wherebi mani compon igf system can identifi forese present mass spectrometri base method valuabl tool better understand complex system use prm protein can easili ad list protein quantifi suitabl peptid quantif identifi support informations1 tableshotgun screen three fraction cat serum obtain size exclus chromatographi result analysi fraction ii iii summar tabl s1a b c respect four target protein high light green data match peptid shown tabl obtain proteom discover use standard format pdf click addit data file s1 filecalcul paramet determin linear rang limit detect limit quantif first sheet show raw data area curv auc fragment appli record calibr curv follow four sheet show statist evalu igf igf ii igfbp igfbp respect skylin softwar appli extract auc fragment built tool data analysi microsoft excel use perform linear regress statist evalu xlsx click addit data file s2 filecalcul concentr seven differ cat sera peak area fragment use quantif shown protein concentr target protein calcul xlsx click addit data file s3 fileanalysi human control sampl control sampl prepar two differ analyst analyz duplic experi individu measur result valu well within specifi rang ng ml xlsx click addit data file', 'label individu viral protein fusion fluoresc molecul conjunct advanc fluoresc imag techniqu greatli expand possibl investig viru cell interact includ live cell imag approach studi dynam intracellular event well super resolut fluoresc microscopi method surmount diffract barrier light microscopi allow analysi fluoresc label structur resolut nm review see human immunodefici viru hiv deriv label fusion fluoresc protein fp structur polyprotein gag accessori protein vpr viral integras respect success employ analyz cell entri well particl assembl hiv live cell fluoresc microscopi e g review sub diffract microscopi employ proof principl studi display distribut mobil hiv gag molecul plasma membran viru produc cell fp becom invalu tool cell biolog virolog properti present disadvantag limit use live cell microscopi fp inferior mani modern synthet fluorophor respect quantum yield photost restrict time resolut durat observ live cell experi ii although continu increas rang fp differ spectral properti avail color rang limit particular blue far red rang fp display photophys properti render suitabl sub diffract microscopi method iii fluorophor fp display rel slow matur kinet consequ newli express fp molecul initi undetect fluoresc microscopi limit use puls chase experi iv fp obligatori multim may affect function cellular fusion partner v final experiment setup cell biolog often involv multi color approach use sever differenti label protein case fp fusion protein individu express construct clone character order obtain differ spectral variant protein interest genet encod non fluoresc label can specif stain use synthet fluoresc dye offer greater flexibl choic label well known exampl type motif six twelv amino acid long tetracystein tc tag attract due small size tc tag employ gener tag hiv deriv howev disadvantag system includ high degre intracellular background stain depend stain redox state tag limit select compat fluoresc dye therefor decid explor use call snap tag label hiv snap tag genet encod label slightli lower molecular mass fp kda deriv mammalian dna repair protein o6 alkylguanin dna alkyltransferas stabli transfer benzyl moieti o6 benzylguanin bg substrat activ site therebi perform self label reaction fluoresc label deriv bg offer substrat analog fp encod sequenc snap tag code sequenc can genet fuse code sequenc protein interest result fusion protein non fluoresc can label upon addit substrat choic avail bg coupl dye repres wide varieti synthet fluorophor good quantum yield photost reactiv snap tag larg independ natur attach fluoresc probe avail synthet dye coupl bg can principl use set describ gener character hiv deriv carri snap tag within main structur polyprotein gag hiv gag necessari suffici format releas viru like particl express cell hiv assembl process gag orchestr incorpor virion compon interact cellular factor requir particl releas fate gag replic cycl hiv studi varieti method review see e g howev elucid especi dynam interact host cellular protein will major interest snap tag hiv deriv hivsnap establish studi function respect viru cell fusion particl assembl allow viru replic tissu cultur gag snap specif stain viral cellular context hivsnap thu repres versatil tool studi hiv cell interact result discussionfor introduct snap tag hiv structur polyprotein gag made use fact gag modular protein consist individu fold subdomain separ flexibl linker region proteolyt process viral proteas pr specif site within linker region trigger morpholog rearrang matur gag subunit matrix ma capsid ca nucleocapsid nc p6 within virion essenti virion infect cryo electron microscopi shown within immatur virion gag molecul arrang parallel manner underneath viral membran region separ globular ma ca domain gag form layer low protein densiti previous demonstr foreign amino acid sequenc can insert within region without affect gag express assembl proteolyt matur small insert toler without affect viru replic tissu cultur exploit construct variou modifi hiv deriv us other base clone snap tag code sequenc codon amino acid ma outlin figur four c termin residu ma retain c termin snap order allow effici process downstream ma snap hiv pr hivsnap figur snap tag deriv gener context infecti hiv 1nl4 base provir plasmid yield pnlcsnap well context non replic compet deriv pchiv lack viral long termin repeat region encod hiv protein except nef pchivsnap addit construct hiv 1nl4 deriv carri snap tag ma ca flank two pr cleavag site pnlcisnap hivisnap figur case egfp label deriv analog construct pnlcegfp display robust replic tissu cultur introduct addit pr cleavag site upstream egfp domain report display nearli wild type wt replic kinet least mt t cell viru particl prepar ultracentrifug tissu cultur supernat 293t cell transfect pnlc4 pnlcsnap pnlcisnap respect analyz immunoblot hiv protein composit proteolyt process polyprotein well presenc snap tag fusion protein particl display expect viral protein composit modifi gag snap polyprotein effici process particl matur figur b data shown fusion protein ma snap kda reactiv immunostain antiserum rais hiv ma well anti snap antiserum shown present hivsnap particl wherea two separ band correspond ma kda snap kda detect immunoblot hivisnap sampl electron micrograph cell transfect either wt figur c snap tag provir plasmid figur d show viral bud profil well immatur matur virion cell transfect snap tag deriv display higher number earli bud structur similar result obtain egfp tag hiv deriv sinc moder reduc amount viru particl pellet supernat hiv wt pchivsnap transfect cell harvest h post transfect see figur black bar phenotyp may explain delay bud kinet result increas number bud structur detect steadi state repres still imag matur hivsnap particl found display wt morpholog figur d journal pone g001figur 1construct character hiv deriv carri snap tag within gag scheme hiv gag open read frame indic snap tag gene insert ma ca code region expand region display junction gag bold snap tag grey box amino acid sequenc separ short linker sequenc ital hivsnap hivisnap construct respect arrowhead indic cleavag site hiv pr b immunoblot analysi wt modifi virion particl releas supernat 293t cell transfect indic provir plasmid purifi ultracentrifug subject immunoblot analysi use indic antisera describ method posit molecular mass standard indic left kda c d morpholog hiv hivsnap virion 293t cell transfect pnlc4 c pnlcsnap d respect fix h post transfect embed em analysi describ method sampl analyz thin section electron microscopi journal pone g002figur 2replic capac snap tag hiv deriv influenc snap tag insert distinct step hiv replic 293t cell transfect pchiv pnlc4 hiv pchivsnap pnlcsnap hivsnap eqimolar mixtur plasmid hivsnap hiv pnlcisnap hivisnap respect virion harvest supernat h post transfect valu normal mean respect control white bar entri effici pchiv deriv particl purifi ultracentrifug sucros cushion measur jc53 cell use β lactamas virion fusion assay describ method mean valu standard deviat triplic sampl shown n d determin light grey bar infect r l u per ng ca pnlc4 deriv particl determin titrat viur supernat tzm bl report cell follow analysi luciferas activ describ method bar repres mean valu standard deviat independ experi black bar determin releas effici amount p24 ca releas supernat h post transfect measur quantit immunoblot divid sum p24 supernat cell lysat mean valu standard deviat three independ experi shown b replic capac hiv deriv equal amount viru ng p24 equival produc 293t cell transfect pnlc4 hiv open circl pnlcsnap hivsnap fill circl pnlcisnap hivisnap fill triangl pnlcegfp hivegfp fill squar respect use infect mt cell indic time point post infect amount ca releas supernat determin quantit dot blot analysi mean valu standard deviat six replic infect shown c retent snap tag sever round replic particl tissu cultur supernat infect mt cell day post transfect analyz immunoblot use indic antisera posit molecular mass standard indic left kda character function properti modifi viru fp label deriv hivegfp shown infecti tissu cultur infect significantli reduc compar wt hiv sustain multipl replic round tissu cultur co transfect cell equimolar mixtur pnlcegfp wt pnlc4 result product mix particl display wt singl round infect introduct foreign sequenc ma ca domain yield hiv deriv vari level infect rang wt infect complet lack particl product unpublish observ despit trend toward smaller insert gener favor observ direct correl molecular mass insert domain infect modifi viru studi compar hivsnap hivisnap wt viru well mix particl carri approxim equimolar amount gag gag snap respect respect effici individu replic step figur order determin effici cytoplasmat entri made use call beta lactamas virion fusion assay blam assay hiv cell fusion assay reli report virion carri beta lactamas blam cytoplasmat deliveri blam upon viru cell fusion monitor load target cell fluoresc substrat ccf chang fluoresc properti upon blam mediat cleavag report particl prepar tissu cultur supernat 293t cell co transfect plasmid pmm310 code vpr blam pchiv pchivsnap equimolar mixtur respect fusogen particl test incub jc53 cell equal amount viru follow ccf stain fluorimetr analysi describ method section found pchivsnap deriv particl hivsnap display compar fusion effici unlabel counterpart hiv mix virion hivsnap hiv respect figur white bar virion infect analyz incub tzm bl report cell particl prepar 293t cell transfect pnlc4 pnlcsnap mixtur plasmid pnlcisnap respect analysi hiv induc luciferas report activ h post infect reveal hivsnap hivisnap virion approxim fold reduc infect compar wt hiv subtl increas infect hivisnap virion compar hivsnap found non signific p determin student s t test full infect tzm bl cell howev restor mix particl figur gray bar sinc hivsnap impair viru cell fusion decreas infect indic defect replic step cytoplasmat entri viral gene express late stage viru replic analyz quantit ca releas supernat rel total amount gag express transfect cell figur black bar hivsnap display signific impair bulk particl releas decreas p determin student s t test observ hivisnap wt properti restor hivsnap upon co transfect equimolar amount wt plasmid order test replic capac modifi viru multipl round infect t cell line particl gener transfect 293t cell use pnlc4 pnlcsnap pnlcisnap respect use infect mt cell amount p24 ca releas tissu cultur supernat monitor day post infect figur b replic kinet hivsnap fill circl significantli delay compar wt hiv open circl compar level releas viru reach day post infect introduct addit pr cleavag site ma snap moieti hivisnap triangl result increas replic capac condit sinc observ signific function improv hivisnap compar hivsnap assay focus hivsnap character fact tag remain associ viral protein even proteolyt gag matur advantag mani experiment setup particular analys hiv entri contrast analog construct hivegfp replic detect level cell line fill squar hivsnap can employ studi viru cell interact infect cell immunoblot analys hivsnap tissu cultur supernat day post infect figur c reveal snap tag gag deriv indic modifi viru stabl sever round replic analys carri use modifi viru absenc snap substrat order test whether stain gag snap affect virion infect purifi hivsnap virion treat tmr star dmso respect test infect titrat tzm bl report cell describ method s1 stain effici analyz parallel confoc microscopi glass bound particl counterstain antiserum rais hiv ca found particl prepar give rise approxim doubl label virion moder impair singl round infect compar dmso control viru wild type hiv use neg control stain tmr star also display similar reduct infect upon tmr star treatment indic reduct due treatment procedur rather presenc ma snap tmr star figur s1 suitabl snap tag label specif detect intracellular hiv gag demonstr transfect hela cell pchivsnap follow stain transfect cell bg tmr star figur co transfect previous character hiv deriv pchivegfp allow effici detect gag use fluoresc microscopi techniqu employ investig snap tag stain specif intracellular local gag snap tmr star reactiv gag protein co local gag egfp viru express cell figur iii v indic gag snap show correct intracellular local gag snap molecul arrang gag assembl access stain procedur specif tmr star stain transfect cell demonstr lack signal non transfect cell figur white asterisk test applic tag physiolog context t cell line c8166 infect wt hiv hivsnap respect stain snap tag reactiv dye tmr star day post infect e sever round viru replic visual infect cell perform counterstain antiserum rais hiv ca unspecif stain tmr star detect cell infect wt hiv figur b contrast c8166 cell infect hivsnap virion display specif stain gag snap fluoresc snap substrat figur c stain absent cell reactiv ca antiserum figur c white asterisk stain pattern tmr star differ somewhat pattern reveal immunolabel tmr star label display higher number distinct punctuat signal plasma membran viru produc cell figur c compar left middl panel explain impair antibodi access epitop within ca assembl viral structur known affect detect intracellular gag assembl immunostain immunoprecipit approach contrast assembl gag snap appear access specif stain yield faith represent intracellular gag distribut conclud hivsnap variant suitabl live cell imag analys infect t cell journal pone g003figur 3specif intracellular stain snap tag gag protein intracellular detect snap tag gag protein transfect hela cell hela cell transfect equimolar mixtur pchivegfp pchivsnap label h post transfect use bg tmr star describ method nuclei stain hoechst figur show confoc imag mid section repres cell green channel red channel ii overlay green red blue channel iii scale bar µm pearson s coeffici green red channel equal imag iv repres enlarg section iii v fluoresc intens profil green red channel along white line shown iv b c intracellular detect snap tag gag protein infect c8166 t cell c8166 cell infect hiv b hivsnap c respect produc transfect 293t cell day post infect cell stain bg tmr star well immunofluoresc use antiserum rais hiv ca nuclei stain hoechst figur show confoc imag mid section immunofluoresc left panel tmr star middl panel overlay αp24 tmr star hoechst signal right panel scale bar µm white asterisk non infect cell presenc snap tag can label varieti synthet dye also make fusion protein amen visual super resolut fluoresc microscopi techniqu stimul emiss deplet sted microscopi stochast optic reconstruct microscopi storm allow local fluoresc molecul analysi label structur resolut well diffract limit given protein interest can specif label suitabl fluorophor genet encod snap tag conjunct appropri dye recent demonstr suitabl sted storm analys live cell hivsnap thu provid basi analysi sub viral structur live cell proof principl appli direct storm dstorm variat storm reli light induc revers photoswitch fluorophor visual purifi hivsnap particl figur c well membran hivsnap express a3 t cell figur d f tirf total intern reflect fluoresc mode shown figur c dstorm imag purifi virion resolv individu punctuat signal averag full width half maximum nm good agreement averag diamet hi virion nm determin cryo electron microscopi dstorm imag plasma membran hivsnap express t cell reveal individu bud site diamet around nm close adjac bud site resolv dstorm analysi figur e f journal pone g004figur 4visual hivsnap virion bud site super resolut tirf microscopi c high resolut microscopi stain hivsnap particl hivsnap particl purifi ultracentrifug supernat transfect 293t cell bound glass coverslip stain use snap surfac sum molecul tirf dstorm b fluoresc imag region interest shown white box indic particl magnifi c scale bar µm c cross section profil deriv dstorm imag individu hiv particl scale bar nm d f hiv bud site plasma membran hivsnap express t cell a3 cell nucleofect pchivsnap stain snap surfac imag describ materi method sum molecul tirf d dstorm e fluoresc imag cell shown f magnifi view box region dstorm imag shown d scale bar nm conclus consid snap tag base label strategi present use expans exist panel fluoresc hiv deriv versatil tool studi differ aspect viral life cycl microscop techniqu combin advantag genet label suitabl live cell analys sensit versatil stain use synthet fluoresc dye fact snap tag molecul can either stain variou fluoresc dye quench non fluoresc substrat allow applic sequenti label protocol puls chase approach may appli analysi intracellular gag traffick site synthesi direct imag studi gag traffick far hamper slow matur kinet fp impair visual newli synthes gag molecul tc tag gag deriv use circumv problem studi use label yield contradict result might explain non specif intracellular stain biarsen dye faster specif stain use hivsnap surmount shortcom therebi complement biochem analys gag distribut addit possibl chose differ color dye render hivsnap versatil tool multi color applic e g investig dynam interact hiv gag individu host cell factor furthermor snap tag viral protein can label synthet dye whose photochem properti tailor requir super resolut microscopi techniqu summari viru deriv describ open varieti possibl will allow detail investig hiv cell interact modern microscop techniqu materi methodsplasmid cell linesth snap tag code sequenc amplifi pcr pss26m covali primer introduc clai restrict site end ggcgcatcgatccgcccagcccaggcttgcc cagggatcgataggcggcatggacaaagactgcgaa respect result fragment subclon pbsmaj clai harbour uniqu clai restrict site posit nl4 sequenc result pbsmajsnap bsshii sphi fragment compris modifi ma sequenc transfer pchiv pnlc4 context obtain pchivsnap pnlcsnap respect construct pnlcisnap snap tag code sequenc amplifi pcr use forward revers primer introduc mlui xbai restrict site respect tgtacaaacgcgtatggacaaagactgc ttttggcttctagagcccagcccaggc result fragment insert pnlc igfp deriv pnlc4 addit hiv proteas cleavag site follow gfp introduc c termin ma insert bsshii sphi fragment plasmid hiv gag igfp obtain pnlcisnap 293t hela jc53 tzm bl cell grown dulbecco s modifi eagl s medium dmem glutamax invitrogen supplement u ml penicillin µg ml streptomycin fc c co2 c8166 mt4 a3 cell kept rpmi1640 glutamax supplement u ml penicillin µg ml streptomycin fc transfect carri use polyethyleneimin pei accord standard procedur 293t cell fugenehd roch accord manufactur s condit a3 t cell electropor cm cuvett invitrogen voltag capac µf volum µl serum free medium use gene pulser xcell system bio rad particl prepar immunoblot characterization293t cell transfect provir plasmid use pei h post transfect cell harvest lyse sd sampl buffer tissu cultur supernat preclear filtrat µm filter virion purifi ultracentrifug w w sucros cushion protein cell lysat pellet particl separ sd page acrylamid bisacrylamid acrylamid transfer nitrocellulos membran semi dri blot membran probe indic primari antisera bound antibodi detect quantit immunoblot use licor odyssey system well reagent protocol softwar provid manufactur analysi virion infectivitytzm bl indic cell seed well plate cell well infect one day seed use serial dilut filter tissu cultur supernat form 293t cell transfect pnlc pnlcsnap pnlcisnap respect h post infect luciferas activ measur infect cell determin use steadyglo assay system promega accord manufactur s instruct β lactamas virion fusion assayentri effici determin standard hiv fusion assay briefli viral particl prepar 293t cell co transfect indic hiv provir deriv pmm310 plasmid ratio µg particl concentr determin quantit immunoblot use antiserum rais hiv ca serial dilut viru use infect jc53 cell seed well one day prior infect follow incub c h cell wash co2 independ dmem invitrogen incub h room temperatur use ccf2 geneblaz invitrogen ltd paisley uk accord manufactur s protocol cell fix pfa pb fluoresc intens em nm nm ex nm determin multi well fluorimet tecan safir ratio fluoresc emiss nm emiss nm calcul normal correspond ratio obtain uninfect cell yield rel entri effici replic kinet hiv derivativeshiv hivsnap hivisnap produc transfect 293t cell plasmid pnlc4 pnlcsnap pnlcisnap respect amount p24 ca supernat determin quantit immunoblot supernat correspond ng p24 ca use infect mt cell sampl tissu cultur supernat collect everi day amount p24 supernat determin quantit dot blot procedur briefli µl supernat spot onto nitrocellulos membran use minifold devic whatman serial dilut purifi recombin hiv ca use standard membran dri block skim milk powder tb tween probe rabbit polyclon antiserum rais hiv ca signal detect quantit immunoblot use licor odyssey system well reagent protocol provid manufactur quantit use odyssey softwar intracellular stain gag snaphela cell seed coverslip h prior experi transfect fugene6 roch incub c h snap label cell incub µm snap cell tmr star new england biolab dmem min c wash incub fresh dmem min c allow diffus excess substrat cell fix paraformaldehyd pfa counterstain hoechst embed mowiol c8166 cell infect hivsnap hiv subject modifi protocol solut use condit differ step cell pellet rpm min follow fixat pfa cell adher fibronectin coat cover slip permeabil incub tritonx pb subject intracellular stain use rabbit polyclon serum rais hiv ca alexa488 goat anti rabbit antibodi invitrogen counterstain nuclei perform use hoechst secondari antibodi solut electron microscop analysi cell samples293t cell transfect pnlc4 pnlcsnap respect use fugen hd roch diagnost gmbh mannheim germani h post transfect cell fix process resin embed describ previous section examin zeiss em10 tem imag taken use gatan multiscan camera digit micrograph softwar dstorm analysi virion viru produc cellsparticl purifi supernat 293t cell transfect equimolar mixtur pchiv pchivsnap ultracentrifug sucros cushion particl adher fibronectin coat glass coverslip fix paraformaldehyd pb virus permeabil triton x second block bovin serum albumin bsa pb min stain µm snap surfac neb accord manufactur s instruct analysi hivexpress cell a3 cell electropor µg pchivsnap h post transfect cell transfer labtek well chamber coverglass fix paraformaldehyd pb min fix cell wash permeabil use triton x min block bsa solut min cell stain µm snap surfac accord manufactur s instruct dstorm imag record custom built microscop use experiment protocol describ earlier briefli multi line laser innova 70c coher usa coupl invert microscop ix71 olympu japan fluoresc signal detect use electron multipli charg coupl devic emccd ixon andor ireland appropri filter dichroic ahf germani photoswitch alexa fluor realiz oxygen free aqueou buffer mm mercaptoethylamin ad use two irradi wavelength nm kw cm2 activ nm kw cm2 read imag reconstruct perform use rapidstorm softwar packag dstorm imag shown consist individu superimpos frame sum molecul tirf imag reconstruct sum singl molecul fluoresc intens complet data set support informationfigur s1infect hivsnap virion tmr star stain hiv hivsnap particl purifi ultracentrifug supernat 293t cell transfect pnlc4 pnlcsnap respect incub µm tmr star solvent control dmso h room temperatur unbound dye remov gel filtrat western blot analysi hiv hivsnap particl stain tmr star dmso use indic antisera posit molecular mass standard indic left kda b stain specif effici determin confoc microscopi particl adher fibronectin coat glass coverslip tmr star stain particl fix pfa permeabil triton x block bovin serum albumin pb hiv ca detect immunostain use polyclon sheep anti ca serum alexa488 secondari antibodi repres confoc microscopi imag percentag signal indic channel depict c infect particl determin titrat stain black bar solvent treat white bar particl tzm bl indic cell describ method valu normal amount input viru determin quantit immunoblot analysi compar purifi ca protein standard mean valu standard deviat triplic titrat shown rlu rel light unit tif click addit data file method s1infect hivsnap particl stain doc click addit data file', 'mate partner violenc ipv women crisi post crisi popul import area public health research still nascent stage although data limit avail studi indic individu exposur arm conflict crise may exacerb ipv sever studi find quantit measur qualit perceiv posit associ exposur polit violenc women s vulner experienc ipv exampl cross section studi palestin found marri women partner expos polit violenc significantli like experi physic sexual ipv compar women whose partner expos polit violenc qualit studi caus ipv post conflict sierra leon liberia women believ men particip wit violenc conflict possibl risk factor ipv perpetr prior research posit increas post crisi ipv like result complex interact factor includ limit increas commun violenc shift gender role econom stress displac studi frequenc risk factor ipv crisi post crisi set start emerg littl inform crisi affect women men conceptu ipv experi impact day day live understand need provid import insight cultur appropri tailor ipv prevent respons program côte d ivoir emerg period crisi instabl mid s recent experienc new wave polit violenc displac contest presidenti elect intens fight ensu follow elect member polit parti commit human right abus crime includ murder rape polit persecut span six month least civilian report kill thousand intern displac mani injur wit violenc major case intern displac peopl idp move abidjan live famili previou research popul present studi found unemploy food insecur hous instabl lack social network common concern idp prior commun base research rural côte d ivoir also document high preval ipv among rural women survey women report experienc lifetim ipv past year estim rang current studi make import contribut measur frequenc describ experi ipv urban ivorian popul experienc arm conflict widespread elect relat violenc perspect women men solicit includ descript multipl form ipv experienc women particularli relat health everyday activ shame studi add small grow bodi work ipv post crisi situat materi methodsthi studi sequenti mix method studi first step administ cross section survey urban crisi affect women next focu group discuss conduct women men increas understand experi women describ survey data collect quantit surveyin juli eighti women systemat sampl household abobo neighborhood abidjan côte d ivoir complet one time survey econom autonomi decis make violenc reproduct health post elect crisi survey undertaken part pilot activ endlin survey random control trial occur rural villag abobo neighborhood select survey due concentr crisi relat violenc dens popul low socio econom statu ethnic divers includ idp four abobo s quartier randomli select particip survey research team first met quartier s leader obtain permiss conduct survey household systemat sampl local train ivorian french speak enumer elig women age older invit particip one hundr women approach consent particip due lack time n partner disapprov n anoth reason n yield final sampl particip languag match train femal research assist administ paper base survey concern women s experi differ form ipv socio demograph characterist abobo juli survey assess gender base violenc côte d ivoir adapt three previou studi multi countri studi women s health domest violenc london school hygien tropic medicin violenc health among women asylum seeker hiv ipv prevent trial uganda instrument also contain addit item e g household decis make exposur conflict gaug facet women s live descript statist use examin preval ipv particip socio demograph characterist focu group discussionsten focu group conduct may june n women n men focu group particip identifi commun leader abobo neighborhood collabor intern rescu committe irc commun partner irc intern humanitarian organ establish histori côte d ivoir commun member age invit seri meet irc present purpos studi meet result format six focu group non idp women non idp men idp women idp men idp women idp men elig criteria focu group includ least year old french speak partner interest join focu group discuss four addit gender stratifi focu group form women particip urban save loan associ usla irc group save program adjam treichvil neighborhood share socioeconom popul densiti characterist abobo focu group seven ten compos usla women usla men usla women usla men usla group facilit separ see program particip differ perspect ipv contribut factor solut reduc ipv urban set compar particip two ivorian facilit led group two note taker present interview guid includ semi structur question free list exercis pair wise rank activ explor follow women famili commun impact elect relat violenc b investig women men understand ipv relat shame health impact everyday life free list produc inventori list offer insight salienc item among respond pair wise rank particip ask compar two differ form ipv e g physic ipv econom ipv import two discuss term shame health impact everyday activ methodolog use stimul convers specif form ipv facilit guid interview particip free list pair wise rank process goal pair wise rank necessarili reach consensu among particip rather methodolog tool explor percept thought process regard impact differ form ipv focu group last approxim two half hour focu group discuss record use digit audio record record transcrib verbatim french nativ ivorian french speaker translat english profession translat train bilingu ivorian research compar english translat french transcript confirm accuraci clarifi term specif region atla ti softwar use organ code transcript ground theori approach use data analysi ground theori emphas induct open end approach toward data analysi encourag elimin preconceiv idea shift gener list emerg theme interview transcript code english two research l g s s descript statement creat reflect emerg theme discrep code discuss princip investig j g k f code organ theme across interview iter process review princip investig code team data collect focu group note taker care record free list pair wise rank result free list respons record paper rank result enter matrix survey focu group particip provid sign inform consent prior particip studi receiv ethic approv institut review board yale univers georg mason univers review ivorian nation ethic review board resultsparticip characteristicsa total women complet survey n report male intim partner within last year approxim n partner women polygam marriag idp statu collect part quantit survey advis irc order minim feel stigma among idp quantit data collect conduct close time elect violenc similar survey sampl focu group particip larg partner n idp n seventi six percent focu group respond employ n three student frequenc ipv quantit resultshalf women partner non partner survey sampl report experienc emot physic sexual ipv past year multipl type violenc emot ipv common follow sexual ipv physic ipv nearli one three women report experienc past year physic sexual ipv among partner women push shove kick drag slap someth thrown hit someth common form physic ipv forc sex result threat intimid physic forc sex common type sexual ipv feel frighten humili common form emot ipv among partner women percept ipv qualit resultsdur focu group women men first creat list problem discrimin experi face crisi affect women afterward creat matric discuss differ form ipv relat feel shame overal health abil perform everyday activ result free list activ pair wise rank discuss present activ particip provid time discuss explain provid exampl choic support quot discuss present follow section although consider overlap exist women men gender differ highlight relev free list resultsth free list prompt focu group particip creat list gener problem type ipv violenc discrimin experienc crisi affect women côte d ivoir result gender present tabl journal pone t001tabl 1free list result focu group interview gender n question type problem women affect elect relat violenc face commun totalwomenmenn n n financi problems16 unemploy lost business11 mental health repercuss trauma11 respons manag household10 death famili member6 forc prostitut transact sex5 loss materi goods5 sexual violenc rape non ipv food insecurity4 physic health repercussions3 hous insecurity3 0abandon partner separ divorce3 poor live conditions2 traumat children2 partner unemploy lost business1 0displacement1 physic intim partner violenc ipv 0emot financi ipv1 0question type violenc discrimin crisi affect women usual experi totalwomenmenn n n physic ipv13 econom ipv13 argument partner11 sexual ipv10 emot ipv8 discrimin commun members8 partner control behavior4 0neglect partner3 0discrimin famili members3 discrimin house2 0infidelity2 gener problem face crisi affect women wide rang although financi concern frequent mention problem women men focu group particip follow financi problem unemploy women like name increas respons manag household mental health problem trauma common problem men identifi similar concern crisi affect women although like identifi sexual violenc non intim partner problem women men compar women smaller number women mention hous insecur partner s unemploy physic ipv emot ipv problem face crisi affect women respect men mention area facilit ask particip describ type violenc discrimin crisi affect women usual experi physic econom sexual emot ipv mention focu group women men argument partner discrimin experienc commun member often form name call gossip social exclus also cite problem women men women men mention differ form ipv problem women except sexual ipv mention approxim women men control neglect partner face discrimin household issu identifi women men pair wise rank discuss resultsin pair wise rank activ focu group particip ask compar contrast differ form ipv relat shame health everyday activ exampl facilit prompt group say now go compar type violenc ll tell us shame type woman man beat wife man insult wife will shame situat women question repeat compar type ipv three domain shame health everyday activ result discuss theme ipv shamefocu group particip ask compar type ipv relat feel shame gener women consid emot violenc shame even compar physic sexual ipv exampl ask compar shame associ emot ipv versu sexual ipv one woman comment think insult shame although forc rape pain well insult will happen front peopl don t want sex will will pain batter anyth sexual issu insult s alway thing s stuck follow everywher femal trader quot illustr emot ipv perceiv shame women also shame close tie social stigma felt depend ipv perpetr public privat broad consensu ipv perpetr public shame result social stigma women express concern commun member may gossip lose respect use knowledg ipv way humili insult women therefor decid whether someth shame highli depend wit awar abus exampl insult woman public describ much shame insult woman privat concern highlight follow quot know peopl know happen household keep respect realiz re regularli batter husband lose respect show longer consider concern other eye shame us re batter front femal hairdress idp furthermor particip resid citi presum anonym due larger popul howev often live close cramp area sens privaci neighbor hear wit see result violenc commonli mention concern women idp urban environ lack privaci contrast experi rural region exampl one femal idp rais issu shame neighbor mock result ipv anoth discuss felt less social support differ experi move abidjan although urban area live common courtyard hous kind hous common courtyard can t realli privat life hous close courtyard common everybodi will hear s happen household husband batter time everybodi will know ll longer respect neighbor even children will disrespect s concern other eye femal hairdress idp woman issu coupl nobodi help neighbor just mock think lack social cohes may explain violenc urban coupl compar rural one femal unemploy idp less consensu among men regard shame emot ipv women men view physic econom abus similarli shame women comparison form violenc exampl physic violenc shame emot violenc emerg three five men s focu group said earlier batter wife put littl detail face goe feel asham detail still shame disappear detail disappear eh swell will shame bring male artist non idp quot focus relationship shame physic violenc similar women element public shame import physic violenc seen shame other detect woman beaten shame appear result actual abus abus partner rather result evid abus can seen other summari result pair wise rank reveal women consid emot ipv particularli form insult shame consensu seen among men s group howev ipv identifi other regardless specif form perceiv shame result social stigmat case addit abus non intim partner e neighbor urban live circumst includ crowd live close built home appear exacerb shame public ipv ipv healthnext particip ask compar describ differ form ipv impact health crisi affect women health defin broadli inclus physic mental health women men identifi physic ipv follow sexual ipv neg impact health women batter pain six teeth husband batter lost almost teeth femal trader idp woman might traumat sexual ipv exampl night fall begin anxiou feel uneasi alreadi worri will happen panic might caus sever diseas stress ulcer diabet will wast slowli femal trader idp discuss becam clear women perceiv relationship differ form ipv health impact distinct exampl physic sexual ipv often describ simultan co occur within episod thu make difficult assess harm health surpris sexual abus often involv threat use physic violenc descript simultan co occur ipv relat health impact shown men quit violent can beat sex women disfigur husband beat ask caus sex will brutal will beat femal trader non ipd lot thing involv rape hit blow head butt whole caus open leg laughter whisper can kill male electr engin non idp someon forc women sex will brutal will gentl will brutal women will suffer pain will throw leg apart s tiresom will necessarili affect will abl anyth morn femal housewif non idp focu group particip provid addit exampl interplay differ kind violenc within intim partner relationship exampl econom ipv often led physic ipv result deleteri physic emot health impact post crisi côte d ivoir econom opportun scarc case women becom financi provid famili see tabl women welcom opportun control resourc relationship also describ perceiv threat partner among men perceiv loss control tradit gender respons discuss underli caus form ipv ipv everyday activitiesin addit ipv specif physic mental health repercuss women ipv also impact abil perform everyday activ includ household chore work famili task similar percept differ form ipv impact health physic sexual form ipv view disrupt complet everyday activ compar econom emot ipv ask compar econom ipv emot ipv four five femal focu group identifi emot ipv disrupt everyday activ contrast comparison four five men s focu group identifi econom ipv disrupt women suggest women men view repercuss emot econom ipv differ shame health particip describ situat form ipv impact daili activ oblig women quot woman describ emot ipv can disrupt daili activ insult hurt realli hurt man will insult way wrong word oblig keep can t tell anybodi keep think word often start attend activ rememb whole word use call longer strength continu get sad re dishearten longer strength continu wonder husband use ugli word good hurt prevent activ femal dyer non idp econom ipv commonli form partner take money wive limit women complet daili task prevent women purchas item leav hous snatch money econom ipv without money busi insult won t effect work femal trader idp five women s focu group thought physic ipv disrupt econom ipv howev two men s focu group unabl reach consensu regard disrupt form ipv three group identifi physic ipv disrupt daili activ econom ipv forc sex will exhaust anyth els forc move will stay home will tire femal trader non idp discussionapproxim one third women studi report past year physic sexual ipv slightli half report physic sexual emot ipv find consist global preval ipv focu group discuss reveal physic sexual emot ipv addit less recogn form violenc women econom abus discrimin commun famili member common problem face crisi affect women shame social stigma play import role ipv perceiv experienc women studi shame social stigma often import factor women discuss harm type ipv public abus almost univers view harm health shame disrupt everyday activ non public ipv previou qualit research rural men côte d ivoir men report eros tradit gender norm conjunct financi stress arm conflict challeng sens masculin recent multi countri studi among displac popul displac believ increas ipv result remov men tradit role head household financi provid result women contribut financi well famili women gain financi household respons degre empower increas tension observ partner turn increas risk ipv within previou studi women s percept chang social gender role influenc ipv post crisi mix women believ empower increas independ result crisi reduc ipv perpetr other cite chang gender role respons post crisi risk factor increas ipv howev present studi chang gender role commonli discuss catalyz ipv protect violenc abus partner although sexual violenc conflict set often receiv focu organ media donor found ipv result shame stigma particularli emot ipv also frequent cite concern crisi affect women shame stigma common theme focu group ipv perpetr public public knowledg perceiv shame regardless type conflict affect women focu group conduct democrat republ congo describ similar phenomenon women specif ask experi repercuss relat sexual violenc congoles war report commun gossip ridicul particularli hurt case shame result sexual violenc equal concern attack alway explicitli discuss focu group s import consid broader structur inequ women regularli can influenc perpetu experi ipv seen abidjan social norm can also play role women focu group experienc ipv found littl support surround commun yet instead blame violenc perpetr sort public shame reinforc ipv legitim mean control limit women s abil seek help reinforc women s perceiv actual lower social statu len mind can truli understand natur ipv abidjan identifi effect way prevent studi result import implic practition research practition critic recogn interplay differ kind violenc within intim partner relationship result indic like woman may experienc multipl form ipv furthermor econom emot ipv may less visibl physic ipv respons servic intervent need work holist around women s need experi design address aspect violenc note focu group men women may differ percept ipv consequ serious thu discrep address within program seek engag men women separ programmat intervent also take account barrier consequ disclosur ipv survivor includ role stigma shame decis disclos ipv experi attent paid creat environ women feel safe support disclos strengthen relationship women increas peer support focu confidenti solidar import recogn less seriou form ipv make sure women feel comfort disclos experi without jeopard safeti studi util free list pair wise rank allow particip identifi priorit issu relev futur gbv research may consid util qualit method allow facilit structur convers sensit topic provid insight percept frequenc sever relev ipv discrimin problem face crisi affect women research regard sexual physic violenc exacerb crisi situat still necessari futur studi also includ investig addit form ipv discrimin given relationship poor health outcom disrupt daili activ limit must acknowledg sampl quantit survey focu group small repres therefor find gener two research perform qualit analysi independ howev pair wise rank result analyz quantit softwar research stigmat behavior ipv experi may report final one first time methodolog use examin peopl perceiv differ form ipv thu addit research need summari studi highlight high frequenc past year ipv provid import insight women men perceiv differ form ipv post crisi urban set violenc experienc women includ physic sexual emot ipv well econom ipv commun discrimin argument partner lack financi resourc unemploy common problem among crisi affect women describ underli sourc ipv research also highlight women often experi differ form ipv concurr final women men report shame stigma play larg role women experi repercuss ipv public episod ipv almost alway seen detriment privat episod ipv result underscor need increas social support mechan women reduc shame stigma isol associ experi creation safe support space women talk challeng social norm may import first step reduc commun shame secreci often surround ipv safe space along broader societ outreach includ challeng men s social posit creat opportun increas econom resourc can turn potenti decreas frequenc ipv deleteri impact woman s well support informations1 surveyintim partner violenc questionnair juli docx click addit data file', 'hard imagin planet look like million year ago green alga first colon terrestri habitat plant now blanket highest alpin peak lowest desert tropic rainforest arctic expans even aquat marin environ microfossil fragment plant tissu middl ordovician mya reveal evid first plant colon pioneer speci green algal progenitor long sinc disappear descend earli pioneer widespread howev beg question extant green algal group closest live rel land plant despit decad molecular phylogenet research land plant green alga question far settl land plant lp embryophyt monophylet group nest within charophyt group fresh water green alga togeth charophyt embryophyt constitut monophylet streptophyta green algal lineag chlorophyta contain divers assemblag marin fresh water green alga nearli decad ago karol et al conclud four gene three genom analysi charophyt charal constitut closest live rel land plant anoth combin data analysi support topolog time appear settl matter past centuri charal sister relationship use wide biolog textbook morpholog standpoint relationship tell good stori charophyt lineag diverg bodi plan grow increasingli complex unicellular mesostigmatal sarcinoid packet chlorokybal un branch filament klebsormidial branch filament zygnematal parenchemat tissu coleochaetal final macrophyt charal bodi plan evolv earli land colon equip complex tissu allow life water similarli sexual reproduct evolv isogami ancestr lineag oogami deriv charophyt lineag spite morpholog support charal sister land plant data conflict interpret plastid gene phylogeni provid support zygnematal sister land plant addit new data base nuclear gene support altern topolog zygnematal conjug sexual green alga filament unicellular flagel form one explan incongru topolog taxon sampl four gene topolog charal lp much broader taxon sampl algal taxa reconstruct support zygnematal lp six charophyt one studi broader taxon sampl algal taxa put zygnematal sister land plant much less support relationship second altern topolog also emerg coleochaet lp molecular data support relationship deriv exclus nuclear ribosom protein gene addit charact plasmodesmata nad5 intron support topolog coleochaetal order reconstruct monophylet phylogeni caus concern overal topolog address uncertainti field sought comprehens genom scale analysi use deep sampl mani gene drawn seven speci distribut across major charophyt lineag charal coleochaetal zygnematal klebsormidial chlorokybal addit includ publish sanger sequenc mesostigma virid est librari analyz alongsid hous transcriptom data identifi set ortholog common across green lineag chlorophyta streptophyta use unbias approach priori gene select yield larg set nuclear encod protein gene use reconstruct phylogeni identifi sister lineag land plant resultsour taxon sampl includ total taxa eight charophyt four land plant two chlorophyt five charophyt newli collect transcriptom tabl sanger sequenc read per taxon gs flx titanium sequenc read per taxon gather assembl raw read contig repres mrna organ time collect contig put code region predict estscan refer unigen number rang unigen per taxon journal pone t001tabl 1primari sequenc data summari cluster result reads5 sanger reads454 clustering454 sanger clusteringunigeneschaetosphaeridium globosumnumb reads884 490averag length bp 562949513656515chlorokybu atmophyticusnumb reads444 607averag length bp 513950726903904klebsormidium flaccidumnumb reads994 881averag length bp 538946629849731penium margaritaceumnumb reads1 880averag length bp 527943571811638nitella hyalinanumb reads949 106averag length bp 547955544682492unigen contig put code region inparanoid tc approach find core ortholog yield put ortholog group filter phylogeni reduc core otholog fig b hamstr identifi hit charophyt core ortholog filter good charophyt taxon represent remov gene amino acid composit bia ortholog gene remain fig c gene annot associ data tabl s1 journal pone g001figur 1ortholog identif method diagram outlin step use identifi ortholog gene phylogenet analysi unresolv phylogenet scheme relat chlorophyt charophyt embryophyt list six taxa fulli sequenc genom use core ortholog determin b core ortholog predict previou six taxa c charophyt orthog predict core ortholog use search protein eight charophyt transcriptom filter good taxon sampl remov ortholog signific amino acid bia result align protein concaten onto one larg multigen data matrix phylogenet analysi use ortholog gene reconstruct evolutionari histori streptophyt two outgroup chlorophyt first concaten protein product gene total amino acid miss gap charact trim poorli align region dataset condens amino acid miss gap charact averag gene present taxa six eight charophyt tabl represent individu gene vari among taxa except mesostigma contain gene presum markedli smaller size dataset two differ phylogenet analys perform trim align result strongli support topolog fig journal pone g002figur 2phylogenet relationship viridiplanta taxa determin concaten protein phylogenet analys summar bi cat poisson model consensu tree branch support valu bi ml analys ml bootstrap bayesian posterior probabl journal pone t002tabl 2summari miss data charophyt taxonnumb genesperc geneschlorokybu atmophyticus160100chaetosphaeridium globosum10565 625coleochaet sp 75klebsormidium flaccidum160100mesostigma viride1811 25nitella hyalina160100penium margaritaceum14288 75spirogyra pratensis10968 125gene present charophyt taxon multigen align total ml bi analys concaten gene dataset recov relationship zygnematal sister land plant strong statist support ml pp coleochaetal sister zygnematal lp clade ml pp charal diverg earlier ml pp follow klebsormidium ml pp final chlorokybal mesostigmatal moder support sister one anoth ml pp togeth compris earliest diverg lineag streptophyt ml pp addit branch order charophyt lineag includ two taxa per order zygnematal coleochaetal recov monophylet lend support classic recogn order larg concaten studi type logic concern subset gene might support altern topolog part ignor multi gene phylogenet analys given propens plant phylogeni gene tree speci tree conflict address issu directli statist test data incongru use program concaterpillar given multi gene dataset analysi use likelihood ratio test identifi compat partit program group gene set incongru leigh et al defin gene phylogenet incompat either due truli differ evolutionari histori systemat error fifteen set rang size gene fig s1 identifi total set gene none partit place charal sister land plant surprisingli largest set gene support zygnematal lp relationship also occur across four addit set total gene s1 d s1 h s1 k s1 l set differ placement mesostigma basal charophyt one noteworthi minor partit recov coleochaetal lp topolog fig s1 c two other coleochaet lp chaetospheridium branch earlier fig s1 j s1 o ensur toss phylogenet inform charact elimin gene amino acid composit bia perform similar phylogenet analys concaten gene set result ml topolog almost exactli bootstrap support everi bipartit except chlorokybu mesostigma lineag support recov howev concaterpil analys larger gene set recov interest gene set one recov set contain gene support nitella lp topolog gene amino acid composit bia fairli well distribut across variou incongru set eight land nitella lp set set topolog recov subsequ gene concaterpil analysi discussionthi studi includ charophyt lineag provid robust well support result lp zygnematal sister lineag believ result warrant seriou reconsider charophyt evolut given phylogenom approach studi confirm plastid encod analys turmel et al recent nuclear genom studi wodniok et al studi use target gene approach reconstruct altern topolog none broad unbias nuclear genom sampl use current studi two phylogenet studi publish past year use next gener sequenc data address similar question pose manuscript howev data collect analyz studi almost complet non overlap consequ three independ analys provid divers perspect difficult deep evolutionari relationship finet et al focus ribosom gene charact select priori transcriptom collect studi despit fact present studi finet et al drew transcriptom dataset five gene overlap two studi core ortholog select final dataset thu analys almost complet independ tree topolog differ assign coleochaet sister lineag land plant addit noteworthi like ribosom protein tree ribosom rna gene tree reconstruct monophylet coleochaetal coleochaetal fact monophylet indic morpholog organellar data suggest form molecular coevolut may underli appar conflict noteworthi studi charophyt phylogenet came wodniok et al also broad transcriptom analysi like finet et al studi make use priori set select gene draw smaller number charophyt taxa six fewer align charact amino acid studi directli compar wodniok et al tree topolog congruent lower branch support charophyt node analysi report base filtrat roughli charact select evid ortholog combin result dataset charact strongli support tree topolog ultim set analysi apart howev priori gene select thu addit intrins phylogenet interest demonstr power new approach data select leverag use high throughput sequenc data howev given genom scale data collect taxon sampl limit may sourc error without addit transcriptom directli test issu long branch attract much less factor amino acid data use appropri model evolut short intern branch shown sourc phylogenet inconsist much harder issu address two analys suggest taxon sampl might confound issu studi turmel et al rrna plastid phylogeni twice taxon sampl recov zygnematal lp relationship use nucleotid base analysi charal lp relationship still emerg reduc karol et al dataset reanalyz approxim taxon sampl second line evid provid tenuou support best worth report due similar taxon spread well support land plant zygnematal topolog use larg suit gene requir rethink charact evolut charophyt lineag lead land colon previou hypothes increas morpholog complex congruent result studi howev multipl gain loss multicellular across green alga well document reduct charact zygnematal zygnematal includ filament unicellular organ unicellular state may well deriv condit branch filament ancestor just flagel stage lost order context stretch imagin charact reduct sister lineag land plant fig result loss homolog charact potenti share common ancestor multicellular complex charal coleochaetal appear independ deriv common branch filament ancestor one like oogam reproduct charact probabl present common ancestor four advanc lineag idea suggest previou investig model howev parenchyma like organ axial growth protonema charal exampl parallel evolut multipl zygot product coleochaet journal pone g003figur 3hypothesi charact evolut charophyt earliest branch streptophyt mesostigma chlorokybu unicellular flagel isogam multicellular form unbranch filament evolv common ancestor remain streptophyt repres klebsormidial recent common ancestor charal coleochaetal zygnematal lp like alga plant like cell divis phragmoplast branch filament oogam sexual reproduct charal went independ evolv complex macrophyt form coleochaetal independ acquir parenchymat tissu matern retain zygot howev zygnematal went rout reduct loss flagel cell reproduct via conjug loss multicelluar desmid loss phragmoplast conclus research lend strong support notion closest live green algal lineag land plant plant like stonewort charal previous thought speci rich assemblag fresh water filament unicellular organ better known pond scum materi methodsalg samplingal seven transcriptom similarli process see timm delwich detail method spirogyra pratensi utex coleochaet sp cfd summari chaetosphaeridium globosum sag penium margaritaceum skd2004_cl18 cultur avail david domozych skidmor colleg saratoga spring ny klebsormidium flaccidum utex chlorokybu atmophyticu utex 2591were grown appropri cultur media c ld photoperiod photon flux µmol s m nitella hyalina kgk0190 cultur avail kenneth karol new york botan garden bronx ny cultur fresh water aquarium room temperatur cultur harvest log phase growth varieti condit maxim divers transcript interv pm pm pm sit dark enclosur hour expos minut c algal cultur pellet 4000rpm nitella requir centrifug drop liquid nitrogen store c rna extract rna isolationfrozen tissu ground cryogen temperatur use spex freezer mill spex certi prep metuchen nj ground cell ad tri reagent molecular research center inc cincinnati oh manufactur s protocol follow extra chloroform extract addit licl precipit requir elimin polysaccharid genom dna contamin isol nucleic acid concentr od ratio quantifi nanodrop thermo scientif nanodroptm spectrophotomet wilmington de qualiti rna determin run µg total rna agaros mop formaldehyd gel appli biosystem ambion austin tx stain ethidium bromid examin rrna band pattern high qualiti clean rna pool mg total rna reach cdna construct dna sequencingtot rna mg ship dri ice agencourt bioscienc corpor beverli ma poli rna total rna isol convert doubl strand cdna size fraction kb clone direct pexpress vector grown t1 phage resist e coli subsequ dna sequenc includ prime sanger read sequenc technolog summari taxon sanger read plu full plate gs flx titanium sequenc gener see tabl exact number sanger sequenc dna clone purifi use agencourt s proprietari solid phase revers immobil spri system purifi dna sequenc use abi dye termin chemistri run abi appli biosystem inc foster citi ca machin addit includ publish sanger sequenc one addit taxon mesostigma virid sequenc ug isol dna nebul mean size rang bp follow size select fragment bp column exclus ampur agencourt bioscienc danver ma isol adapt ligat onto fragment select use librari captur bead singl strand fragment isol follow standard librari dilut librari amplifi onto dna captur bead emuls pcr empcr dna captur bead collect sequenc primer anneal thermocycl bead genom place picotitr plate sequenc roch gs flx instrument analyz base call softwar use default paramet transcriptom cluster methodth cluster taxon perform two step process first read cluster use mira vs second raw sanger read combin contig respect qualiti score process est2uni pipelin use varieti method remov low qualiti sequenc vector contamin low complex region cluster clean read cap3 use bp plu percent ident overlap estscan predict protein code region contig singleton use arabidopsi thaliana score matrix cluster process result set predict protein unigen taxon use downstream analys ortholog predict use extend hamstr approach fig hamstr approach ortholog predict use well curat set gene core ortholog identifi put ortholog est librari core ortholog hamstr search set unigen identifi set put ortholog present curat set ortholog exist entir green lineag set build six fulli sequenc genom chosen construct core ortholog four embryophyt two chlorophyt fig arabidopsi thaliana uniprot v populu trichocarpa jgi v oryza sativa plantbiolog v physcomitrella paten jgi v ostreococcu tauri jgi v chlamydomona reinhardtii jgi v phylogenet posit core ortholog taxa ideal purpos unless gene loss ortholog present embryophyt chlorophyt also present charophyt protein sequenc six genom use infer set core ortholog use modifi inparanoid approach inparanoid tc genom duplic embryophyt can caus paralog issu use phylogenet filter confirm true ortholog fig b briefli align put ortholog group use muscl trim align trimal gt w st reconstruct maximum likelihood ml phylogeni use raxml f m protgammawag use hous perl script run paup filter command identifi ml topolog consist well known phylogenet relationship ortholog pass filter consid core ortholog fig b viridiplanta core ortholog use input program hamstr instead identifi set ortholog transcriptom modifi hamstr program extract top hit present singl put ortholog eight transcriptom modif allow us submit top hit directli phylogenet analysi eight hamstr analys preform align made use muscl gather set core ortholog least one match charophyt fig c ortholog collect phylogenet purpos filter good taxon sampl least one charophyt major charophyt lineag chlorokybu klebsormidium nitella coleochaet chaetosphaeridium penium spirogyra fig c lastli gene span diverg taxa one billion year diverg time chang amino acid composit heterogen time issu want minim spirit use tree puzzl identifi ortholog signific amino acid bia assumpt phylogenet analys assum charact composit chang time remov gene signific amino acid bia elimin possibl sourc systemat error last filter step produc set align ortholog gene good taxon sampl amino acid composit bia fig c concaten onto one larg multi gene data matrix detail follow section reconstruct multi gene phylogenyw align amino acid unigen use muscl default paramet concaten use hous perl script trim poorli align region use trimal gt w st estim model evolut ml analysi use protest2 ran phylogenet analys multi gene dataset maximum likelihood ml lg g f model use raxml bayesian infer bi cat poisson model use phylobay bi analysi allow us test effect appli site heterogen model evolut cat multi gene amino acid data matrix measur phylogenet stabil bootstrap perform ml analysi posterior probabl pp infer bi analysi data accessth individu read transcriptom deposit genbank http www ncbi nlm nih gov sanger read locat dbest follow access number chlorokybu atmophyticu genbank ho407395 ho431109 chaetosphaeridium globosum genbank ho348296 ho407394 klebsormidium flaccidum genbank ho431110 ho486407 nitella hyalina genbank ho486408 ho574687 penium margaritaceum genbank ho574688 ho651665 sequenc sequenc read archiv sra c atmophyticu genbank srx025846 c globosum genbank srx025844 k flaccidum genbank srx025847 n hyalina genbank srx025843 p margaritaceum genbank srx025845 cluster sanger read deposit transcriptom shotgun assembl sequenc databas tsa c atmophyticu genbank jo192127 jo204622 c globosum genbank jo157958 jo182157 coleochaet sp genbank jo233843 jo252228 k flaccidum genbank jo252229 jo277141 n hyalina genbank jo277142 jo317756 spirogyra pratensi genbank jo182540 jo192126 p margaritaceum genbank jo204623 jo233842 trim align ml tree bi consensu tree upload treebas access follow url http purl org phylo treebas phylow studi tb2 s10897 support informationfigur s1concaterpillar ml tree deriv compat partit multigen align set number determin concaterpillar list figur descend size tif click addit data file tabl s1tab delimit text file contain annot summari data ortholog use phylogenet analysi txt click addit data file']",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "\u001b[1;32m/home/ubuntu/anaconda3/lib/python3.5/site-packages/gensim/models/doc2vec.py\u001b[0m in \u001b[0;36m__iter__\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    960\u001b[0m             \u001b[1;31m# Things that don't have seek will trigger an exception\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 961\u001b[1;33m             \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msource\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mseek\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    962\u001b[0m             \u001b[1;32mfor\u001b[0m \u001b[0mitem_no\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mline\u001b[0m \u001b[1;32min\u001b[0m \u001b[0menumerate\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msource\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mAttributeError\u001b[0m: 'list' object has no attribute 'seek'",
      "\nDuring handling of the above exception, another exception occurred:\n",
      "\u001b[1;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-28-0fc7a0001ad9>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m()\u001b[0m\n\u001b[0;32m      1\u001b[0m \u001b[1;31m#documents = [doc for doc in TaggedLineDocument('/volume/processed_docs.txt')]\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 2\u001b[1;33m \u001b[0mdocuments\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;33m[\u001b[0m\u001b[0mdoc\u001b[0m \u001b[1;32mfor\u001b[0m \u001b[0mdoc\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mTaggedLineDocument\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mbods_sm\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[1;32m<ipython-input-28-0fc7a0001ad9>\u001b[0m in \u001b[0;36m<listcomp>\u001b[1;34m(.0)\u001b[0m\n\u001b[0;32m      1\u001b[0m \u001b[1;31m#documents = [doc for doc in TaggedLineDocument('/volume/processed_docs.txt')]\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 2\u001b[1;33m \u001b[0mdocuments\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;33m[\u001b[0m\u001b[0mdoc\u001b[0m \u001b[1;32mfor\u001b[0m \u001b[0mdoc\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mTaggedLineDocument\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mbods_sm\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[1;32m/home/ubuntu/anaconda3/lib/python3.5/site-packages/gensim/models/doc2vec.py\u001b[0m in \u001b[0;36m__iter__\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    964\u001b[0m         \u001b[1;32mexcept\u001b[0m \u001b[0mAttributeError\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    965\u001b[0m             \u001b[1;31m# If it didn't work like a file, use it as a string filename\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 966\u001b[1;33m             \u001b[1;32mwith\u001b[0m \u001b[0mutils\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msmart_open\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msource\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0mfin\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    967\u001b[0m                 \u001b[1;32mfor\u001b[0m \u001b[0mitem_no\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mline\u001b[0m \u001b[1;32min\u001b[0m \u001b[0menumerate\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mfin\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    968\u001b[0m                     \u001b[1;32myield\u001b[0m \u001b[0mTaggedDocument\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mutils\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mto_unicode\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mline\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0msplit\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m[\u001b[0m\u001b[0mitem_no\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m/home/ubuntu/anaconda3/lib/python3.5/site-packages/smart_open/smart_open_lib.py\u001b[0m in \u001b[0;36msmart_open\u001b[1;34m(uri, mode, **kw)\u001b[0m\n\u001b[0;32m    213\u001b[0m         \u001b[1;32mreturn\u001b[0m \u001b[0muri\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    214\u001b[0m     \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 215\u001b[1;33m         \u001b[1;32mraise\u001b[0m \u001b[0mTypeError\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m'don\\'t know how to handle uri %s'\u001b[0m \u001b[1;33m%\u001b[0m \u001b[0mrepr\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0muri\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    216\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    217\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mTypeError\u001b[0m: don't know how to handle uri ['pulmonari prostat cancer common malign tumor often develop bone metastas tumor cell spread bone mainli hematogen metastasi howev mechan underli bone metastasi pulmonari prostat cancer differ specif pulmonari cancer cell metastas bone mainli pulmonari vein wherea prostat cancer cell spread bone mainli via vertebr venou system differ rout metastasi can produc differ distribut featur bone metastas although studi morgan et al dodd et al support viewpoint bone scintigraphi import techniqu detect bone metastas evalu stage malign tumor prognosi patient well assess tumor respons therapi effect therapeut schedul tool can use scan entir skeleton patient therebi allow bone lesion display entireti thu bone scintigraphi use studi distribut featur bone metastas analyz relationship pathway tumor spread distribut metastat lesion numer studi bone metastas pulmonari prostat cancer compar statist analys mani studi shown predilect site bone metastas pulmonari prostat cancer similar includ vertebra pelvi rib howev littl data differ distribut bone metastas pulmonari prostat cancer understand differ will help differenti diagnosi cancer classifi patient accord total number bone metastas use lesion base analysi investig chang distribut metastat bone lesion case differ number lesion compar distribut featur bone metastas pulmonari prostat cancer found distribut characterist bone metastas differ cancer type materi methods1 clinic patientsthi retrospect studi data extract pictur archiv commun system pac januari april zhongnan hospit wuhan univers hubei china bone scintigraphi perform patient pulmonari cancer men women age median age male patient prostat cancer age median age definit diagnosi use patholog techniqu made patient patient result whole bodi bone scan perform diagnosi confirm patholog select studi need follow bone scan use diagnost refer clinic studi limit specif diseas stage approv ethic committe zhongnan hospit data analyz anonym consent waiv imag methodbon scintigraphi perform use singl head gamma camera low energi high resolut collim e cam siemen hoffman estat il usa patient instruct drink ml water within h intraven inject mbq 99mtc methylen diphosphon 99mtc mdp empti urin bone scintigraphi planar bone scan includ anterior posterior project perform approxim h inject imag reagent accord follow condit patient supin postur matrix zoom movement veloc examin bed cm min necessari addit local planar bone imag singl photon emiss comput tomographi spect scan perform imag interpret analysi findingsanalys planar bone scintigraphi spect bone scan made consensu read two nuclear medicin physician x ray comput tomographi ct magnet reson imag mri made consensu read nuclear medicin physician radiologist accord diagnost method even sapir et al use follow criteria diagnos bone metastasi bone lesion increas uptak 99mtc mdp consid bone metastas vertebr lesion involv posterior aspect vertebr bodi pedicl extens involv vertebra rib lesion appear elong tumor lamellar bone lesion present multipl site scrambl arrang focal bone lesion increas uptak 99mtc mdp regard malign exclud benign bone diseas fractur bone lesion decreas uptak 99mtc mdp categor bone metastas postradiotherapi chang metal influenc benign bone diseas bone cyst exclud bone lesion abnorm uptak 99mtc mdp deem malign simultan confirm bone metastas x ray ct mri compar result bone scan perform differ time new bone lesion consid malign diagnos benign bone scan show flare phenomenon bone metastasi note bone scintigraphi find follow circumst abnorm radiotrac uptak detect indetermin decreas radioact local bone bone lesion show increas uptak 99mtc mdp around joint bone lesion abnorm radiotrac uptak character benign condit bone fractur bone cyst hyperosteogeni osteophyt bone bridg degen osteoarthropathi inflamm group bone metastasesaccord method wilson calhoun fraction whole bone five region thorac bone includ rib sternum collarbon bladebon vertebra includ cervic spine thorac spine lumbar spine pelvi includ sacrococcyx ilium ischium pubi skull includ bone cerebr cranium facial cranium extrem includ humeru femur radioulna tibiofibula studi relationship distribut bone metastas total number lesion metastas bone compar differ distribut bone metastas pulmonari prostat cancer divid patient three group accord total number bone metastas bone metastas moder bone metastas extens bone metastas statist analysisdata analyz spss statist softwar version spss inc chicago il usa chi squar test perform compar differ proport bone metastas differ group pulmonari prostat cancer p valu less consid statist signific results1 total distribut bone metastasesof patient malign tumor bone metastas lesion bone metastasi detect incid bone metastasi prostat cancer significantli higher pulmonari cancer χ2 p bone metastas pulmonari prostat cancer mainli distribut vertebra pelvi thorac bone result tabl show distribut metastat lesion pelvi e g sacrococcyx ilium ischium pubi s1 tabl patient prostat cancer slightli greater patient pulmonari cancer χ2 p wherea distribut metastat lesion thorac bone mainli rib bladebon s1 tabl patient pulmonari cancer slightli higher prostat cancer patient χ2 p gener signific differ pulmonari prostat cancer regard differ bone region tabl journal pone t001tabl 1comparison total distribut bone metastas n pulmonari prostat cancer skeletonpulmonari cancer n prostat cancer n χ2p valuen n vertebrae63327 146pelvis49621 000thorac bones90639 002skull813 584extremities1637 902note n lesion number bone metastas chi squar test likelihood ratio perform compar differ proport bone metastas pulmonari prostat cancer comparison bone metastas pulmonari prostat cancer patient bone metastasest summar distribut metastat bone lesion patient bone metastas proport prostat cancer metastasi vertebr column two fold pulmonari cancer χ2 p lumbar vertebra account larg part differ s2 tabl proport thorac bone metastas pulmonari cancer approxim four fold prostat cancer χ2 p mainli due differ number metastas rib bladebon s2 tabl differ proport bone metastas pelvi skull extrem pulmonari prostat cancer signific p data show significantli differ distribut metastat lesion vertebra thorac bone patient pulmonari prostat cancer bone metastas compar moder extens metastas journal pone t002tabl 2comparison bone metastas pulmonari prostat cancer patient bone metastas n skeletonpulmonari cancer n prostat cancer n χ2p valuen n vertebrae7128 000pelvis4719 398thorac bones9739 000skull62 extremities2510 208note n lesion number bone metastas chi squar test likelihood ratio perform compar differ proport bone metastas pulmonari prostat cancer comparison bone metastas pulmonari prostat cancer patient moder bone metastasesth distribut bone metastas pulmonari prostat cancer patient moder bone metastas list tabl proport vertebr metastas prostat cancer greater pulmonari cancer χ2 p proport thorac bone metastas pulmonari cancer prostat cancer χ2 p howev increas proport patient moder bone metastas lower patient bone metastas furthermor distribut prostat cancer metastas pelvi significantli pulmonari cancer χ2 p journal pone t003tabl 3comparison bone metastas pulmonari prostat cancer patient moder bone metastas n skeletonpulmonari cancer n prostat cancer n χ2p valuen n vertebrae14329 010pelvis8818 000thorac bones19440 000skull173 787extremities377 911note n lesion number bone metastas chi squar test likelihood ratio perform compar differ proport bone metastas pulmonari prostat cancer comparison bone metastas pulmonari prostat cancer patient extens bone metastasesth distribut metastat bone lesion patient extens bone metastas shown tabl proport vertebr metastas prostat cancer slightli lower pulmonari cancer χ2 p differ thorac bone lesion pulmonari prostat cancer signific χ2 p contrast result patient moder bone metastas distribut bone metastas pelvi prostat cancer slightli pulmonari cancer χ2 p howev distribut metastat lesion skull extrem significantli differ pulmonari prostat cancer thu distribut bone metastas pulmonari prostat cancer similar patient extens bone metastas journal pone t004tabl 4comparison bone metastas pulmonari prostat cancer patient extens bone metastas n skeletonpulmonari cancer n prostat cancer n χ2p valuen n vertebrae41926 015pelvis36123 001thorac bones61539 275skull583 571extremities1016 363note n lesion number bone metastas chi squar test likelihood ratio perform compar differ proport bone metastas pulmonari prostat cancer comparison bone metastasi distribut differ lesionsin pulmonari cancer distribut metastat lesion pelvi patient extens bone metastas slightli patient moder bone metastas χ2 p fig distribut bone metastas vertebra χ2 p thorac bone χ2 p skull χ2 p extrem χ2 p significantli differ overal distribut differ bone pulmonari cancer similar differ lesion journal pone g001fig 1comparison pelvi metastas pulmonari prostat cancer total number bone metastas increas distribut pelvi pulmonari cancer present smaller differ χ2 p prostat cancer present signific differ χ2 p prostat cancer distribut bone metastas pelvi χ2 p skull χ2 p extrem χ2 p significantli differ howev distribut consider differ vertebra χ2 p thorac bone χ2 p increas total number bone metastas decreas tendenc metastas vertebr column fig increas tendenc spread thorac bone fig therefor significantli differ distribut metastas vertebra thorac bone prostat cancer littl differ distribut pulmonari cancer journal pone g002fig 2comparison vertebr metastas pulmonari prostat cancer result show increas bone metastas distribut vertebr metastas prostat cancer present quickli decreas tendenc χ2 p pulmonari cancer present signific differ χ2 p journal pone g003fig 3comparison thorac bone metastas pulmonari prostat cancer result show increas bone metastas distribut thorac bone metastas prostat cancer present gradual increas tendenc χ2 p pulmonari cancer present signific differ χ2 p comparison bone metastas vertebra pelvisin patient bone metastas greater distribut metastas vertebra pelvi prostat cancer pulmonari cancer χ2 p prostat cancer metastas vertebra pelvi frequent pulmonari cancer earli stage bone metastas seldom metastas bone except vertebra pelvi especi sternum collarbon bladebon bone upper extrem s1 tabl vertebra pelvi progress carcinomat metastasi rare prostat cancer spread bone howev pulmonari cancer can metastas bone rib s1 s2 fig femur s2 fig patient moder bone metastas distribut prostat cancer metastas pulmonari cancer χ2 p howev patient extens bone metastas signific differ distribut metastas pulmonari prostat cancer χ2 p condit cancer cell frequent metastas multifari bone bone metastas pulmonari s3 fig prostat cancer s4 fig also mainli distribut vertebra pelvi prostat cancer differ distribut metastat lesion vertebra pelvi significantli differ χ2 p contrast pulmonari cancer χ2 p fig journal pone g004fig 4comparison vertebra pelvi metastas pulmonari prostat cancer result show increas bone metastas proport vertebra pelvi metastas prostat cancer present gradual decreas tendenc χ2 p pulmonari cancer present signific differ χ2 p comparison bone metastas lumbar thorac cervic vertebraeth distribut bone metastas lumbar thorac cervic vertebra differ prostat cancer s2 s4 tabl patient bone metastas high proport metastas lumbar vertebra gradual decreas tendenc spread lumbar thorac vertebra cervic vertebra s2 tabl patient moder extens bone metastas distribut thorac vertebra lumbar vertebra s3 s4 tabl result indic prostat cancer frequent metastas lumbar vertebra earli stage thorac cervic vertebra howev pulmonari cancer frequent metastas thorac vertebra s3 s4 tabl discussionboth pulmonari prostat cancer great avid bone frequent lead pain untreat consequ patient advanc stage diseas frequent bone metastas result show high distribut metastat lesion vertebra pelvi thorac bone pulmonari prostat cancer demonstr bone predilect site bone metastas cancer result accord studi pulmonari prostat cancer notwithstand small differ distribut bone metastas pelvi thorac bone pulmonari prostat cancer result show total distribut metastat lesion differ region bone similar two cancer type tabl consist data morgan et al although spread pathway differ pulmonari prostat cancer data explain relationship differ metastat pathway distribut bone metastas howev understand relationship import will allow detect primari cancer lesion accord featur metastat lesion will allow differenti benign bone lesion metastat bone involv base characterist known primari tumor clearli total distribut featur bone metastas pulmonari prostat cancer aid detect primari tumor lesion differenti benign malign lesion batson thought prostat cancer cell metastas earli stage pelvi vertebra vertebr venou system bubendorf et al analyz metastat pattern prostat cancer autopsi studi patient result strongli support metastat pattern vertebr vein howev result morgan et al dodd et al show differ distribut bone metastas prostat pulmonari cancer nonprostat cancer signific thu support concept vertebr vein uniqu substanti role dissemin prostat cancer similar morgan et al dodd et al result total distribut bone metastas pulmonari prostat cancer also support role metastasi vertebr vein nevertheless result strongli support role batson s vertebr venou plexu metastat pattern prostat cancer studi patient moder bone metastas overwhelm major bone metastas prostat cancer distribut vertebra pelvi similar distribut featur prostat cancer batson venou plexu pulmonari prostat cancer differ distribut featur bone metastas distribut bone metastas prostat cancer unstabl correl total number bone metastas chang number metastas increas promin chang occur vertebra thorac bone proport vertebra thorac bone metastas patient prostat cancer invers correl total number bone metastas indic distribut bone metastas prostat cancer character preferenti metastasi vertebra thorac bone specif earli stage prostat cancer metastas occur lumbar vertebra follow thorac cervic vertebra featur variabl distribut bone metastas patient prostat cancer interpret carcinomatosi theori batson vertebr vein studi proport vertebr metastas prostat cancer gradual decreas increas total number bone metastas decreas result decreas actual number vertebr metastas rather due rel slow increas speed vertebr metastas mani metastat lesion occupi vertebra limit capac contrast prostat cancer distribut bone metastas pulmonari cancer significantli chang increas total number bone metastas addit proport metastat lesion bone region larg similar differ lesion distribut featur bone metastas pulmonari cancer may explain metastat pattern pulmonari vein pulmonari cancer cell spread bone differ region approxim changeless proport pulmonari vein therefor distribut bone metastas pulmonari cancer character random stabil proport metastat lesion pulmonari prostat cancer differ featur distribut bone metastas simpli result differ spread pathway earli distribut bone metastas present great differ pulmonari prostat cancer result show earli stage prostat cancer cell frequent encroach vertebra especi lumbar vertebra frequent metastas thorac bone pulmonari cancer cell frequent encroach vertebra also metastas thorac bone differ earli distribut bone metastas pulmonari prostat cancer use differenti benign malign bone diseas detect primari tumor patient extens bone metastas despit fact small differ distribut bone metastas pulmonari prostat cancer boni distribut two tumor still similar overal similar manifest one hand despit differ pathway tumor cell dissemin final predilect site bone metastas pulmonari prostat cancer ident vertebra pelvi thorac bone hand distribut bone metastas reflect differ dissemin pathway time therefor differ distribut bone metastas pulmonari prostat cancer result differ spread pathway present patient extens bone metastas occur earli bone metastas conclusionsa common malign tumor pulmonari prostat cancer frequent dissemin bone studi show distribut featur bone metastas pulmonari prostat cancer differ distribut bone metastas prostat cancer correl total number bone metastas differ featur differ lesion howev distribut bone metastas pulmonari cancer stabl differ lesion prostat cancer character earli dissemin vertebra metastasi thorac bone wherea pulmonari cancer character random spread differ bone rel stabl proport differ featur distribut mainli present earli bone metastas extens bone metastas result confirm distribut bone metastas pulmonari prostat cancer correl differ pattern hematogen dissemin pulmonari vein vertebr vein system separ play import role dissemin pulmonari prostat cancer earli stage bone metastas support informations1 figbon scintigraphi result year old male patient pulmonari squamou cell carcinoma bone scintigraphi pneumonectomi figur show metastat boni lesion whole bodi b bone scintigraphi 8th month pneumonectomi figur show injur rib white arrow due surgic procedur present increas uptak c bone scintigraphi 22nd month pneumonectomi figur show radioact uptak injur rib lower 22nd month white arrow 8th month two rib metastas green arrow detect tif click addit data file s2 figbon scintigraphi year old male patient pulmonari adenocarcinoma figur show bone metastas distribut rib femur without vertebra pelvi metastasi tif click addit data file s3 figbon scintigraphi year old male patient bronchioloalveolar carcinoma figur show extens bone metastas distribut mainli vertebra pelvi tif click addit data file s4 figbon scintigraphi year old male patient prostat cancer figur show extens bone metastas distribut mainli vertebra pelvi tif click addit data file s1 tablecomparison total distribut bone metastas n pulmonari prostat cancer doc click addit data file s2 tablecomparison bone metastas pulmonari prostat cancer patient bone metastas n doc click addit data file s3 tablecomparison bone metastas pulmonari prostat cancer patient moder bone metastas n doc click addit data file s4 tablecomparison bone metastas pulmonari prostat cancer patient extens bone metastas n doc click addit data file', 'voic disord dysphonia can caus neurolog structur function problem affect breath phonat articul reson prosodi product sound level larynx varieti respiratori tract disord includ chronic cough laryng tension can lead reduc voic qualiti dysphonia can caus sever drawback commun significantli impair qualiti life given import vocal commun human interact subject abnorm voic pattern high risk anxieti disord depress patient voic disord score significantli lower health statu subscal measur sf form highli valid questionnair assess qualiti life cystic fibrosi cf common autosom recess disord preval approxim live birth peopl european descent diseas caus mutat cystic fibrosi transmembran regul gene encod epitheli chlorid channel dysfunct ion channel lead abnorm transport chlorid sodium across epitheli membran result product thick viscou secret variou organ includ respiratori tract respiratori dysfunct short breath chronic cough hallmark cf major caus morbid cf patient therefor current medic practic larg part cf treatment dedic mitig effect respiratori dysfunct howev potenti effect cf respiratori complic vocal capac cf patient studi detail hypothes cf patient given characterist respiratori disord also present intrins voic alter true cf patient potenti benefit voic therapi way improv qualiti life test hypothesi measur vocal paramet use object subject clinic evalu method male femal cf patient undergo convent treatment compar age sex match control methodssubject select ethic statementsubject age year divid four group male control group n femal control group n male patient cf n femal patient cf n analys cf patient n control subject n pool independ sex cf patient diagnos base standard sweat test famili histori presenc chronic pulmonari diseas pancreat insuffici previou laryngoscop examin conduct prophylact part patient clinic monitor confirm select cf patient drastic vocal cord dysfunct laryng diseas vocal cord polyp laryng carcinoma laryng paralysi cf patient control subject never receiv voic therapi patient cf receiv individu regular treatment accompani physician dietician physiotherapist psychologist time studi none cf patient sign infect medic inhalatori antibiot hyperton salin inform clinic statu subject can found tabl s1 s4 includ bodi mass index bmi fev1 common measur lung function defin volum air exhal first second forc expir normal mean valu popul low number cf patient sex limit studi due limit pool will cf patient fit necessari criteria studi approv research ethic committe joão de barro barreto univers hospit subject legal caretak sign inform consent form vocal recordingssubject ask produc sustain vowel phonat usual intens maximum voic time voic record conduct use hand held microphon pg42 lc shure alway posit six centimet subject s mouth angl ensur compar intens measur initi second record alway exclud analysi paramet measur three second time window follow period signal record sampl rate khz analyz praat softwar object vocal analysisw measur follow quantit vocal paramet fundament frequenc f0 intens jitter index f0 variabl shimmer index intens variabl harmon nois ratio hnr index glottal turbul nois hoars paramet extens valid quantit object measur vocal qualiti routin use voic care profession diagnost tool low valu vocal intens hnr high valu jitter shimmer alter f0 potenti sign dysphonia subject vocal analysisin addit object acoust variabl also conduct perceptu assess voic qualiti cf control subject use grba grade rough breathi asthenia strain scale vocal assess method evalu patient s gener grade dysphonia repres letter g four subject paramet rough r breathi b asthenia strain s variabl determin voic care profession quantifi percept patient voic zero normal one mild alter two moder alter three sever alter abovement factor reliabl method extens valid order avoid confirm bia analys ask independ practic clinic voic therapist tie research project perform grba evalu record evalu receiv record pseudo random order complet blind structur experiment protocol project s object identif diagnosi subject evalu year profession experi voic therapi grba analysi method instruct analyz record exactli perform clinic practic data analysi statisticsdiffer object subject vocal paramet evalu mann whitney test data distribut non gaussian mani variabl defin shapiro wilk normal test tabl s5 therefor data repres median valu median interquartil rang iqr statist signific level initi set p account multipl comparison within object subject categori vocal paramet bonferroni correct method appli procedur adjust signific level p analys resultsrepres recordingsvoic signal record spectrogram repres individu studi group shown figur control group record show clear featur euphon voic high period wide amplitud rang figur b1 b1 contrast signal subject cf group show remark aperiod reduc amplitud figur b2 b2 spectrogram cf patient also show high nois level loss high frequenc harmon relat control figur c2 c2 journal pone g001figur 1repres voic record spectrogram femal patient cf red healthi control blue sound record vowel phonat femal control subject a1 femal patient cf a2 note markedli reduc amplitud rang signal cf patient relat control b amplifi view record present a1 a2 note irregular voic signal cf patient relat control c spectrogram frequenc domain represent record present a1 a2 note higher level background nois low formant segreg cf patient relat healthi control journal pone g002figur 2repres voic record spectrogram male patient cf red healthi control blue sound record vowel phonat male control subject a1 male patient cf a2 note markedli reduc amplitud rang signal cf patient relat control b amplifi view record present a1 a2 note irregular voic signal cf patient relat control c spectrogram frequenc domain represent record present a1 a2 note higher level background nois low formant segreg cf patient relat healthi control cf relat chang vocal parametersanalysi object voic paramet reveal cf patient present signific decreas intens figur b p increas jitter figur c p shimmer figur d p much lower hnr figur e p relat control differ observ f0 figur p two group journal pone g003figur 3object measur vocal paramet control subject cf patient horizont line error bar repres median iqr variabl subject pool independ sex valu f0 group b valu intens group note signific reduct intens cf group c valu jitter group note signific increas jitter cf group d valu shimmer group note signific increas shimmer cf group e valu hnr group note signific reduct variabl cf group p perceptu assess voic qualiti grba scale also reveal clear sign dysphonia cf patient relat control group patient cf present overal increas r figur b p b figur c p figur d p addit cf patient show increas g relat control figur p interestingli differ observ s score cf patient healthi control figur e p median valu iqr studi variabl statist comparison group summar tabl s6 journal pone g004figur 4subject measur vocal paramet male femal control subject cf patient horizont line error bar repres median valu group subject pool independ sex valu g group note signific increas g cf group b valu r group note signific increas r cf group c valu b group note signific increas b cf group d valu group note signific increas cf group e valu s group p p import note highli unlik cf relat chang vocal paramet relat age lung function subject none object variabl affect cf patient signific correl age fev1 figur s1 s2 r2 p correl age fev1 intens jitter shimmer hnr influenc sex cf relat dysphoniaw also analyz data segreg control cf group accord sex order reveal possibl influenc sex cf relat dysphonia analys reveal male femal cf patient relat match control present signific decreas intens figur b1 b2 p male femal increas jitter figur c1 c2 male p femal p male shimmer figur d1 d2 p femal p male interestingli femal cf patient show drastic lower valu hnr figur e1 p relat control group featur observ male cf patient figur e2 p compar respect control differ cf patient control subject observ f0 sex figur a1 a2 p comparison journal pone g005figur 5object measur vocal paramet male femal control subject cf patient horizont line error bar repres median iqr variabl valu f0 femal a1 male a2 subject group b valu intens femal a1 male a2 subject group c valu jitter femal a1 male a2 subject group d valu shimmer femal a1 male a2 subject group e valu hnr femal a1 male a2 subject group note femal cf patient lower hnr relat match control p p relat subject vocal paramet analyz grba scale male femal patient cf present overal increas r figur b1 b2 p femal p male b figur c1 c2 p femal p male figur d1 d2 p femal p male compar match control howev femal cf patient show increas g relat control figur a1 p observ male subject figur a2 p differ observ s score cf patient healthi control sex figur e1 e2 p comparison median valu iqr studi variabl statist comparison cf patient control subject segreg sex summar tabl s7 journal pone g006figur 6subject measur vocal paramet male femal control subject cf patient horizont line error bar repres median valu group valu g femal a1 male a2 subject group note femal patient signific chang g relat match control b valu r femal a1 male a2 subject group c valu b femal a1 male a2 subject group d valu femal a1 male a2 subject group e valu s femal a1 male a2 subject group p p discussionour result show subject cf present significantli alter vocal paramet object subject knowledg first systemat investig voic dysfunct cf find suggest dysphonia relev manifest cf patholog object vocal paramet affect cf intens jitter shimmer hnr chang vocal intens can observ case vocal microtrauma neurolog dysfunct obstruct respiratori diseas vocal intens depend fundament subglott air pressur upper airway airflow glottal resist observ decreas intens cf patient thu explain ineffici lung function partial upper airway obstruct characterist cf physiopatholog chronic cough major symptom cf also contribut effect chang jitter shimmer typic relat irregular vocal fold vibrat also usual relat vocal harsh presenc nois vocal signal differ variabl observ dataset can due presenc thick mucou secret vocal fold cf patient can potenti interfer oscillatori motion vocal fold addit chronic cough also known caus dysfunct vocal fold movement decreas hnr caus increas variat vocal amplitud frequenc upper airway turbul produc distort vocal signal emphas sub harmon compon vocal break consequ reduc rel contribut harmon compon overal vocal signal importantli report high vocal nois low hnr characterist sign dysphonia cf patient show drastic low hnr valu can consid patholog hoars highli detriment normal voic product decreas hnr physiolog underpin chang jitter shimmer name accumul mucu chronic cough chang object vocal paramet cf patient confirm subject evalu vocal qualiti use grba scale cf patient show signific differ perceptu vocal paramet except s previou studi shown increas r b strongli relat increas shimmer agreement find three variabl higher cf patient relat control increas caus decreas airflow rate upper airway common featur mani respiratori diseas case subglott pressur rise appropri level voic product caus asthenia hoars dataset cf patient featur can relat observ decreas intens differ g repres gener degre vocal disord e subject summat perceptu paramet make g import index within grba scale significantli higher valu g cf patient indic individu chang r b combin produc notic condit dysphonia notabl find studi femal cf patient appear vocal alter relat control male cf patient data sex analyz separ femal cf patient present signific lower valu hnr higher valu g compar match control differ sex may due intrins differ structur vocal apparatu observ men women averag men thicker vocal fold larger glottal area airflow lower laryng airway resist women data show cf vocal patholog probabl due disord vocal fold oscil obstruct upper airway dysfunct can exacerb associ thinner vocal fold higher airway resist respect taken togeth gender relat structur differ like major factor make femal patient suscept cf relat dysphonia addit sever studi report healthi male voic significantli lower hnr healthi femal across differ languag age rang also case dataset record male control subject significantli lower hnr femal control subject figur e1 e2 p femal male control intrins differ might explain alreadi mention gender relat differ structur vocal apparatu social influenc author specul women better vocal train men use voic frequent percept normal appropri voic depend expect person s gender age social group deviat vocal paramet must compar match control inde healthi women might expect higher hnr men fair predict significantli larger decreas hnr observ femal cf patient might highli deleteri impact qualiti life data suggest group femal patient voic affect pathophysiolog cf degre gener percept voic presum commun function significantli affect nevertheless import point subject male cf patient group also present low valu hnr 5db even though median valu group significantli differ control addit male cf subject also present level g valu observ male control group mean even though femal cf patient might suscept deleteri effect cf vocal capac thu present dysphon symptom male individu male cf patient might also develop signific chang hnr g result open possibl cf patient may benefit voic therapi clinic intervent strategi reduc dysphonia increas life qualiti voic therapi consist seri techniqu appli mitig voic disord includ enhanc patient s awar dysphonia applic vocal health guidelin hear train muscl relax psychodynam vocal train form therapi shown effect treatment reduc dysphon symptom sever diseas includ respiratori disord capabl least partial restor qualiti life affect patient dysphon characterist observ cf patient can potenti attribut dysfunct vocal fold movement partial upper airway obstruct can caus accumul mucu chronic cough standard symptom cf respiratori patholog avail data therapi adequ cf patient therapi vocal disord hyperfunct origin shown effect patient chronic cough given chronic cough major manifest cf patholog strategi potenti appli cf patient type intervent usual base voic educ vocal hygien strategi cough suppress also appli exercis improv dysfunct vocal fold vibrat accord data probabl major featur cf relat dysphonia cours studi must conduct confirm efficaci form treatment well form voic therapi patient cf conclusionw show patient cf exhibit symptom dysphonia chang object subject vocal paramet may relev featur cf patholog morbid voic alter pronounc femal patient exhibit mark reduct hnr overal subject voic qualiti result suggest cf patient might potenti benefit voic therapi support informationfigur s1linear correl analys age object vocal paramet control cf group p valu indic slope linear regress line significantli differ zero linear correl age f0 group note rel high invers correl r2 around two variabl control cf group b linear correl age intens group c linear correl age jitter group d linear correl age shimmer group e linear correl age hnr group p ep click addit data file figur s2linear correl analys fev1 object vocal paramet cf group fev1 common measur lung function defin volum air exhal first second forc expir normal mean valu popul p valu indic slope linear regress line significantli differ zero note small correl found fev1 object vocal paramet linear correl fev1 f0 group b linear correl fev1 intens c linear correl fev1 jitter d linear correl fev1 shimmer e linear correl fev1 hnr ep click addit data file tabl s1age bodi mass index bmi subject femal control group docx click addit data file tabl s2age bodi mass index bmi subject male control group docx click addit data file tabl s3age bodi mass index bmi fev1 medic statu femal cystic fibrosi group docx click addit data file tabl s4age bodi mass index bmi fev1 medic statu male cystic fibrosi group docx click addit data file tabl s5summari mean standard error valu normal test result studi group docx click addit data file tabl s6summari median iqr valu pool data cf control subject statist comparison includ valu mann whitney u u z score z effect size r p docx click addit data file tabl s7summari median iqr valu data cf control subject segreg accord sex statist comparison includ valu mann whitney u u z score z effect size r p docx click addit data file', 'dementia typic defin clinic syndrom cognit declin suffici sever interfer social occup function umbrella term group cognit disord character progress declin cognit function interf independ carri activ daili life due brain damag diseas relat delirium depress alzheim s diseas ad common caus dementia late life account case ad neurodegen syndrom character multidimension progress consist three core dimens cognit function psychiatr symptom function symptom defin decreas abil independ perform daili life activ preval increas rapidli due age societi though incid seem declin peopl high educ level high incom countri review focus specif late onset alzheim s diseas load defin ad onset year age load preval gener slowli progress cours compar earli onset ad current imposs provid patient famili reliabl predict cours diseas substanti variabl rate declin among individu load know factor associ declin use understand slow diseas progress well individu prognosi potenti influenti factor comorbid comorbid defin addit co exist ailment patient particular index diseas case load shown comorbid preval among individu load compar demograph match control addit review indic comorbid contribut declin load howev unclear exactli comorbid affect separ facet load sinc mani studi mere report relat comorbid one dimens load despit multifacet natur syndrom order provid multidimension overview review investig whether evid associ comorbid diseas burden cognit function psychiatr symptom individu load cross section longitudin methodsth articl identifi use electron databas medlin embas psycinfo cochran updat januari comprehens search strategi develop separ four databas s1 s2 s3 s4 appendix keyword alzheim observ studi progress comorbid use subsequ combin either cognit daili function behavior disord along synonym order meet inclus criteria articl examin cognit function neuropsychiatr outcom relat comorbid individu diagnos load age onset restrict year public use order summar avail evid associ comorbid diseas burden dementia symptom longitudin cross section studi includ sinc review address somat comorbid diseas burden gener influenc individu diseas beyond scope studi protocol review regist prospero can access dio crd42015027046 databas search yield articl paper identifi mean snowbal method yield seven articl addit search grey literatur onlin databas opengrey open doar googl scholar result identif five new articl total articl origin identifi duplic exclud titl abstract articl independ screen two review l r v m l h articl exclud meet inclus criteria anoth studi exclud base full text assess perform duplic well l r v m l h discrep two review resolv third review r j f m remain articl critic apprais two independ review l r v m l h use newcastl ottawa qualiti assess cohort studi assess select particip method control confound assess outcom cross section studi adapt version scale use question regard follow left overview select process provid fig first two author review l r v m l h co author includ studi j s l first author one includ studi r j f m moreov m j s l m g m o r r j f m co author one includ studi journal pone g001fig 1prisma flow diagram resultsout studi deem elig screen examin load dimens outcom studi influenc comorbid diseas burden focu load remain articl includ review publish overview studi provid tabl diagnosi criteria use load nincd adrda nation institut neurolog commun disord stroke alzheim s diseas relat disord associ dsm diagnost statist manual mental disord comorbid diseas burden measur use cumul ill rate scale geriatr cir g charlson comorbid index cci gener medic health rate gmhr studi count comorbid base hospit record physic examin patient caregiv report although comorbid measur differ across studi studi use person approach either interview medic examin physician journal pone t001tabl 1descript select studi author year participantscohortstudi designcomorbid measurestatist analysismean age sd yr settingmeasur interv data sourcelyketso et al n 344clinic cohort cross sectionalgener medic health ratingpearson s correlations76 nabaltimor u s naindepend assess physiciantekin et al n 143clinic cohortcross sectionalcumul ill rate scale geriatricspearson s correl stepwis linear regress baselin covariates76 8lo angel u s nanadoraiswami et al n 679mix cohort cross sectionalcumul ill rate scale geriatricsgener linear model80 na13 site state u s named histori physic examinationformiga et al n 289clinic cohortcross sectionalcharlson comorbid indexlogist regress baselin covariates81 0barcelona spainnainterview patient caregiv medic recordsoosterveld et al n 213clinic cohortcross sectionalcumul ill rate scale geriatricspearson s correl linear regress baselin covariates75 site netherlandsnamed examin physicianaguero torr et al n 46popul base cohortlongitudinalpres chronic condit ye linear regress annual rate chang baselin covariates86 6stockholm sweden3 yearsinform interviewboksay et al n 40clinic cohortlongitudinalcomorbid countna69 2new york u s yearsnasolomon et al n 102clinic cohortlongitudinalcumul ill rate scale geriatricsordin logist regress categori declin base annual rate chang baselin covariates75 2bucharest romania2 yearsmed record report patient caregiversleoutsako et al n 230popul base cohortlongitudinalgener medic health ratingquadrat mix model random effect intercept time includ baselin time vari covariates85 3utah u s month time vari year time invari interview patient caregiv medic recordsm et al n 251popul base cohortlongitudinalpres chronic conditionsquadrat mix model baselin covari random effect intercept time85 5stockholm sweden3 yearsstockholm inpati registeraubert et al n 170clinic cohortlongitudinalcharlson comorbid indexlogist regress baselin covariates83 4nant france1 yearna time comorbid measur analyz progress clinic retir nurs home popul n number particip includ analysi na inform avail five studi cross section six longitudin studi maximum follow rang year overal mean age particip across studi year rang qualiti assess one studi deem low qualiti score due lack correct confound unrepres sampl adjust baselin age unclear two studi adjust educ lack unclear five studi examin cognit adjust baselin symptom interest unclear one six longitudin studi overview qualiti assess includ studi provid s5 appendix nine studi indic symptom wors least one three dimens load individu increas comorbid diseas burden two studi fail find associ follow section will address result three differ dimens load studi global cognit abilitiesfour cross section six longitudin studi examin cognit outcom overview studi includ measur scale result provid tabl eight studi use mini mental state examin mmse measur cognit one use global deterior scale gd one use composit score neuropsycholog test presenc comorbid relat decreas cognit abil seven ten studi examin cognit three cross section four longitudin studi one longitudin studi time vari comorbid burden time invari baselin comorbid associ decreas cognit abil tabl journal pone t002tabl 2descript studi global cognit abil author year cognit measurestudi designestim se resultsmeasur interv tekin et al mini mental state examinationcross sectionalnacumul ill rate scale geriatr relat cognit statusnadoraiswami et al mini mental state examinationcross sectionalr2 p 0001higher cumul ill rate scale geriatr relat lower cognit statusnaformiga et al mini mental state examinationcross sectionalmean δ p 02higher charlson comorbid index relat lower cognit statusnaoosterveld et al neuropsycholog assessmentcross sectionalr p 01higher cumul ill rate scale geriatr relat poorer cognit statusnaaguero torr et al mini mental state examinationlongitudinalb p 694the presenc chronic condit relat chang cognition3 yearsboksay et al global deterior scalelongitudinalmean δ p 05the presenc higher number comorbid relat faster declin cognition4 yearssolomon et al mini mental state examinationlongitudinalb p 02higher cumul ill rate scale geriatr relat faster declin cognition2 yearsleoutsako et al mini mental state examinationlongitudinalβ p 01lower gener medic health rate relat decreas cognit abil analyz time vari covari use time invari baselin covariate6 month time vari year time invari β p 61meli et al mini mental state examinationlongitudinalb p 17the presenc either comorbid relat cognit cross section longitudin yearsaubert et al mini mental state examinationlongitudinalor ci p 03higher charlson comorbid index relat faster declin cognition1 yearna avail se standard error ci confid interv time comorbid measur analyz progress mix model interact linear slope report studi daili functioningfour cross section three longitudin studi examin daili function studi summar tabl function impair measur use instrument activ daili live adl four studi clinic dementia rate scale cdr one studi health util index subscal one studi psychogeriatr depend rate scale pgdr one last studi five seven studi examin daili function found comorbid relat lower function abil three cross section two longitudin one longitudin studi time vari comorbid burden time invari baselin comorbid burden associ function declin longitudin studi conduct meli et al also cross section associ baselin comorbid burden baselin function statu found two smallest studi one longitudin one cross section find associ journal pone t003tabl 3descript studi daili function author year daili function measurestudi designestim se resultsmeasur interv lyketso et al psychogeriatr depend rate scalecross sectionalβ p 001lower gener medic health rate relat increas function impairmentnatekin et al instrument activ daili livingcross sectionalr p 991cumul ill rate scale geriatr relat functioningnadoraiswami et al subscal self care health util indexcross sectionalr2 p 0001higher cumul ill rate scale geriatr relat greater function impairmentnaoosterveld et al instrument activ daili livingcross sectionalr p 001higher cumul ill rate scale geriatr relat lower function statusnasolomon et al instrument activ daili livinglongitudinalor ci 6higher cumul ill rate scale geriatr tend relat increas declin function significant2 yearsleoutsako et al clinic dementia rate sum boxeslongitudinalβ p 001lower gener medic health rate relat decreas function analyz time vari covari use time invari baselin covariate6 month time vari year time invari β p 13meli et al activ daili livinglongitudinalb p 006presenc chronic condit baselin cross section relat lower baselin function statu also longitudin faster declin functioning3 yearsna avail se standard error ci confid interv time comorbid measur analyz progress mix model interact linear slope report studi neuropsychiatr symptomsa shown tabl three studi examin neuropsychiatr symptom np use neuropsychiatr inventori npi two studi cross section one longitudin two studi one cross section one longitudin found comorbid relat increas np one longitudin studi time vari comorbid burden time invari baselin comorbid burden associ np one cross section studi found associ journal pone t004tabl 4descript studi neuropsychiatr symptom author year neuropsychiatr measurestudi designestim se resultsmeasur interv tekin et al neuropsychiatr inventorycross sectionalr p 05cumul ill rate scale geriatr relat neuropsychiatr symptomsnaoosterveld et al neuropsychiatr inventorycross sectionalr p 001higher cumul ill rate scale geriatr relat neuropsychiatr symptomsnaleoutsako et al neuropsychiatr inventorylongitudinal4 p 01lower gener medic health rate relat neuropsychiatr symptom analyz time vari covari use time invari baselin covariate6 month time vari year time invari p 38na avail se standard error time comorbid measur analyz progress mix model interact linear slope report discussion4 discuss current scientif evidencealthough total evid avail review limit main find increas somat comorbid diseas burden associ increas cognit function neuropsychiatr symptom load nine studi show associ comorbid diseas burden load symptom two studi found associ primarili cross section associ found comorbid burden three dimens load prospect studi evid longitudin associ baselin comorbid burden load progress inconsist three studi examin dimens load simultan two found associ comorbid burden dimens load third studi tekin et al cross section find associ argu associ possibl obscur rel low level comorbid mean sd cir g young age mean sd year studi popul one studi evalu time vari associ found three dimens associ time vari comorbid burden seven ten studi examin cognit abil found signific associ increas comorbid diseas burden lower cognit abil three studi found associ two longitudin conduct cohort third studi tekin et al mention previous five seven studi examin daili function found decreas function statu associ comorbid diseas burden two neg studi studi tekin et al smallest studi daili function solomon et al detect non signific trend two three studi examin np found comorbid relat increas np neg studi studi tekin et al overal qualiti avail evid rate high accord newcastl ottawa qualiti assess s5 appendix except one studi result interpret caution note assess distinguish longitudin cross section studi studi review cross section report adjust confound found inconsist across studi although studi adjust age correct educ far less common worth mention qualiti assess assess studi sampl size tabl although take follow rate end studi account length studi ignor two thing clearli relat altogeth major studi review suggest comorbid contribut rapid worsen symptom load accord broader conceptu load consequ dynam interact diseas relat individu factor howev associ comorbid burden load progress reduc linear causal relat exposur higher level comorbid burden link prospect dementia outcom rather relat complex dynam will expand next paragraph observ associ timeth studi leoutsako et al studi use time invari time vari covari studi analyz comorbid diseas burden baselin time invari predictor analyz comorbid diseas burden time vari covari mean look relationship comorbid load facet correspond point time compar two analysi approach offer interest perspect analyz associ baselin medic health rate subsequ load progress signific relationship found howev upon examin rate time vari covari clear associ cognit function psychiatr progress emerg base result leoutsako et al postul associ comorbid diseas burden load progress immedi proxim one patient facet load given point time affect health time result review provid support notion sinc associ predominantli found studi analyz cross section associ near futur progress rare observ studi analyz progress distant futur exampl examin studi comorbid cognit six seven studi report associ measur cognit cross section near futur word time comorbid measur analyz symptom now refer measur interv studi shorter year tabl extent longitudin studi measur interv longer year avail evid associ baselin comorbid burden cognit progress lack possibl explan pattern comorbid statu fluctuat dilut relationship baselin comorbid diseas burden cognit progress time short associ comorbid cognit appear time vari e dynam hypothesi support previou studi specif scope vascular co morbid found associ chang comorbid measur progress cognit impair use comorbid time vari covari possibl elucid relationship progress take fluctuat comorbid statu across follow account although gener accept prove causal hardli possibl observ studi must note particularli time vari analysi sinc establish tempor relationship imposs anoth import methodolog consequ studi occurr relat time vari way level exposur possibl risk factor need establish follow up predictor inform may avail follow assess assess less rigor detail cohort studi potenti mechan effect comorbidityth potenti mechan comorbid may affect differ dimens load numer exampl comorbid often associ increas stress level shown stress experi associ increas risk dementia possibl imbal adrenocort axi studi mice show short stress simul condit may exacerb cognit deficit preclin load acceler amyloid patholog reduc synaps number anoth common featur comorbid disrupt sleep known increas risk cognit impair especi peopl load sleep depriv may contribut wors cognit function np sinc load alreadi associ delay circadian phase line find detriment influenc comorbid cognit also observ peopl parkinson s diseas prospect studi includ elderli show excess polypharmaci logic consequ increas comorbid diseas burden also associ decreas cognit capac moreov polypharmaci found contribut function declin commun dwell patient load fact comorbid diseas burden appear posit associ cognit function declin surpris given two strongli relat load fact function impair ad appear follow cognit impair tempor impair daili function turn may decreas amount leisur social activ known protect cognit declin lower level healthi behavior self care similar mechan state previou paragraph therefor drive patient neg spiral function cognit deterior relationship diseas burden daili function also observ sever larg popul base studi healthi elderli indic comorbid condit may lead function impair irrespect load diagnosi exampl condit affect mobil although number studi support associ comorbid increas np load small multipl studi differ popul support relat increas comorbid diseas burden psychiatr disord anxieti depress cognit function consequ increas comorbid diseas burden like contribut social depriv stress found signific predictor psychosi depress compar includ studiesdur critic apprais studi methodolog challeng emerg diverg sampl frame one three studi popul base seven use clinic sampl one studi sampl obtain multipl set tabl although heterogen can increas extern valid differ studi set can also potenti influenc result due differ case mix howev compar popul base non popul base studi analyz similar dimens pattern discrep found result thu associ somat comorbid progress appear independ studi set differ inclus criteria among studi also affect case mix therefor hinder compar studi studi boksay et al use stringent criteria exclud patient histori variou comorbid might hamper compar along small sampl size lack correct age educ baselin cognit statu analys four studi analyz result load separ dementia type sinc four studi report major sampl suffer load result appear accord studi includ probabl minor influenc result given high qualiti cross section studi decid includ longitudin cross section studi review provid integr overview avail studi topic although cross section studi address diseas progress time mostli line longitudin studi use measur interv year strength limitationson strength review multidimension approach unambigu patient also experi impair activ daili live behavior chang load defin cognit impair alon narrow approach load progress adopt mani studi therefor worrisom take account three dimens review provid comprehens perspect load limit review larg variat progress measur comorbid index data sourc studi design includ studi tabl hamper quantif associ comorbid diseas burden progress differ studi popul also pose problem given larg heterogen age gender stage load medic use moreov question whether measur certain dimens truli reflect construct whether comorbid measur sensit enough captur comorbid burden suffici detail therefor meta analysi perform anoth limit review none studi took onset durat comorbid account might much amount sever comorbid burden relev rather length exposur comorbid burden without inform hypothesi imposs verifi refut given dementia long period insidi onset revers causat rule even studi focus effect comorbid burden point load becam incid contrast mani studi focu singl comorbid condit review aim examin relat overal somat comorbid diseas burden load progress provid generaliz overview howev drawback use scale overal comorbid diseas burden potenti circular studi examin np caus presenc psychiatr domain comorbid measur cir g choic studi overal comorbid burden also render imposs draw conclus individu comorbid understand mechan extent singular comorbid affect cours load might enabl us slow multidimension progress provid individu prognosi howev beyond scope review conclusionit evid cognit function psychiatr declin address simultan obtain comprehens understand load progress one first observ although highli relev three studi address three dimens load simultan therefor addit multidimension longitudin studi need provid scientif basi evid base care grow number individu affect load comorbid diseas review provid evid associ somat comorbid multifacet load progress given comorbid diseas burden given time point seem associ load facet around moment long term seem like dynam relationship comorbid diseas burden load progress comorbid burden possibl modifi factor contribut load result stress import optim treatment monitor comorbid peopl load monitor progress might particularli import case somat comorbid manifest load onset given associ comorbid load progress near futur prevent accur treatment comorbid health care profession may prevent rapid progress load moreov review emphas relev take comorbid burden account investig load progress diagnosi also follow futur studi might gain knowledg consid possibl dynam interconnect comorbid diseas burden load progress mean repeatedli measur comorbid statu preclin phase load onward analyz time vari covari conclud clear associ comorbid diseas burden load progress associ reduc simpl linear caus effect relat therefor futur studi clinic practic may benefit regard comorbid modifi factor possibl fluctuat influenc load support informations1 appendixsearch strategi medlin pdf click addit data file s2 appendixsearch strategi psycinfo pdf click addit data file s3 appendixsearch strategi embas pdf click addit data file s4 appendixsearch strategi cochran pdf click addit data file s5 appendixqu assess pdf click addit data file s6 appendixprisma checklist pdf click addit data file s7 appendixreview protocol pdf click addit data file', 'non small cell lung cancer nsclc account approxim primari lung cancer patient diagnos advanc stage stage iii iv although chemotherapi involv platinum agent repres one common first line treatment patient year surviv rate remain less clinic factor patient featur age perform statu diseas extens roughli character stage remain major determin prognosi nsclc howev variabl outcom still observ patient similar clinic featur seem host inherit factor may import role determin treatment outcom nsclc highlight necess identifi genet marker optim individu therapi consid platinum agent use chemotherapi caus dna damag cell death activ cell signal pathway host cellular dna repair capac possibl influenc outcom nsclc patient chemotherapi previou studi shown suboptim dna repair capac within tumor may lead decreas remov dna lesion therefor increas sensit platinum base chemotherapi result better clinic outcom nucleotid excis repair ner major pathway repair platinum induc dna cross link mammalian cell xpd gene encod atp depend helicas mediat dna unwind initi ner sever studi shown xpd polymorph appear effect dna repair capac possibl alter function protein product common variant xpd gene found correl decreas cancer risk clinic epidemiolog evid indic xpd lys751gln polymorph significantli associ chemotherapi effect howev polymorph xpd arg156arg xpd asp711asp epidemiolog data clinic outcom nsclc patient still scarc therefor prognost import xpd polymorph remain unclear xpd asp312asn rs1799793 lys751gln rs13181 polymorph nonsynonym singl nucleotid polymorph snp result chang amino acid sequenc protein wherea arg156arg rs238406 asp711asp rs1052555 polymorph silent mutat previou studi shown variant genotyp xpd arg156arg associ increas risk seriou hematolog toxic chines han popul base observ hypothes four potenti function snp xpd codon may influenc nsclc prognosi studi use dna sampl obtain seri nsclc patient assess associ xpd polymorph surviv advanc nsclc patient treat platinum base chemotherapi materi methodspati recruit follow upth studi design subject recruit describ previous patient inoper histolog confirm stage iii iv nsclc consecut recruit march august shanghai chest hospit shanghai china elig patient studi least year old requir fulfil follow criteria presenc measur lesion eastern cooper oncolog group perform statu ecog ps eastern cooper oncolog group perform statu criteria use assess diseas affect daili life abil patient grade grade absolut neutrophil count anc cell l platelet cell l serum creatinin upper limit normal aspart aminotransferas ast alanin aminotransferas alt upper limit normal estim creatinin clearanc ml min patient exclud prior histori malign except non melanoma skin cancer carcinoma situ uterin cervix alreadi cure tumor y diseas free surviv previou chemotherapi radiotherapi surgeri activ congest heart failur cardiac arrhythmia recent mo date treatment myocardi infarct sever mental disord infecti diseas need immunotherapi written inform consent provid patient studi carri approv ethic review committe hospit treatment patient receiv evalu includ complet medic histori health examin score perform statu routin clinic biochemistri test chest radiograph comput tomographi chest abdomen data demograph clinic characterist includ age sex smoke statu tumor histolog obtain clinic medic record review oncologist smoke statu smoke less one cigarett per day less year lifetim defin non smoker otherwis consid smoker inform surviv statist collect sever sourc includ follow call social secur death index inpati outpati clinic medic record investig blind genet polymorph statu patient patient enrol studi inoper receiv first line platinum base chemotherapi chemotherapeut regimen follow navelbin mg m2 day day plu cisplatin mg m2 carboplatin auc day repeat everi week gemicitabin mg m2 day plu cisplatin mg m2 carboplatin auc day repeat everi week taxol mg m2 plu cisplatin mg m2 carboplatin auc day repeat everi week docetaxel mg m2 plu cisplatin mg m2 day repeat everi week patient given platinum base chemotherapi chemotherapi drug administ intraven treatment two six cycl patient respons treatment evalu first line cycl chemotherapi respons evalu criteria solid tumor recist guidelin version total patient advanc nsclc particip studi complet follow statist signific differ observ distribut demograph clinic featur patient includ studi data shown result final analysi limit patient snp genotypingblood sampl collect subject time recruit genom dna extract use qiaamp dna maxi kit qiagen gmbh xpd arg156arg asp312asn asp711asp polymorph determin use sequenom massarray iplex platform matrix assist laser desorpt ioniz time flight mass spectromet previous describ lys751gln identifi pcr base sequenc primer sequenc avail request overal genotyp success determin snp qualiti control sampl subject randomli select re genotyp duplic sampl genotyp concord statist analysishardi weinberg equilibrium test snp good fit x2 test pearson x2 test categor variabl student s t test continu variabl use compar demograph clinic characterist patient achiev complet respons cr partial respons pr defin respond patient stabl diseas sd progress diseas defin non respond addit analys done group patient cr pr sd defin patient clinic benefit versu pd defin patient without clinic benefit overal surviv os calcul time death date diagnosi progress free surviv pf calcul time progress death without progress date diagnosi kaplan meier method use plot pf os curv log rank test appli compar distribut group multivari cox proport hazard model use estim hazard ratio hr confid interv ci clinic variabl log rank p univari analysi enter multivari analysi due limit number homozyg variant genotyp asp312asn asp711asp lys751gln polymorph model domin model linkag disequilibrium ld analysi d r2 valu genotyp snp calcul haploview softwar http www broad mit edu person jcbarret haplo haplotyp assess perform use phase data analyz use spss version spss inc p valu two side statist signific set level evalu chanc obtain fals posit associ due multipl hypothesi test use bayesian fals discoveri probabl bfdp test calcul probabl associ moder rang prior probabl presenc associ bfdp threshold set fals non discoveri rate four time costli fals discoveri resultspati characterist clinic outcomesdemograph clinic featur patient present tabl median age rang year patient male among subject stage iiia diseas stage iiib stage iv diseas consid histopatholog type patient diagnos adenocarcinoma squamou cell carcinoma adenosquamocarcinoma carcinoma journal pone t001tabl 1clinic characterist nsclc patient patient characteristicsn total patients353median age rang gendermale246 female107 ecog ps0 tmn stageiiia34 iiib107 iv212 histolog typeadenocarcinoma213 squamou cell75 adenosquamocarcinoma12 other smoke statusnev smokers154 ever smokers199 chemotherapi regimensplatinum navelbine187 platinum gemcitabine54 platinum paclitaxel73 platinum docetaxel18 platinum combinations20 note ecog ps eastern cooper oncolog group perform statu tnm tumor node metastasi other includ mix cell neuroendocrin carcinoma undifferenti carcinoma associ polymorph clinic benefitgenotyp inform present tabl genotyp distribut accord hardi weinberg equilibrium p associ polymorph efficaci outcom respons rate clinic benefit assess use pearson x2 test univari logist regress snp signific predictor respons rate clinic benefit overal tabl journal pone t002tabl 2xpd polymorph tumor respons univari analysi clinic benefit cr pr sd n respons rate cr pr n polymorphismsno ci p ci p arg156argc c73 00reference0 00reference0 682c a154 51a a57 39asp312asng g251 00reference0 00reference0 305a g a30 48asp711aspc c258 00reference0 00reference0 339c t t t28 55lys751glna a249 00reference0 00reference0 440a c c c32 63note cr complet respons pr partial respons sd stabl diseas odd ratio comput pearson chi squar test estim use univari logist regress associ xpd polymorph haplotyp pf ostabl show pf os analysi data accord examin polymorph overal median pf month confid interv month although lys751gln polymorph show margin correl pf signific differ pf respect xpd genotyp journal pone t003tabl 3pf os accord xpd polymorph patientspolymorphismsno median pf mo ci log rank pmedian os mo ci log rank parg156argc c85 759c a194 a70 asp312asng g308 006a g a38 asp711aspc c319 006c t t t34 lys751glna a304 014a c c c43 note pf progress free surviv os overal surviv ci confid interv asp312asn asp711asp lys751gln polymorph show statist signific associ os log rank test tabl tabl fig xpd asp312asn lys751gln polymorph median surviv time patient variant genotyp month month respect shorter wild type homozygot mst month log rank p respect signific remain adjust perform statu stage treatment regimen factor significantli associ os log rank test tabl s1 cox regress model adjust p respect tabl asp711asp polymorph t carrier genotyp associ reduc surviv compar wild type c c genotyp month versu month log rank p margin signific p valu observ adjust clinic featur adjust hr ci signific differ arg156arg os observ journal pone g001figur 1kaplan meier curv overal surviv accord xpd asp312asn polymorph b xpd haplotyp journal pone t004tabl 4polymorph associ os median os multivari analysisbfdp priorpolymorphismsmo ci log rank padjust hazard ratio ci p 05asp312asng g19 refer 88a g a13 asp711aspc c19 refer 90c t t t14 lys751glna a19 refer 88a c c c15 xpd haplotypehaplotyp gca copi number refer copi number note os overal surviv hr hazard ratio ci confid interv bfdp bayesian fals discoveri probabl bold figur remain noteworthi bfdp level suggest true associ data estim multivari cox proport hazard model adjust patient characterist p univari analysi perform statu clinic stage type treatment regimen haplotyp compos order asp312asn asp711asp lys751gln gca common haplotyp pairwis linkag disequilibrium ld four snp present tabl s2 moder ld observ among asp312asn asp711asp lys751gln variant d common haplotyp gca order asp312asn asp711asp lys751gln found account studi popul surviv patient two copi gca haplotyp wild type significantli longer patient zero one copi tabl bfdp valu observ associ calcul two level prior probabl tabl prior probabl two snp asp312asn lys751gln haplotyp remain noteworthi bfdp subgroup analysi associ xpd haplotyp overal survivalth effect asp312asn haplotyp nsclc surviv evalu subgroup analysi stage histolog type chemotherapi regimen perform statu tabl obviou evid associ haplotyp os observ stage iiib patient log rank p variant haplotyp associ significantli decreas surviv mst month adjust hr ci compar wild type gca haplotyp mst month statist signific differ also observ subgroup patient ecog perform statu patient adenocarcinoma tabl moreov haplotyp distribut differ significantli among nsclc patient consid clinic factor histolog type clinic stage ps tabl s3 journal pone t005tabl 5subgroup analysi associ xpd haplotyp overal surviv haplotyp gca copi number copi number bfdp priorvariablesdeath patientsmst month death patientsmst month log rank padjust hr ci adjust p 05total340tnm stageiii b45 31iv104 ecog ps0 44chemotherapi regimensplatinum navelbine91 platinum gemcitabine25 platinum paclitaxel31 histolog typeadenocarcinoma93 73squamou cell37 note ecog ps eastern cooper oncolog group perform statu tnm tumor node metastasi mst median surviv time hr hazard ratio bfdp bayesian fals discoveri probabl bold figur remain noteworthi bfdp level suggest true associ haplotyp compos order asp312asn asp711asp lys751gln gca common haplotyp stratifi test estim multivari cox proport hazard model adjust patient characterist p univari analysi perform statu clinic stage type treatment regimen bfdp conduct stratifi analysi use prior probabl tabl observ associ remain noteworthi even prior probabl discussionthi studi evalu whether common xpd polymorph influenc clinic outcom chines nsclc patient treat platinum base chemotherapi found variant genotyp haplotyp asp312asn asp711asp lys751gln polymorph signific contribut shorter surviv time compar correspond wild type homozyg genotyp adjust clinic factor xpd haplotyp still significantli associ os effect predomin patient stage iiib diseas addit bfdp correct suggest observ associ snp main effect subgroup analysi probabl due fals discoveri xpd member nine subunit complex tfiih act ner helicas activ requir initi ner process vivo vitro studi indic variat xpd gene may influenc clinic benefit platinum base therapi polymorph xpd codon investig sever studi consensu reach genet variat codon nonsynonym polymorph result chang amino acid sequenc protein previou studi seker et al report lymphoblastoid cell carri variant genotyp codon display higher apoptot respons uv compar carri wild type genotyp besid sever studi suggest xpd gln substitut might produc signific conform chang protein lead low number chromatid aberr decreas risk suboptim dna repair result consist previou experiment epidemiolog find variant genotyp associ effici dna repair capac human tissu result decreas effect cytotox chemotherapi asp711asp polymorph common silent substitut asp711asp lys751gln polymorph strong ld d exact function asp711asp elucid yet possibl affect stabil mrna influenc rate translat convert high usag codon low usag one altern biolog plausibl correl mediat linkag disequilibrium lys751gln potenti function snp analysi signific associ found reduc surviv haplotyp analysi effect still signific adjust clinic factor adjust p cumul effect xpd haplotyp might result synergist effect snp vitro vivo studi base combin three loci help investig true biolog mechan surviv differ haplotyp appar patient stage iiib diseas highli accord studi gurubhagavatula et al one possibl explan individu stage iv diseas may accumul mani mutat cours tumor growth may drive treatment resist overwhelm genet chang may alter dna repair capac recent meta analysi point none asp312asn lys751gln alon significantli associ os nsclc patient receiv platinum base chemotherapi howev asian popul includ lys751gln polymorph one studi includ patient elig final os analysi asp312asn studi elig os analysi minor allel frequenc three polymorph consider lower asian popul european popul adequ sampl size need boost power studi therefor examin snp chines popul will also help elucid mechan interethn differ outcom patient chemotherapi statist signific differ os snp also observ patient adenocarcinoma sinc adenocarcinoma common tumor type chines popul tend show wors prognosi find meaning effect predict particular subgroup lung cancer patient howev xpd statu tumor cell need determin tumor specimen although surviv outcom differ across xpd genotyp respons therapi differ among subgroup suggest genet factor respons short term efficaci like differ os studi sever strength compar publish studi rel larg number advanc nsclc patient treat platinum base chemotherapi first line treatment enrol studi rel homogen treatment standard limit potenti confound effect patient recruit data collect carri without knowledg genet statu addit consist subgroup analysi indic find like biolog plausibl limit work includ retrospect singl center design lack dna repair gene confirm multi center prospect studi result studi interpret sinc incid egfr mutat expect particularli high east asian popul clinic trial examin xpd snp nsclc patient regard egfr mutat may help clarifi whether xpd polymorph haplotyp act predict marker chemotherapi conclus result provid evid predict role xpd asp312asn asp711asp lys751gln polymorph haplotyp nsclc prognosi among nsclc patient treat platinum base chemotherapi suggest xpd polymorph might use risk assess chemotherapi effect predict individu treatment optim support informationt s1comparison overal surviv accord clinic characterist patient doc click addit data file tabl s2linkag disequilibrium d r2 snp xpd doc click addit data file tabl s3haplotyp distribut accord clinic factor doc click addit data file', 'endosom rout consid default pathway load class ii mhc molecul mhc molecul encount intern protein serv antigen sourc insid cell acid lysosom like compart miic howev experi fix cell mhc express cell lack key compon process pathway indic mhc load can take place also directli cell surfac appli optim size peptid also larger polypeptid chain even full length protein particular immatur dendrit cell dc util pathway dc contain larg fraction empti class ii mhc molecul cell surfac may allow direct captur antigen extracellular space cell cell surfac process seem repres major antigen load pathway cell caus irregular immun respons name matur dc activ b cell ligand present cell surfac accur reflect peptid composit insid miic compart presum safeguard mechan evolv prevent accident load class ii mhc molecul mhc molecul lost ligand rapidli convert stabl inact state non recept free peptid neither recept non recept conform structur defin yet character sole kinet paramet principl convers two form revers equilibrium larg shift toward non recept conform consequ cell surfac load usual ineffici hinder induct product immun respons peptid vaccin endosom process pathway mhc load facilit hla dm chaperon stabil peptid recept state previou studi shown surprisingli also small organ compound can exhibit effect similarli hla dm mhc load enhanc mle stabil peptid recept state result acceler antigen load ligand exchang demonstr simpl organ chemic also amino acid side chain can mediat effect experi short dipeptid demonstr can provok ligand exchang peptid load target conserv p1 anchor pocket class ii mhc molecul presenc peptid mle t cell assay therefor significantli improv cell surfac load antigen present cell apc peptid antigen directli translat increas sensit antigen specif t cell respons resultsstudi synthet organ mhc ligand exchang catalyst point alreadi p1 pocket specif target site mhc load enhanc mle pocket locat bind groov close n termin side peptid ligand ligand complex pocket accommod side chain key anchor residu peptid fig 1a therefor assum mle effect may also achiev small natur like compound consist amino acid order test assumpt solubl hla dr1 molecul incub high affin peptid ligand ha306 presenc amino acid short peptid free amino acid exhibit effect data shown simpl dipeptid tyr arg yr acceler mhc load ha306 peptid dose depend way fig 1b effect observ ala arg ar dipeptid lack aromat anchor side chain indic replac tyrosin alanin complet abrog mle effect journal pone g001figur 1amino acid side chain short peptid fragment can catalyz format mhc ligand complex locat p1 h bond network class ii mhc molecul left panel top view peptid bind site class ii mhc molecul hla dr1 α1 blue ribbon β1 domain mhc molecul red ribbon depict posit p1 indic backbon peptid ligand ha306 anchor side chain fill p1 pocket shown yellow mhc residu form h bond backbon label grey right panel side view p1 pocket load tyrosin anchor side chain surfac pocket indic yellow amino acid residu form pocket indic peptid shown spacefil mode green imag base crystal structur ha306 hla dr1 pdb 1dlh b catalyt impact dipeptid side chain format antigen complex influenc short peptid complex format rate ha306 solubl hla dr1 determin load reaction carri presenc titrat amount dipeptid tyr arg yr fill circl ala arg ar open circl absenc dipeptid dash line complex format determin elisa express rel enhanc refer spontan complex format absenc catalyst amount catalyt peptid fragment mle concentr indic x axi illustr fig 1a stabil mhc ligand complex maintain h bond network form backbon peptid consider number bond form immedi vicin p1 pocket stabil dipeptid maxim number h bond acetyl amid group introduc n c termini dipeptid comput dock acetyl dipeptid amid ac yr nh2 p1 pocket hla dr1 indic much five conserv h bond can form minim peptid coordin dock enclos supplement pdb file pdb_coordin s1 compar free dipeptid yr fold increas catalyt activ observ ac yr nh2 fig 2a partial mle effect observ also ac yr yr nh2 wherea ac ar nh2 still complet inact confirm import natur peptid structur dipeptid analogu ac yr nh2 employ tyrosin replac β homotyrosin b3hi introduct amino acid increas distanc side chain addit ch2 group result total loss activ fig 2b likewis replac standard l amino acid respect d enantiom abrog catalyt activ also dipeptid ac ry nh2 compos d amino acid invers sequenc show effect indic strict stereo specif catalyst fig 2c journal pone g002figur 2structur activ relationship catalyt dipeptid role h bond catalyt activ dipeptid variou h bond bridg proxim p1 pocket stabil ligand complex compar fig 1a n termin acetyl c termin amid introduc yr dipeptid facilit util h bond network minim peptid mle catalyst influenc demonstr load reaction ha306 sol hla dr1 presenc titrat amount yr fill circl ac yr open circl yr nh2 open triangl ac yr nh2 open squar control ac ar nh2 open diamond b impact elong side chain space dipeptid deriv use side chain space elong singl ch2 group use l β homotyrosin ac b3hyr nh2 open circl instead tyrosin ac yr nh2 fill circl c influenc d amino acid complex format carri presenc titrat amount ac yr nh2 fill circl ac ry nh2 open circl ac ry nh2 open triangl ac ry nh2 open squar ac yr nh2 open diamond ac yr nh2 open triangl ac yr nh2 open hexagon d amino acid indic small letter d structur requir catalyt anchor side chain p1 pocket hla dr1 interact prefer bulki hydrophob anchor side chain compar catalyt activ known structur prefer p1 complex format ha306 hla dr1 shown ac fr nh2 fill circl ac wr nh2 fill triangl ac yr nh2 fill squar ac lr nh2 open circl ac mr nh2 open triangl ac ir nh2 open squar ac vr nh2 open diamond ac er nh2 open triangl steric requir h bond usag particular failur dipeptid lack aromat side chain support assumpt effect mediat dimorph p1 pocket pocket hla dr1 drb1 contain residu β86g result prefer aromat lower extent aliphat anchor residu determin whether prefer reflect catalyt activ peptid mle collect acetyl dipeptid amid test tyrosin residu ac yr nh2 replac one two aromat amino acid phenylalanin f tryptophan w aliphat amino acid leucin l methionin m isoleucin valin v line expect strongest increas observ dipeptid contain f y w dipeptid aliphat side chain show weaker activ fig 2d enhanc detect ac er nh2 tyrosin substitut glutam e belong residu fit p1 pocket hla dr1 mean catalyt mle activ summar tabl solubl hla dr1 drb1 catalyt rate enhanc coeffici determin mm mm mm minim peptid mle contain f y w respect compar ac fr nh2 dipeptid aliphat mle side chain exhibit l v activ similar catalyt activ also detect unmodifi tripeptid well two peptid deriv invari chain lrmk lrmklpk ii key describ facilit mhc load target alloster invari chain bind site locat outsid p1 pocket activ howev significantli higher unmodifi tripeptid combin use activ peptid mle ac fr nh2 show cooper data shown notabl effect observ n termin fragment invari chain octapeptid lrkppkpv although fragment report facilit antigen load catalyz self releas invari chain peptid ic106 clip least experiment system catalyt effect observ journal pone t001tabl 1catalyt activ short peptid load solubl hla dr1 ha306 318compound catalyt rate enhanc m rel cat activ minim peptid mle1ac fr nh26 21002ac yr nh23 0573ac wr nh23 9544ac lr nh20 08125ac mr nh20 0086ac ir nh20 0177ac vr nh20 0248ac er nh20 0209ac ar nh20 000b catalyt tripeptides10yfr0 291111ykt0 12912kyv0 15813gyv0 168c invari chain deriv peptides14lrmklpk0 211515lrmk0 15816lrkppkpv0 minim peptid mle catalyt tripeptid introduc studi catalyt activ invari chain deriv peptid report lrmk lrmklpk lrkppkpv catalyt rate enhanc coeffici k repres rel increas spontan load rate rspont presenc catalyt peptid pcat total rate rtot can calcul rtot rspont k pcat rspont rel cat activ indic rel catalyt activ peptid deriv express percentag refer catalyt rate enhanc ac fr nh2 far impact peptid mle determin load empti mhc molecul evalu influenc complex dissoci solubl class ii mhc molecul preload medium affin clip peptid fig although peptid bind hla dr1 lower affin ha306 virtual spontan decay detect left panel appli also experi carri presenc dipeptid mle situat look differ ha306 peptid ad right panel less h hla dr1 clip complex disappear ac fr nh2 present dissoci notabl absenc catalyst complex still remain intact even h incub indic dipeptid mle abl increas also rate peptid ligand presenc ac yr nh2 ac lr nh2 half life shorten h h ac ar nh2 limit effect revers acceler complex format complex dissoci therefor correl anchor prefer p1 pocket journal pone g003figur 3catalyt dipeptid trigger revers ligand exchang demonstr peptid mle can catalyz revers ligand exchang complex dissoci clip hla dr1 induc peptid mle determin absenc left panel presenc µg ml free ha306 right panel experi mm ac fr nh2 fill circl ac yr nh2 fill triangl ac lr nh2 open circl ac ar nh2 open triangl catalyst cross use percentag clip hla dr1 complex remain indic time point determin elisa order formal demonstr catalyt side chain peptid mle act p1 pocket mutant hla dr1 gener glycin residu β86 floor p1 replac either valin β86v tyrosin ß86i fig hla dr β86v repres natur dimorph altern β86g occup β86 valin produc shallow hydrophob pocket abl accommod aliphat side chain contrast β86g pocket small bulki aromat residu non natur substitut β86i shown produc mhc molecul highli recept contain p1 pocket block tyrosin residu peptid can bind bind depend p1 pocket therefor load experi therefor carri abl908 pentadecapeptid deriv abl kinas can form complex three variant höpner et al manuscript prepar fig upper panel absenc peptid mle abl908 bind equal strong wt hla dr1 β86g hla dr1 β86g v due inher increas recept mutant exhibit highest spontan rate hla dr1 β86g y also addit peptid mle result increas load reaction fig lower panel wt hla dr1 β86g enhanc abl908 load correspond result obtain ha306 aromat dipeptid show stronger enhanc aliphat ac lr nh2 peptid pattern revers hla dr1 β86g v line anchor prefer shallow p1 pocket best enhanc obtain ac lr nh2 weaker amplif detect aromat dipeptid enhanc observ hla dr1 β86g y even slight reduct detect highest dipeptid concentr use chlorophenol pcp simpl disubstitut benzen known act independ p1 still exhibit mle effect journal pone g004figur 4allel select catalyt dipeptid recombin solubl hla dr1 molecul mutat insid p1 pocket use load experi abl908 peptid abl bind wt well mutat form hla dr1 s höpner unpublish upper panel spontan load abl908 shown wt hla dr1 β86g hla dr1 β86g v hla dr1 β86g y format abl908 hla dr complex express count per minut cpm dash line indic background signal lower panel allel select effect catalyt dipeptid shown influenc hla dr load shown ac fr nh2 fill circl ac wr nh2 fill triangl ac yr nh2 fill squar ac lr nh2 open circl p chlorophenol pcp cross dash line simpl aromat mle compound act independ p1 µg ml abl908 use wt hla dr1 hla dr1 β86g v µg ml hla dr1 β86g y complex format express rel enhanc refer spontan complex format absenc catalyst load determin elisa exposur cell synthet organ mle facilit antigen load directli cell surfac mhc molecul determin whether appli also peptid mle cell express hla dr1 gfp fusion protein drb1gfp incub absenc presenc ac fr nh2 biotinyl ha306 peptid stain fluoresc label streptavidin imag cell confoc laser scan microscopi reveal strike increas amount peptid bound cell surfac presenc ac fr nh2 fig 5a almost ha306 peptid detect load carri absenc dipeptid mle addit catalyst result bright surfac stain coloc hla dr1 gfp fusion protein journal pone g005figur 5enhanc load cell surfac mhc peptid mle confoc laser scan analysi cell surfac load drb1gfp cell express gfp tag hla dr1 molecul incub biotinyl ha306 peptid absenc presenc ac fr nh2 stain streptavidin cy5 imag taken confoc laser scan microscopi scale bar repres µm b impact apc load t cell respons fibroblast transfect express either wt hla dr1 left panel mutat hla dr1 β86g v right panel incub abl908 presenc titrat amount ac fr nh2 fill circl ac wr nh2 fill triangl ac yr nh2 fill squar ac lr nh2 open circl absenc peptid mle upper panel analysi cell surfac load fac fibroblast cell incub µg ml biotinyl abl908 4h peptid load determin fac express geometr mean geo mean lower panel enhanc abl908 specif t cell respons fibroblast cell express wt hla dr1 hla dr1 β86g v incub h ng ml ng ml abl908 wash use challeng saabl1 g2 abl908 specif t cell hybridoma recogn peptid hla dr1 molecul respons express il releas dash line repres t cell respons trigger absenc mle compound detail analysi peptid load cell analyz fac fig 5b experi fibroblast cell use express endogen class ii mhc molecul transfect full length version wt hla dr1 β86g mutat hla dr1 β86g v previou experi cell incub biotinyl mhc bind peptid abl908 absenc presenc titrat amount catalyt dipeptid fig 5b upper panel quantif peptid load fac reveal similar pattern observ solubl mhc molecul compar fig fibroblast express wt hla dr1 strongest enhanc observ aromat dipeptid aliphat ac lr nh2 peptid show weakest effect similar effect also observ bone marrow deriv dendrit cell obtain hla dr1 transgen mice data shown cell express mutat β86g v molecul aliphat ac lr nh2 effect peptid mle aromat side chain thu also enhanc cell surfac load correl allel specif anchor prefer p1 importantli increas load effici translat directli improv cd4 t cell respons fig 5b lower panel cd4 t cell hybridoma specif abl epitop saabl g2 show strongest respons stimul fibroblast cell load presenc dipeptid pattern enhanc reflect catalyt effect antigen load directli correl allel specif p1 anchor prefer aromat dipeptid effici wt hla dr1 β86g aliphat ac lr nh2 show best stimul cell express mutat hla dr1 β86g v shallow p1 pocket influenc catalyt dipeptid cd4 t cell respons studi vitro t cell assay t cell apc expos free peptid antigen peptid mle experi ha306 use antigen challeng two differ hla dr restrict cd4 t cell mous t cell hybridoma evha x5 fig 6a upper panel human t cell line pd2 fig 6a lower panel cell line presenc peptid mle result drastic increas sensit t cell respons titrat peptid mle suboptim antigen dosag reveal maxim enhanc t cell respons concentr around mm left panel concentr dose respons curv ha306 antigen shift fold toward lower concentr right panel half maxim respons absenc catalyst detect concentr ng ml evha x5 ng ml pd2 ac fr nh2 lower threshold ng ml ng ml respect line previou data weaker effect determin ac lr nh2 journal pone g006figur 6amplif antigen specif t cell respons enhanc vitro t cell respons influenc catalyt peptid antigen specif cd4 t cell respons test mous t cell hybridoma evha x5 upper panel human t cell line pd2 lower panel recogn ha306 antigen context hla dr1 left panel show influenc titrat amount ac fr nh2 fill circl ac yr nh2 fill triangl ac lr nh2 open circl evha x5 pd2 presenc ng ml ha306 respect respons absenc catalyst indic dash line right panel show dose respons curv ha306 presenc mm ac fr nh2 fill circl ac lr nh2 open circl mm ac yr nh2 fill triangl absenc peptid mle cross dash line indic background b enhanc ex vivo t cell respons lymph node cell isol hla dr1tg mice prime ha306 peptid ny eso ex vivo respons determin ifn γ elispot assay challeng cell ng ml ha306 upper panel ng ml ny eso lower panel respect bar repres number spot detect absenc black bar presenc mm ac fr nh2 grey bar spot origin singl ifn γ secret cell dash line indic background signal lastli confirm peptid mle mediat enhanc can observ also primari cell lymph node cell hla dr1tg mice challeng ex vivo absenc presenc ac fr nh2 mice prime either ha306 ny eso cd4 t cell epitop deriv ny eso protein associ variou solid tumour day antigen specif ex vivo respons determin ifn γ elispot assay fig 6b line previou result catalyt dipeptid found significantli increas sensit assay concentr ng ml ha306 upper panel ng ml ny eso lower panel number spot repres singl ifn γ secret cell significantli higher ac fr nh2 ad thu short peptid exhibit mle like activ can amplifi immun respons also primari cultur contain natur cd4 t cell profession apc discussionour experiment data show short peptid fragment can influenc ligand composit class ii mhc molecul catalyt way place amino acid side chain defin pocket mhc molecul trigger ligand exchang antigen load mutat analysi indic alreadi occup pocket p1 crucial catalyt effect organ mle compound demonstr human molecul hla dr1 similar role also establish ligand exchang driven short peptid p1 present mhc class ii molecul locat within peptid bind site accommod side chain key anchor residu peptid ligand locat pocket conserv contain polymorph residu determin allel specif prefer anchor residu sinc structur requir also dictat interact catalyt side chain short peptid exhibit effect allel select way shown simpl organ compound mle mechan base stabil peptid recept conform earlier studi show alreadi substitut residu β86g tyrosin result fill p1 pocket produc mhc molecul elev recept p1 locat proxim bind site hla dm bind studi suggest hla dm interact specif flexibl empti hydrophob p1 pocket activ convers non recept molecul hla dm recent question undisput chaperon interact region proxim p1 stabil peptid recept conform recent public introduc model transit non recept state directli correl structur chang insid pocket p1 experiment evid taken observ p1 target mle compound prevent transit strict correl catalyt activ structur requir p1 introduc studi provid addit support hypothesi stabil p1 prevent transit non recept state molecular dynam md simul confirm pocket p1 inde quickli lost peptid ligand strip mhc molecul rupp et al manuscript prepar fig calcul base coordin crystal structur hla dr1 ha306 complex reveal signific transit detect near p1 pocket shift result narrow two α helic 7å fig 7a also led complet loss p1 pocket less ns p1 caviti fill side chain remov distort fig 7c d notabl collaps prevent prior md simul ac fr nh2 dock p1 pocket fig 7b journal pone g007figur 7molecular dynam md calcul empti peptid mle stabil hla dr1 coordin mhc compon crystal hla dr1 ha306 complex 1dhl use carri ns md calcul empti mhc molecul dynam empti mhc molecul floor compos β plate sheat depict magenta α helic start structur shown red α helic structur obtain ns shown blue approxim posit p1 indic dynam carri extracellular domain bind site shown α1 β1 domain b dynam peptid mle stabil mhc molecul md calcul carri fig 7a except coordin hla dr1 molecul use prior md calcul peptid mle ac fr nh2 dock p1 pocket c p1 pocket peptid load mhc complex imag show cross section hla dr1 ha306 complex surfac mhc molecul shown yellow peptid ligand red posit p1 pocket indic d loss p1 empti mhc molecul cross section shown fig 7c peptid load mhc shown empti molecul obtain ns md calcul structur p1 pocket can longer locat base model even partial occup bind site short peptid suffici stabil recept state long posit anchor side chain insid p1 pocket supplement pdb file pdb_coordin s1 p1 therefor seem function sensor peptid load occup lead stabil open conform requir accommod peptid ligand studi group alreadi shown load statu p1 play crucial role indic intracellular antigen process pathway interact hla dm seem depend load state catalyt activ report mediat βh81 conserv residu locat top p1 pocket insid cell occup state p1 seem control interact key compon process pathway cell surfac may regul transit non recept conform function trigger safeguard mechan close bind site soon ligand lost studi show small peptid fragment can pass mechan catalyt way particularli strike effect ligand exchang peptid mle abl increas load empti hla dr molecul also dissoci hla dr molecul preload lower affin ligand revers reaction effect account increas antigen load cell surfac mhc molecul translat directli improv cd4 t cell respons molecular tool mle compound may therefor find applic experiment therapeut set improv antigen load desir particular suitabl field may peptid base tumour immun intervent exposur antigen hostil proteolyt environ extend limit access recept mhc molecul surfac profession apc import cd4 t cell product tumour immun respons just begun fulli discov role induct autoimmun respons long acknowledg evid instanc strong genet link class ii mhc molecul fact experiment autoimmun diseas can often induc adopt transfer auto aggress cd4 t cell respect accident load cell self antigen peptid mle may therefor trigger unwant auto aggress respons vitro shown alreadi presenc simpl organ mle compound can enhanc encephalitogen t cell respons may also appli coliti celiac diseas intestin dendrit cell known penetr gut epithelia cell expos dendrit insid gut lumen extrem high polypeptid concentr origin diet commens debri captur solubl antigen immatur dc lymph blood hand also seem import mechan toler induct direct cell surfac load discuss altern process pathway immatur dendrit cell natur protein fragment present blood lymph act peptid mle may therefor particip process mediat direct transfer antigen onto cell surfac mhc molecul materi methodscompound reagentsth follow peptid use ic106 kmrmatpllmqalpm clip peptid ha306 pkyvkqntlklat ny eso efylampfatpm human abl kgklsrlkpappppp hopner et al unpublish n termin biotinyl introduc use two amino hexano acid spacer unit stock solut short peptid mm prepar dmso pb ultrasound sonic follow dmso concentr yr ar lrmk yfr gyv ac ar nh2 ac ry nh2 ac ry nh2 ac ry nh2 ac yr nh2 ac yr nh2 ac b3hyr nh2 ac fr nh2 ac yr nh2 ac lr nh2 ac er nh2 lpkppkpv ac wr nh2 ac vr nh2 ac mr nh2 ac ir nh2 ac ry nh2 peptid produc emc microcollect gmbh tübingen germani analyz rp hplc nm esi ms antibodi solubl hla dr1phycoerythrin pe conjug streptavidin purchas caltag α hla dr pe l243 obtain bd bioscienc unlabel α hla dr l243 α ifn γ an18 r4 6a2 purifi hybridoma supernat prot prot g column ge healthcar r4 6a2 label nh biotin accord manufactur recommend pierc solubl wt hla dr1 dra drb1 produc s2 insect cell describ mutant form hla dr1 express baculoviru express system briefli dna code extracellular domain dra dr1b separ clone transfer vector pfastbac invitrogen leucin zipper domain ad c termini α β chain describ site direct mutagenesi hla dr1 β chain carri use quickchang site direct mutagenesi kit stratagen recombin virus gener s frugiperda cell sf21 express protein cell co infect virus α β chain cellsth follow class ii express cell line use l929 fibroblast atcc transfect wt drb1 mutat hla dr1 hla drb1 β86v ebv transform b cell atcc htr drb1gfp cell produc stabli transfect cell hla dr ß chain drb1 c termin fuse egfp falk et al unpublish follow t cell use drb1 restrict ha306 specif mous hybridoma line evha x5 human cd4 t cell line pd2 abl specif t cell hybridoma saabl g2 gener fuse cd4 t cell line gener hla dr1 tg mice bw cell hopner et al unpublish peptid load solubl hla dr1 moleculesload experi solubl mhc molecul carri describ briefli nm hla dr1 incub µg ml biotinyl ha306 peptid pb ph c h amount peptid mhc complex form determin elisa α hla dr captur antibodi l243 atcc eu3 label streptavidin delfia wallac use victor 3v reader perkin elmer ligand exchang experi carri preload hla dr1 clip complex µm hla dr1 µg ml biotinyl clip h ph ethanol pb dilut incub without µg ml ha peptid presenc absenc mm dipeptid experi carri time peptid load cell surfac mhc moleculesload experi carri describ briefli hla dr express cell well incub biotinyl mhc bind peptid presenc absenc catalyt dipeptid h c dmem fc well v bottom plate fac analysi cell stain streptavidin pe analyz facscalibur instrument bd bioscienc dead cell exclud propidium iodid stain experi carri twice confoc laser scan microscopybriefli hla dr1 express cell drb1gfp per well incub µg ml biotinyl ha peptid presenc absenc mm ac fr nh2 h c dmem fc well v bottom plate cell wash incub poli l lysin sigma coat plate min c rpmi medium gibco follow min formaldehyd fixat wash cell stain streptavidin cy5 amersham mount vectashield vector lab fix cell microscopi perform zeiss lsm510meta confoc setup phase contrast plan apochromat oil object experi carri twice t cell assayst cell assay carri describ briefli hla dr express cell well incub mhc bind peptid presenc absenc catalyt dipeptid c dmem fc well round bottom plate assay antigen puls apc cell wash h t cell ad perman exposur assay t cell ad directli without prior remov peptid experi t cell hybridoma cultur supernat remov h t cell respons determin measur il releas secondari assay ctll cell atcc describ previous experi t cell line apc radiat gy 3h thymidin ad 48h incorpor determin use microbeta counter wallac experi carri twice detect ex vivo respons elispot assayhla dr1tg mice prime µg ha306 µg ny eso incomplet freud s adjuv sigma µg cpg ond biotez gmbh day lymph node cell isol incub elispot plate multiscreen ht well filter plate millipor coat α ifn γ clone an18 cell incub densiti splenocyt well indic amount ha306 ac fr nh2 peptid h c co2 rpmi fc detect carri accord manufactur s recommend use biotinyl α ifn γ detect antibodi clone r4 6a2 avidin hrp enzym conjug sigma diaminobenzidin tablet sigma spot count use immunospot reader c t l europ gmbh experi carri twice calcul catalyt rate enhanc catalyt rate enhanc coeffici determin load assay nm solubl hla dr1 µg ml ha306 titrat amount catalyt peptid mle h c ph curv fit carri hyperbola regress f x ax b x use sigmaplot version softwar systat softwar inc coeffici determin form averag start slope b independ experi dock molecular dynam calculationth benzen ring phenylalanin residu backbon ac fr nh2 dipeptid superimpos residu y308 v309 ha306 peptid ha306 hla dr1 crystal structur 1dlh follow conform search arginin side chain dipeptid find optim orient subsequ complex structur minim use tripo softwar sybyl tripo inc st loui usa gromac forc field empti mhc structur ac fr nh2 mhc complex ns molecular dynam simul gromac forc field perform rupp et al manuscript prepar simul done physiolog condit nacl k equilibr period ps use posit restraint kjmol 1nm frame store everi ps visualis trajectori arrang figur realis use vmd support informationpdb_coordin s1the text file contain calcul coordin complex ac fr nh2 hla dr1 pdb file format dock ac fr nh2 benzen ring phenylalanin residu backbon dipeptid superimpos residu y308 locat within p1 pocket v309 ha306 peptid ha hla dr1 crystal structur 1dlh subsequ complex minim use tripo gromac forc field chain hla dr1 α chain dra chain b hla dr1 β chain drb1 chain c ac fr nh2 mb txt click addit data file', 'taylorella equigenitali gram neg coccobacillu classifi alcaligenacea famili caus agent contagi equin metriti cem sexual transmit infect hors first report current detect mani countri variou hors breed notifi oie world organis anim health cem character infect mare abund mucopurul vagin discharg variabl degre vagin endometr cervic usual result temporari infertil stallion clinic sign observ asymptomat carrier mare also report cem usual transmit sexual contact asymptomat carrier stallion indirect genit contact infect mare stallion vice versa also import factor spread cem sinc infect semen indirect vener contact use contamin fomit vagin specula artifici vagina wash bucket tail bandag can dissemin infect term biochem properti t equigenitali genu fastidi growth requir depend enrich bacteriolog media microaerophil incub condit grow bacterium report independ glycolysi hexos monophosph pathway depend tricarboxyl acid tca cycl oxid phosphoryl cell energi vitro vivo morpholog studi shown t equigenitali capsul express pili vivo t equigenitali remain abl replic equin neutrophil describ invas replic abil equin derm cell invas assay date precis virul factor report t equigenitali discoveri new bacteri isol two jack mare clinic sign taylorella genu consist one speci newli identifi bacterium character slight differ coloni morpholog notabl slower growth rate diverg immunofluoresc characterist compar t equigenitali classifi follow taxonom studi new speci name taylorella asinigenitali due high degre related remain difficult differenti two taylorella speci use classic identif techniqu alreadi report t asinigenitali incorrectli identifi t equigenitali date detect t equigenitali hors lead declar cem howev question whether declar case cem follow infect t asinigenitali remain relev sinc report mare experiment infect t asinigenitali develop clinic sign metriti cervic order understand differenti two close relat taylorella speci particularli term metabol virul capac herein report first genom sequenc t asinigenitali carri compar genom analysi sequenc recent describ genom sequenc t equigenitali resultst asinigenitali t equigenitali genom properti gener featurest asinigenitali figur 1a 1c singl bp circular chromosom overal g c content contain code sequenc cdss rrna gene trna gene tabl figur 1a plasmid found identifi protein code gene averag length bp correspond protein code content gene assign predict function tabl present t asinigenitali previous describ t equigenitali genom characterist figur 1b 1d accord gc skew analysi g c g c like origin replic t asinigenitali t equigenitali chromosom replic termin site chromosom appear diametr oppos origin can consist propos figur 1a 1b direct comparison predict cdss t asinigenitali t equigenitali perform reciproc fasta use minimum cutoff amino acid similar length result reveal cdss total gene predict t asinigenitali t equigenitali respect common taylorella speci figur averag nucleotid ident gene common strain averag amino acid ident moreov identifi t asinigenitali sequenc gave hit non signific hit t equigenitali tabl s1 reciproc t equigenitali absent t asinigenitali tabl s2 journal pone g001figur 1circular represent t asinigenitali mce3 t equigenitali mce9 genom b circular represent t asinigenitali mce3 chromosom t equigenitali mce9 chromosom respect outer circl show posit bp second blue third circl red show forward cdss revers cdss respect fourth circl show rrna black trna pink fifth circl show g c content plot innermost circl show gc skew purpl indic neg valu oliv posit valu replic origin clearli detect c d scan electron micrograph t asinigenitali mce3 observ x30 t equigenitali mce9 observ x33 respect cell observ stationari growth phase major diverg observ transmiss electron microscopi analysi t asinigenitali t equigenitali coccoid shape t asinigenitali rode shape t equigenitali howev studi necessari confirm observ sinc shown t equigenitali harbor bacillari coccoid form within singl coloni journal pone g002figur 2venn diagram illustr number put protein associ t asinigenitali t asinigenitali diagram construct reciproc fasta use minimum cutoff amino acid similar sequenc surfac proport number gene journal pone t001tabl 1gener featur genom t asinigenitali mce3 t equigenitali mce9 size bp gc cdsscode code densiti averag cd length bp rrna clusterstrnasinsert elementsaplasmidt asinigenitali mce31 33800t equigenitali mce91 33800aaccord finder http www biotoul fr html e valu t asinigenitali mce3 t equigenitali mce9 respect burkholderial phylogenyburkholderial phylogeni construct base put core ortholog gene bacteri genom sequenc burkholderial order identifi use scissor implement imomi framework result phylogenom analys figur consist previous describ rrna deriv β proteobacteria phylogeni show two taylorella speci markedli distant member alcaligenacea journal pone g003figur 3phylogenom analysi repres burkholderial speci select set genom belong burkholderial order one outgroup genom rhodococcu equi tabl s3 put core ortholog gene identifi use scissor implement imomi framework similar distanc matrix built averag percentag amino acid sequenc similar provid clustalw comparison distanc averag percent similar use infer neighbor join tree mega softwar genom alignmentth artemi comparison tool act use examin conserv gene order synteni t asinigenitali t equigenitali genom figur align show vast major common gene order averag ident align portion genom bp despit global conserv synteni genom align reveal larg chromosom invers symmetr across replic axi major diverg genom region describ tabl determin invers conserv t asinigenitali t equigenitali strain construct pcr primer set base genom sequenc t asinigenitali t equigenitali tabl s3 determin long pcr analysi orient larg invert genom region t asinigenitali t equigenitali strain tabl s4 result experi reveal orient larg genom fragment specif conserv speci given chromosom invers t asinigenitali compar t equigenitali symmetr across replic axi event chang gene orient respect replic axi thu lead gc skew discontinu journal pone g004figur 4sequenc align t asinigenitali mce3 t equigenitali mce9 genom genom t asinigenitali mce3 t equigenitali mce9 compar use blastn comparison visual artemi comparison tool act red blue line connect homolog region direct revers orient respect gap indic uniqu dna gray bar repres forward revers strand blue region number arrow indic t asinigenitali mce3 specif region pink region number arrow indic t equigenitali mce9 specif region black region number arrow indic variabl region rearrang region strain specif region briefli describ tabl analyz detail addit file journal pone t002tabl 2main characterist diverg region t asinigenitali mce3 t equigenitali mce9 genom t asinigenitali mce3t equigenitali mce9region noahypothet functionblength kbp specif genehypothet functionlength kbp specif gene1region unknown function33 130region unknown function5 552crispr associ region11 45restrict modification10 694antigen o region9 05antigen o region20 5127restrict modification3 02invers rearrang region1 438invers rearrang region7 98invers rearrang region9 059region unknown function10 04yada hep_hag relat region3 133region unknown function9 235prophag region50 9646region unknown function2 4510hemagluttinin relat region25 4511abc transport relat region14 01112efflux system5 8313region unknown function4 6514type iv secret system45 65715rh relat region15 210anumb region correspond region shown figur bdetermin basi sequenc homolog strain specif gene region t asinigenitali t equigenitalisstrain specif region t asinigenitali t equigenitali determin use act softwar specif region genom manual curat strain specif region number posit shown figur summar tabl detail addit file t asinigenitali genom contain three specif region region figur tabl s2 compos cdss furthermor t asinigenitali specif cdss mainli compos hypothet protein tabl s2 randomli insert genom region compos three hypothet protein ii four hypothet protein dnaj hypothet chaperon protein respect tabl s2 region largest t asinigenitali specif region specif cdss tasi_0412 tasi_0476 distribut genom region kb figur tabl s2 region assign put prophag prophag element identifi t equigenitali genom t equigenitali genom contain six strain specif region region figur tabl s1 contain uniqu cdss anoth t equigenitali specif cdss distribut t equigenitali genom tabl s1 region encod five protein two annot hemagglutinin abl induc agglutin erythrocyt thu involv virul phylogenet relat bordetella genu region therefor classifi hemagglutinin relat region tabl region encod six hypothet protein five protein potenti involv transmembran transport includ three abc transport relat protein thu classifi abc transport relat region region contain three put efflux system transmembran rnd resist nodul cell divis protein previous determin involv virul resist antimicrobi compound region compos four hypothet protein protein contain relaxas domain pfam03432 potenti involv horizont transfer genet inform classifi region unknown function region longest t equigenitali specif region specif cdss encod type iv secret system t4ss system membran associ transport complex use variou bacteria deliv substrat molecul wide rang target cell particular involv toxin secret inject virul factor eukaryot host target cell sever mammalian pathogen describ region classifi rearrang hot spot rh relat region compos cdss includ three rh famili protein contain repeat motif potenti locat cell surfac rh like element determin involv bacteriocin product pseudomona savastanoi pv savastanoi region specif t asinigenitali t equigenitali genom six region exist strain differ gene content design variabl region speci region compos hypothet protein must therefor classifi region unknown function region detail figur compos cluster regularli interspac short palindrom repeat crispr restrict modif r m system t asinigenitali t equigenitali respect crispr r m system mediat resist infect foreign dna genet materi e g bacteriophag conjug plasmid transpos element thu inhibit horizont gene transfer t asinigenitali crispr system contain two gene similar cas1 cas3 gene tasi_0215 tasi_0216 blast e valu e figur direct repeat bp spacer sequenc bp long blast analysi one spacer sequenc appear homolog prophag sequenc one genom part intracellular pathogen rickettsia bellii tabl s5 sequenc homolog found spacer sequenc alreadi describ e coli sulfolobu sulfataricu leader sequenc found t asinigenitali crispr loci mobil element found near crispr locu correspond t asinigenitali crispr cluster locu t equigenitali genom display six gene relat type restrict modif system figur tabl s1 r m system compos gene encod restrict enzym modif methylas act defens mechan protect host bacterium invad attack non self dna interestingli although content region diverg taylorella speci locu nonetheless contain mechan defens invad attack non self dna journal pone g005figur 5compar analysi t asinigenitali mce3 crispr t equigenitali mce9 r m system associ loci t asinigenitali mce3 crispr associ locu t equigenitali mce9 r m system locu compar use blastn comparison visual act red line connect homolog region direct orient gap indic uniqu dna gray bar repres forward revers strand repeat shown dark blue ca gene appear green neighbor open read frame light blue gc content plot bp window shown top bottom figur region correspond detail view region figur region t asinigenitali t equigenitali compos gene involv lipopolysaccharid lp o antigen biosynthesi capac induc intens host immun respons lp o antigen consid potenti virul relat factor structur analysi lp produc t asinigenitali atcc t equigenitali atcc show o antigen structur speci differ chemic structur serolog characterist observ consist fact lp o antigen use specif marker identifi differenti t equigenitali t asinigenitali character chromosom region encod lp o antigen t asinigenitali t equigenitali may allow find still unknown o antigen variant foster develop specif detect assay distinguish two speci region locat edg larg invert region genom contain one put restrict modif r m system compos restrict enzym dna cytosin methyltransferas t asinigenitali three hypothet protein t equigenitali presenc r m locu edg larg invert region alreadi describ differ genom propos involv genom invers region t asinigenitali includ seven hypothet protein tripartit atp independ periplasm transport trap content region t equigenitali quit differ includ four hypothet protein outer membran receptor protein region t asinigenitali contain three hypothet protein encod gene one potenti atp depend dna helicas recg play critic role recombin dna repair region t equigenitali includ one yada like protein one hep_hag famili protein one hypothet protein protein contain yada hep_hag domain associ autotransport share protein domain architectur hemagglutinin invas shown import virul relat role act multimer surfac protein modul cell interact host environ exampl burkholderia mallei protein contain yada hep_hag domain shown gener strong antibodi respons experiment equin model glander gener speak presenc locu rearrang two genom suggest recent speciat consist close phylogenom relationship two speci shown burkholderial phylogenom tree present figur basic nutrit metabolismth t asinigenitali t equigenitali genom predict complet tca cycl figur wherea three main pathway allow convers glucos pyruv miss sinc phosphofructokinas gene glycolysi embden meyerhof parna pathway absent ii pentos phosphat pathway lack non oxid branch transaldolas iii identifi gene entner doudoroff pathway consist observ biolog gen iii microplatetm assay show three organ acid metabol carbon sourc two speci taylorella genu malat glutam α ketoglutar tabl s6 figur malat α ketoglutar intermedi tca cycl glutam de amin α ketoglutar glutam deshydrogenas figur can also incorpor tca cycl previou studi report t equigenitali respir stimul tca cycl intermedi malat citrat succin glucos fructos maltos sucros observ partial consist observ sinc metabol activ detect experi presenc citrat succin differ explain strain variabl metabolit requir specif transport system exampl differ relat experiment procedur journal pone g006figur 6propos carbon flux taylorella genu enzym particip major reaction number thu pyruv dehydrogenas tasi_0903 tequi_1387 citrat synthas tasi_1018 tequi_1584 aconitas tasi_0659 tequi_1215 isocitr dehydrogenas tasi_0396 tequi_1024 α ketoglutar dehydrogenas tasi_0983 tequi_1309 succinyl coa synthetas tasi_0746 tequi_1545 succin dehydrogenas tasi_1020 tequi_1586 fumar hydratas tasi_0400 tequi_1028 malat dehydrogenas tasi_1024 tequi_1590 malic enzym tasi_0984 tequi_1308 glutam dehydrogénas tasi_1163 tequi_0187 pyruv phosphat dikinas tasi_0871 tequi_1418 trios phosphat isomeras tasi_0409 tequi_1037 fructos bisphosph aldolas tasi_1324 tequi_0348 fructos bisphosphatas tasi_0582 tequi_1137 glucos phosphat isomeras tasi_1244 tequi_0262 transketolas tasi_1328 tequi_0352 carbon sourc identifi metabol t asinigenitali mce3 t equigenitali mce9 gen iii micopl experiment tabl s6 highlight green dot line indic gene miss analysi appear acetyl coa need suppli tca cycl mainli produc convers malat pyruv malic enzym figur follow convers pyruv acetyl coa pyruv dehydrogenas figur furthermor compound requir purin pyrimidin lipopolysaccharid biosynthesi pathway produc gluconeogenesi pathway partial pentos phosphat pathway figur assum carbon sourc metabol t equigenitali t asinigenitali combin requir glycolysi partial pentos phosphat biosynthesi pathway synthes purin pyrimidin lipopolysaccharid partli account slow growth rate t equigenitali t asinigenitali moreov although high atmospher concentr co2 sever effect cellular physiolog alter membran properti probabl modifi intracellular ph can assum t asinigenitali t equigenitali co2 requir partli due util substrat sever carboxyl reaction involv amino acid pyrimidin biosynthesi pathway gene content analysi main gener metabol pathway t asinigenitali t equigenitali reveal differ gene composit suggest slower growth rate t asinigenitali compar t equigenitali due differ gene express enzym effici substrat suppli lack metabol pathway transport systemsth uptak efflux solut mediat transport system embed plasma membran membran compon feed use cognat high affin periplasm solut bind protein scaveng specif ligand s date three solut import famili identifi abc transport atp bind cassett trap transport ttt tripartit tricarboxyl transport t asinigenitali transport system consist gene gene encod compon abc transport system encod complet abc transport system encod trap transport five encod ttt encod miscellan protein t equigenitali transport system consist gene gene encod compon abc transport system encod complet abc transport system encod trap transport five encod ttt encod miscellan protein tabl s7 three carbon sourc metabol taylorella speci glutam α ketoglutar malat constitut substrat sever transport put glutam aspart abc transport system put proton glutam symport protein put c4 dicarboxyl transport tabl s7 howev number transport suggest taylorella speci abl transport metabol carbon substrat yet identifi despit report inabl t equigenitali util sugar confirm herein taylorella speci biolog gen iii microplatetm assay tabl s6 identifi t asinigenitali t equigenitali genom sever compon phosphotransferas system pt gener involv transport phosphoryl carbohydr identifi gene encod pt enzym tasi_1132 tequi_0099 phosphocarri protein hpr tasi_1133 tequi_0100 one cytoplasm protein eiia tasi_1134 tequi_0101 one eiia like protein ptsn tasi_0239 tequi_0851 one hpr kinas phosphorylas hprk p tasi_0238 tequi_0850 context bacteria unabl use sugar presenc gene involv pt seem surpris howev lack eiib eiic homolog suggest pt dedic sugar transport phosphoryl taylorella speci rather altern rout substrat inde previou studi pt paralog protein shown involv altern phosphotransferas rout includ unusu pt depend util dihydroxyaceton establish connect carbon nitrogen metabol explain presenc gene taylorella genom respiratori capacitysequ analysi t asinigenitali t equigenitali genom reveal presenc gene synthesi nadh dehydrogenas succin dehydrogenas cytochrom c reductas complet set gene atp synthas one termin oxidas belong cbb3 type cytochrom c oxidas tabl s8 cbb3 type cytochrom c oxidas due great affin oxygen involv microaerob metabol suggest express requir success colon anox tissu consequ cbb3 type cytochrom c oxidas may import determin pathogen taylorella speci oxid stress tolerancedur taylorella genom analysi identifi speci one superoxid dismutas tasi_0915 tequi_1375 one catalas tasi_1292 tequi_0317 one glutathion reductas tasi_0256 tequi_0384 one thiol peroxidas tasi_0972 tequi_1320 one alkylhydroperoxidas protein d tasi_0501 tequi_1062 one alkyl hydroperoxid reductas protein c tasi_0502 tequi_1063 two antioxid thioredoxin tasi_0667 tasi_1027 tequi_1592 tequi_1225 two thioredoxin reductas tasi_0294 tasi_1178 tequi_0201 tequi_0906 protein repair peptid methionin sulfoxid reductas msra b tasi_1464 tequi_0502 analysi show speci share ident set gene involv oxid stress resist suggest compar capac face oxid stress moreov number gene identifi involv oxid stress resist appear taylorella speci well equip face oxid stress potenti encount host secret systemsprotein secret key virul mechan pathogen symbiot bacteria make investig secret protein effector crucial understand molecular bacterium host interact secret system requir transport protein across cell membran play role virul fit analysi taylorella genom identifi three secret system t asinigenitali four t equigenitali tabl s9 show list put secret system identifi basi comput predict t asinigenitali t equigenitali type ii secret system t2ss consid main termin branch gener secret pathway found wide rang gram neg speci respons extracellular transport hydrolyt enzym toxin protein crucial pathogenesi mani microorgan t2ss requir presenc n termin signal peptid order util sec twin arginin transloc tat pathway protein transloc cytoplasm periplasm sec depend tat depend secret protein first produc precursor contain n termin cleavabl signal sequenc transport inner membran via proteinac complex export signal peptid cleav signal peptidas matur protein releas periplasm space fold protein transloc across outer membran taylorella speci identifi complet sec tat transloc pathway tabl s9 signal peptidas spase requir n termin signal peptid cleavag secret protein tasi_0543 tequi_1105 signal peptidas spase ii requir cleavag lipoprotein signal peptid tasi tequi_0053 signalp predict secret protein allow us identifi protein total protein respect potenti harbor signal peptid thu potenti secret via t2ss t asinigenitali t equigenitali respect tabl s10 s11 potenti locat host pathogen interfac protein constitut interest subject taylorella pathogenesi studi taylorella genom identifi type iii secret system t3ss potenti encod type ivb tight adher tad pili tabl s9 consid ubiquit pili mediat host colon persist mechan shown tad pili essenti biofilm format colon pathogenesi numer genera includ haemophilu pasteurella pseudomona yersinia data consist previous report observ pili express vivo t equigenitali found gram posit gram neg bacteria well archaea t4ss use transport macromolecul protein dna across cell envelop t4ss can mediat transport monomer protein multi subunit protein toxin nucleoprotein complex t4sss use transfer protein found pathogen bacteria play import role virul exampl establish pathogen host interact transfer toxic effector protein protein complex host cell s cytoplasm t equigenitali identifi nine t4ss relat protein virb1 virb4 virb5 virb6 virb8 virb9 virb10 virb11 vird4 tabl s9 overal structur t equigenitali t4ss region seem relat cytotoxin associ gene cag pathogen island found highli virul helicobact pylori strain form syring like pilu structur inject virul factor caga effector protein host target cell lack t4ss t asinigenitali partli explain differ virul capac two taylorella speci structur analysi recent identifi type vi secret system t6ss compon suggest secret system mimic bacteriophag machineri punctur target cell membran transloc effector protein host cell repres novel mechan deliv solubl effector t6sss contribut virul develop variou pathogen often activ upon contact target cell may also foster commens mutualist relationship bacteria eukaryot mediat cooper competit interact bacteria taylorella genom analysi identifi six t6ss relat gene tabl s9 includ hcp hemolysin coregul protein vgrg valin glycin repeat might serv conduit t6ss specif solubl effector protein regulatori functionsrel gene encod transcript regul identifi t asinigenitali t equigenitali total potenti transcript regul identifi respect includ six two compon system two sigma factor tabl s12 put extracytoplasm function ecf type σ factor identifi featur like reflect adapt stabl nutrit environ fewer biosynthet function fewer adapt requir virul factorsa cem infect remain genit tract invad damag host tissu like virul associ determin t equigenitali involv factor relat attach host extracellular matrix host cell intercellular adhes rather damag tissu keep observ identifi silico sever gene potenti involv bind colon host cell base homolog known microbi virul factor autom genom wide screen virul associ motif identifi enzym caus damag host tissu hyaluronidas hemolysin gene common speci identifi potenti involv bind colon host cell identifi abovement o antigen encod gene gene encod protein contain ankyrin sel1 subtyp tetratricopeptid repeat motif tpr sel1 protein encod eukaryot domain shown import interact variou intracellular bacteri pathogen eukaryot host cell within t asinigenitali genom identifi six tpr sel1 repeat contain protein tasi_0026 tasi_0290 tasi_0331 tasi_0362 tasi_0643 tasi_0687 one ankyrin protein tasi_0860 t equigenitali genom identifi five tpr sel1 repeat contain protein tequi_0900 tequi_0945 tequi_0979 tequi_1197 tequi_1243 two ankyrin protein tequi_1429 tequi_1600 t equigenitali specif gene identifi potenti involv bind colon host cell can cite abovement hemagluttinin relat protein three put efflux system transmembran rnd protein t4ss yada hep_hag domain contain protein tabl tabl s1 also identifi among t equigenitali specif cdss randomli insert genom virul associ gene tonb depend lactoferrin transferrin receptor tequi_0057 tequi_0058 tequi_0902 tequi_0903 heat shock protein hsp60 tequi_0973 tonb depend outer membran receptor lactoferrin transferrin identifi allow iron import mammalian iron carrier lactoferrin transferrin across outer membran iron essenti microbi growth abil acquir ferric iron host directli relat virul suggest virul charact t equigenitali due better iron acquisit capac t asinigenitali hsp60 character particular legionella pneumophila multifunct chaperonin can express bacteri cell surfac act invas factor non phagocyt cell releas host cell act effector capabl alter organel traffick organ actin microfila cell signal pathway absenc protein t asinigenitali suggest cell invad capac specif t equigenitali t asinigenitali genom screen identifi t asinigenitali specif gene potenti involv virul absent t equigenitali discussionlittl known molecular level mechan taylorella pathogen neither virul mechan host resist known first compar genom analysi two member taylorella genu present reveal close relationship two speci limit size taylorella genom conserv synteni suggest quit strong select pressur good adapt ecolog nich fact main genet differ concentr rearrang loci mainli link mobil genet element e g bacteriophag rearrang hot spot r m suggest restrict adapt driven mobil element rather need adapt divers environ observ appear consist conserv metabol pathway strict nutrit requir two speci context can hypothes hors infect aris contamin contact anim display asymptomat carriag taylorella speci unidentifi environment sourc contamin inde bacteria lack catabol pathway requir surviv mani environ seem unlik taylorella speci abl propag outsid host perspect intracellular facult lifestyl t equigenitali put t asinigenitali assum slow growth rate small number metabol carbon sourc despit usual avail larg varieti carbon sourc mammalian host cell due filter nutrient suppli allow surviv expens slow growth inde order surviv long possibl within infect host cell bacteria withdraw mani basic nutrient essenti host cell metabol host will soon starv death bacteria quickli lose protect nich chromosom invers across replic axi taylorella strain gener characterist x shape symmetr dna dot plot data shown alreadi report numer bacteria seem frequent bacteri evolut although function invers often determin suggest maintain distort replichor induc insert foreign genet element gener genet shuffl creat novel gene pool can enhanc virul environment fit fact major strain specif gene locat within specif region gener associ atyp gc content figur suggest region incorpor genom recent horizont gene transfer time decay genom wide averag gc content moreov given bacteria share vivo nich may consid genit equida microbiom constitut sourc horizont transfer gene screen system mediat resist infect foreign dna genet materi show t asinigenitali genom seem effici equip defend phage integr prophag integr one crispr system one r m system t equigenitali can defend one r m system despit prophag detect t asinigenitali genom t equigenitali genom differ phage phage resist gene content confirm strain speci order determin featur repres speci level may therefor mean term phage interact impact gene transfer potenti identifi numer secret system taylorella genom complet t2ss t3ss t6sss identifi strain t4ss identifi t equigenitali genom protein secret key virul mechan pathogen bacteria crucial pathogenesi molecular bacterium host interact great interest studi system absenc t4ss t asinigenitali partli explain differ virul capac two taylorella speci two main characterist explain differ virul capac t asinigenitali t equigenitali potenti better capac t equigenitali acquir ferric iron host reveal presenc lactoferrin transferrin receptor t equigenitali absent t asinigenitali ii presenc t equigenitali alon hsp60 homolog protein can express bacteri cell surfac act invas factor moreov although virul factor gener consid associ host interact pathogen note mani can also consid fit factor non virul context adhesin exampl import colon manner nich although colon necessarili lead infect diseas can illustr asymptomat carriag t equigenitali t asinigenitali mani mare previous report given close overal similar genom sequenc futur function investig speci specif cdss appear interest particular respect inter speci differ term growth abil anim host prefer pathogen capac addit file context benefici experiment determin whether t asinigenitali like t equigenitali abl invad replic cultur cell order concentr pathogen studi gene belong one speci sequenc two relat speci share similar lifestyl provid insight biolog organ notabl refin expand knowledg phylogeni metabol virul comparison t equigenitali genom led identif sever speci depend gene studi region will help us clarifi intrins differ taylorella genu potenti host specif virul associ factor analysi suggest t equigenitali effici equip t asinigenitali term pathogen relat factor investig requir determin whether justifi declar cem caus t asinigenitali now taylorella genom sequenc annot appear necessari develop molecular genet tool includ transform taylorella order develop function studi mechan involv virul materi methodsbacteri strain cultur conditionsth t asinigenitali strain isol genit tract year old donkey jack stud farm loir et cher franc identif strain maintain french nation refer laboratori cem ans dozulé laboratori equin diseas franc t asinigenitali t equigenitali strain inocul readi use chocol agar media ae chemunex combourg franc plate incub c v v co2 air h h respect genom dna extract previous describ biolog gen iii micropl assay biolog inc http www biolog com perform accord manufactur s recommend micropl incub h c v v co2 air result analyz sequenc assemblywhol genom sequenc t asinigenitali entail combin gs flx solexa pair end sequenc technolog carri beckman coulter genom danver ma unit state genom librari contain kb insert construct read includ pair end read produc use gs flx system give fold coverag genom assembl four larg contig one potenti larg scale scaffold use mira softwar total million read averag length bp gener use illumina solexa genom analyz ii map contig use cons softwar correct error gener technolog order orient four larg contig confirm pcr assembl singl sequenc protein similar kegg protein databas use kegg ortholog pathway assign annotationannot result merg result obtain rast rapid annot use subsystem technolog server trnascan se rnammer follow manual curat overal subsystem categori distribut t asinigenitali t equigenitali genom similar figur s1 crispr loci detect crisprfind secret protein identifi effect analysi http effector org t asinigenitali genom sequenc deposit embl genbank databas access cp003059 access number genom sequenc use compar analys list tabl s13 analysi occurr t asinigenitali t equigenitali larg genom invers pcrthe orient larg chromosom invert region t asinigenitali t equigenitali chromosom depict figur examin la pcr method takara otsu japan use site specif primer pair tabl s3 t asinigenitali strain inclus t equigenitali strain inclus tabl s4 briefli pcr perform follow c min one cycl c sec c min cycl c min one cycl amplifi fragment separ use agaros gel electrophoresi visual ethidium bromid stain electron microscopytaylorella cultur rins pb ph fix glutaraldehyd cacodyl buffer m ph overnight c fixat cell sediment thermanox coverslip coat poli l lysin cell rins cacodyl buffer m ph presenc m sucros post fix hour osmium tetroxyd cacodyl buffer m ph presenc m sucros c protect light cell rins cacodyl buffer m ph presenc m sucros cell dehydr progress bath ethanol critic point dri cpd leica microsystem cell sputter platinum observ jeol 6400f scan electron microscop jeol ltd tokyo japan support informationfigur s1subsystem distribut cdss t asinigenitali mce3 t equigenitali mce9 rast subsystem base annot success categor predict code sequenc t asinigenitali mce3 subsystem t equigenitali mce9 subsystem overal subsystem categori distribut t asinigenitali mce3 t equigenitali mce9 similar variat includ rna metabol cell wall capsul amino acid deriv docx click addit data file tabl s1t equigenitali mce9 specif cdss gene homolog t asinigenitali mce3 reciproc fasta use minimum cutoff amino acid similar sequenc xlsx click addit data file tabl s2t asinigenitali mce3 specif cdss gene homolog t equigenitali mce9 reciproc fasta use minimum cutoff amino acid similar sequenc xlsx click addit data file tabl s3primer use orient analysi larg genom invers region taylorella strain docx click addit data file tabl s4taylorella strain use studi larg genom invers docx click addit data file tabl s5characterist crispr loci found t asinigenitali mce3 sequenc similar crispr spacer spacer similar determin blastn ncbi nucleotid collect descript origin blast e valu indic similar found databas xlsx click addit data file tabl s6result biolog gen iii microplatetm growth assay t asinigenitali mce3 t equigenitali mce9 xlsx click addit data file tabl s7list predict transport system t asinigenitali mce3 t equigenitali mce9 xlsx click addit data file tabl s8list gene potenti involv t asinigenitali mce3 t equigenitali mce9 respiratori capac xlsx click addit data file tabl s9predict gene composit secret system t asinigenitali mce3 t equigenitali mce9 xlsx click addit data file tabl s10t asinigenitali mce3 secret protein accord signalp predict xlsx click addit data file tabl s11t equigenitali mce9 secret protein accord signalp predict xlsx click addit data file tabl s12put transcript regul two compon signal transduct system identifi taylorella speci xlsx click addit data file tabl s13genbank access number taxon number genom use phylogenet analysi docx click addit data file', 'sulin like growth factor ii igf ii import regul growth metabol human anim adult human almost igf bound insulin like growth factor bind protein igfbp addit modul igf bioavail exert biolog effect adult human igf circul mainli ternari complex bound igfbp igfbp acid labil subunit igfal ternari complex prolong half life igf thu major determin igf concentr igf system well describ cat indic import differ cat human understand igf system cat improv clinic diagnos benefici abl measur igf ii igfbp felin medicin igf mainli analyz diagnosi growth hormon disord also research igf ii igfbp routin analyz clinic practic knowledg commerci valid assay cat larg variabl human igf immunoassay report colleg american pathologist cap profici test program igf demonstr interlaboratori variabl cv septemb march mass spectrometri base method demonstr better reproduc cv one studi demonstr larg variabl measur felin igf four non cat specif immunoassay appli human immunoassay analysi sampl speci might caus problem includ weak reactiv unwant cross reactiv assay therefor need thoroughli valid use measur igf immunoassay difficult due interfer igfbp may caus fals high fals low valu depend assay target mass spectrometri base method attract altern immunoassay approach restrict select speci time consum expens work produc affin reagent circumv concept target select peptid precursor quantif base fragment peptid target ms usual perform tripl quadrupol refer select reaction monitor multipl reaction monitor srm mrm time consum difficult part srm mrm method develop find good precursor product ion pair late altern approach refer parallel reaction monitor prm develop quadrupol orbitrap mass spectromet prm analysi transit target precursor measur select fragment quantif done post acquisit combin high select quadrupol ms high resolut orbitrap ms make good method target proteom complex matric serum plasma commonli use strategi absolut quantif srm mrm experi includ synthet heavi isotop label refer peptid studi recent launch product name qprest use intern standard qprest amino acid long sequenc segment human protein heavi isotop label 15n 13c lysin arginin develop within human protein atla project qprest digest togeth sampl give potenti advantag incomplet unspecif digest corrupt result can issu use synthet isotop label peptid similar reagent market call qconcat construct qconcat artifici protein consist tryptic peptid sever protein sequenc variant qconcat avail includ reagent natur flank sequenc qprest produc alreadi exist librari well valid construct cover human protein code gene human sever quantit mass spectrometri base method set determin igf ii igfbp public srm mrm top approach recent also shown mass spectrometri base method decreas interlaboratori varianc compar affin base method regard speci mass spectrometri base quantif studi publish igf hors plasma serum best author knowledg mass spectrometri base quantif studi publish felin igf ii igfbp aim studi therefor set quantit target mass spectrometri method igf ii igfbp igfbp felin sera demonstr prm base strategi enabl accur quantif four target protein addit qprest origin develop repres human protein shown use intern standard also applic concern felin protein materi methodschem reagentsacetonitril acn aceton formic acid fa purchas merck darmstadt germani ammonium bicarbon nh4hco3 urea dithiothreitol dtt iodoacetamid iaa obtain sigma aldrich st loui mo usa tryptic digest trypsin sequenc grade modifi promega madison wi usa use ultrapur water prepar milli q water purif system millipor bedford ma usa felin serum sampl gel fraction felin serumapprov blood sampl cat given swedish ethic committe c301 swedish board agricultur blood sampl centrifug minut room temperatur serum frozen c use serum one cat separ size exclus chromatographi superdex column ge healthcar littl chalfont u k acid condit separ igf igfbp protocol publish mohan baylink follow except sampl incub m acet acid contain m nacl minut load onto column short ml serum dilut ml acet acid nacl solut incub minut room temperatur filter remov particl whatman rezist μm ge healthcar volum ml sampl load onto column elut ml min fraction collect everi second minut dri speedvac system commerci avail igf elisa mediagnost reutlingen hous igf ii assay use immunoreact measur fraction three gel fraction fraction ii iii select analysi mass spectrometri total seven felin sera sampl includ studi g sampl chosen repres cat potenti differ level target protein three sampl collect healthi cat c three sampl cat diabet mellitu d f sampl f collect insulin treatment cat e final sampl cat diabet mellitu diagnos acromegali includ sampl g sampl g fraction protein standardsto abl match tryptic peptid qprest felin sequenc emboss needl use sequenc align human felin amino acid aa sequenc see fig qprest contain peptid match felin igf ii qprest22489 igfbp qprest23429 igfbp qprest23781 qprest23782 isotop puriti peptid puriti obtain atla antibodi stockholm sweden igf two peptid gpetlcgaelvdalqfvcgdr lemycaplkpak synthes heavi label 15n 13c lysin arginin isotop puriti peptid puriti purchas new england peptid refer neptun peptid gardner ma usa human recombin igf igf ii protein purchas immunolog biochem testsystem binzwangen germani human control serum specifi concentr igf control ks2 valid mediagnost igf e20 elisa purchas mediagnost reutlingen germani journal pone g001fig 1homolog studi four select cat protein human analogu human felin amino acid sequenc qprest sequenc underscor human sequenc igfbp two avail qprest igf ii igfbp one tryptic peptid qprest match peptid found felin sequenc market bold ital green peptid use quantif red one evalu use igf tryptic peptid qprest match felin peptid blue peptid synthet neptun peptid use quantif red peptid evalu use shorter matur protein mark igf igf ii similar score emboss needl present sequenc solut tryptic digestionth protein content felin sera measur bradford protein assay bio rad laboratori hercul ca usa aliquot correspond approxim μg total protein taken solut digest volum adjust m nh4hco3 ph total volum μl qprest igfbp spike final concentr fmol μl respect qprest igf ii spike fmol μl sampl sonic minut μl mm dtt ad sampl kept c min reduc protein irrevers carbamidomethyl cystein μl mm iaa ad follow min incub room temperatur dark digest trypsin w w ad sampl incub night c heavi label synthet peptid spike final concentr fmol μl tryptic digest sampl divid aliquot correspond μg protein aliquot desalt ziptip c18 column merck millipor aliquot dri speedvac system re dissolv μl fa tip activ x μl acn equilibr x μl fa sampl coupl matrix repeat cycl μl sampl load tip wash x μl fa final sampl elut μl acn fa cycl aspir dispens desalt sampl dri speedvac system analysi nanolc ltq orbitrap mass spectrometri peptid aliquot re dissolv μl fa milli q water protocol adjust gel fraction felin serum sampl amount dtt iaa reduc μl ziptip c18 column step exclud sinc pre purif sampl obtain size exclus chromatographi step human control serum prepar twice exactli way felin sera sampl two differ analyst shotgun nanolc ltq orbitrap ms ms analysisonlin nano lc separ obtain easi nlc ii system thermofish volum μl sampl load onto pre column easi column cm inner diamet μm μm c18 a1 thermofish scientif maximum pressur bar peptid elut onto easi column cm inner diamet μm μm c18 a2 thermofish scientif use separ flow rate nl min use mobil phase milli q water fa b acn fa set separ min step gradient b b min follow min wash step b use easi nlc ii system connect via nano flex ion sourc ltq orbitrap velo pro etd mass spectromet thermofish scientif spray voltag set kv instrument oper data depend mode automat switch high resolut mass spectrum low resolut ltq system control ltq tune plustun xcalibur survey scan perform m z resolut m z abund ion peak cid fragment full scan cycl screen done charg state dynam exclus set second mass window precursor ion select set m z ms ms normal collis energi activ time ms activ q use fragment scan low pressur cell ion trap detect secondari electron multipli nanolc q exact plu prm analysisth prm analys perform q exact plu orbitrap mass spectromet thermofish scientif easi nlc system thermofish scientif use peptid separ column ion sourc analog use easi nlc ii system shotgun set flow rate nl min use mobil phase milli q water fa b acn fa use separ four μl tryptic digest felin serum sampl inject min step gradient b b min b b min follow min wash step b use system control q exact plu tune xcalibur prm method combin two scan event start full scan event follow target ms ms doubli tripli charg precursor ion schedul inclus list min retent time window full scan event employ m z mass select orbitrap resolut m z automat gain control agc target valu maximum fill time ms target ms ms run orbitrap resolut m z agc target valu maximum fill time ms target peptid isol use m z unit window fragment perform normal collis energi nce ev repeat charg state regard signal intens chosen select peptid total nine peptid correspond heavi peptid compris inclus list differ two charg state obviou kept analysi felin sera tabl journal pone t001tabl 1target peptid includ prm method bold underscor peptid use final quantif c termin arginin r lysin k heavi label cystein carbamidomethyl fragment select quantif given fragment singli charg igf m z th chargesequencepositionrt min fragments769 gpetlcgaelvdalqfvcgdr light 5y4 y5 y6 y7 y10 b9773 gpetlcgaelvdalqfvcgdr heavi lemycaplkpak light lemycaplkpak heavi lemycaplkpak light lemycaplkpak heavi lem ycaplkpak light lem ycaplkpak heavi 6igf ii m z th chargesequencert min giveeccfr light 8y3 y4 y5 y6 y7 b3590 giveeccfr heavi 8igfbp 3rt min m z th chargesequence506 eteygpcr light 0y2 y4 y5511 eteygpcr heavi 0igfbp m z th chargesequencert min gvclnek light gvclnek heavi eheepttsemaeetyspk light eheepttsemaeetyspk heavi fvggaentahpr light fvggaentahpr heavi fvggaentahpr light 1y2 y7 y10422 fvggaentahpr heavi qeseqgpcr light qeseqgpcr heavi hmeaslqelk light hmeaslqelk heavi hmeaslqelk light hmeaslqelk heavi 7data analysisprotein identif shotgun run perform use proteom discover version thermofisch scientif search perform use sequest ht includ percol search done felin refer proteom without isoform taxonomi download www uniprot org paramet search set fix modif carbamidomethyl c variabl modif deamid n q oxid m precursor mass toler ppm fragment mass toler da maximum two miss cleavag site s n threshold set search result valid use percol fals discoveri rate fdr use minimum two uniqu peptid per protein use identif data analysi quantif prm run skylin softwar use quantif base sum area curv auc three six fragment select peptid ratio sampl peptid fragment heavi isotop peptid fragment sampl measur three time mean standard deviat determin concentr calcul determin linear limit detect limit quantificationqprest longer neptun peptid use spike experi determin linear limit detect lod limit quantif loq target protein appli optim prm method qprest digest thereaft spike digest cat sera final concentr fmol μl neptun peptid spike sampl without prior treatment final concentr fmol μl respect sampl analyz three replic run lod loq calcul base linear regress follow formula lod 3sa b loq 10sa b sa standard deviat y intercept b slope standard dilut curv skylin softwar appli extract auc fragment built tool data analysi microsoft excel use perform linear regress statist evalu resultssampl screen intern standard selectionth aim studi set target mass spectrometri method quantif igf igf ii igfbp igfbp felin sera sinc felin protein standard avail gel fraction perform concentr target protein remov interf abund protein target protein classifi uncharacter protein uniprot databas therefor import valid sequenc prior peptid select guidanc result elisa run target igf ii three gel fraction select mass spectrometri analysi shotgun analysi ltq orbitrap velo pro etd mass spectromet result number detect protein four target protein among identifi one see tabl support inform s1a s1c tabl detect sequenc coverag igf igf ii igfbp respect thu result confirm part uncharacter sequenc show number peptid potenti use quantif journal pone t002tabl 2result shotgun analys gel fraction cat sera sampl fraction ifract iifract iiitot number detect proteins755027igf ipresentpresentpresentigf iinot presentpresentpresentigfbp 3presentnot presentnot presentigfbp 5presentnot presentnot presentan addit object studi explor human deriv qprest s use intern standard quantif cat protein align human canon sequenc use felin sequenc reveal sequenc matur form igf aa ident human sequenc matur form igf ii aa differ aa human sequenc first gap felin igfbp sequenc consid similar felin human protein moreov demonstr three four target protein match tryptic peptid least one qprest fig igf ii igfbp one felin tryptic peptid per protein match sequenc five match tryptic peptid origin two qprest s identifi igfbp therefor conclud qprest s use intern standard quantif three protein igf match qprest avail even though matur human felin igf protein ident therefor type intern standard requir quantif igf synthet heavi isotop label peptid neptun select method optimizationgiven sequenc similar recombin human igf igf ii protein use method optim prm method q exact plu orbitrap ms minut lc gradient appli ensur good separ tryptic peptid sever paramet includ agc maximum inject time resolut isol window nce optim final set method can found experiment section inclus list doubli tripli charg peptid base tryptic qprest peptid neptun peptid set includ prm method tabl care evalu one peptid per protein select quantif see tabl peptid igf provid six ms ms fragment use quantif overal better perform igf observ methionin oxid occur peptid igf tabl result differ run igf ii peptid also produc six reproduc fragment igfbp peptid produc one domin fragment total three fragment use quantif igfbp challeng protein quantifi sinc lowest concentr peptid igfbp select quantif base spectrum reproduc signal intens optim method evalu linear limit detect lod limit quantif loq spike experi tryptic digest cat serum perform heavi label peptid e qprest s neptun peptid ad known amount normal toward correspond nativ peptid linear regress normal signal four intern standard peptid result correl coeffici igf igf ii igfbp igfbp respect fig lod loq attomol μl pm level establish sampl matrix e tryptic digest cat serum see tabl detect limit also recalcul correspond concentr nativ serum assum tryptic digest protein sampl matrix complet calcul shown support inform s1 file journal pone g002fig 2intern standard dilut seri qprest neptun peptid spike cat serum analyz prm method differ concentr ratio synthet nativ peptid plot spike concentr journal pone t003tabl 3lod loq valu quantifi peptid dilut felin serum correspond valu nativ serum igf iigf iiigfbp 3igfbp 5dilut serumn serumdilut serumn serumdilut serumn serumdilut serumn serumlod fmol μl 1528loq fmol μl 5193quantif felin serafin concentr igf igf ii igfbp igfbp determin felin serum sampl get indic repeat method one sampl analyz three replic two differ prepar six measur gave accept rel standard deviat valu igf igf ii igfbp igfbp respect concentr four target protein determin three replic run shown seven cat sera sampl fig raw data calcul given support inform s2 file observ igf ii concentr higher igf concentr non acromegal cat serum cat suffer acromegali contain significantli higher level igf igfbp igfbp serum healthi diabet cat igf ii elev cat journal pone g003fig 3quantifi concentr four target protein seven sampl felin sera averag concentr standard deviat given n sampl b g n sampl sampl c sampl healthi cat d e collect cat diabet mellitu insulin treatment sampl f collect cat sampl e insulin treatment sampl g collect cat acromegali discussionin studi prm method set quantif four felin growth relat hormon igf ii igfbp previous establish method measur felin igf ii igfbp igfbp knowledg present method first one develop quantifi four protein cat serum one advantag ms base method immunoassay target protein measur within experiment run reduc variat due methodolog amount serum need analysi can great advantag cat small anim four target protein classifi uncharacter protein uniprot databas howev shotgun analysi confirm part sequenc reveal potenti target peptid studi first one investig applic qprest quantif protein non human sampl felin serum advantag use qpreststm protein standard includ qconcat digest togeth target protein compens incomplet cleavag addit protein express e coli therefor rel cheap produc purchas digest sever peptid avail quantif even though qprest human origin high similar cat human target protein confirm fig support use reagent felin studi repeat result obtain three target protein quantifi use qprest howev limit quantifi non human protein demonstr studi gener fewer tryptic peptid can select quantif sole one tryptic fragment avail two protein igf ii igfbp qprest still consid good option sinc produc alreadi exist librari well valid construct built sequenc known low sequenc similar protein human proteom studi demonstr natur flank sequenc improv perform qconcat synthet peptid tryptic peptid deriv qprest flank nativ human sequenc felin human sequenc similar proxim cleavag site fig advantag mani valid ms base method reli quantif one singl tryptic peptid surprisingli match qprest found igf despit fact matur human felin igf protein ident explan qprest produc toward sequenc e domain pro igf part matur igf sampl studi select aim analyz serum healthi cat well cat igf routin measur clinic practic e diabet acromegal cat protein concentr determin categori sampl prm method deliv detect limit attomol μl pm level sampl matrix analysi igf igf ii igfbp gave concentr calcul loq investig cat serum sampl lowest concentr determin igfbp five seven sampl lod protein sampl acromegal cat sampl g gave valu calcul loq thu exact quantiti protein determin significantli higher concentr measur serum acromegal cat peptid use quantif igfbp elut earli gradient might therefor set affect void volum gold standard method analysi igf cat refer materi avail henc difficult state true concentr explor accuraci prm approach human control serum use igf elisa specifi igf concentr ng ml analyz sinc present method optim igf peptid common human cat protein method well applic analysi human sampl analysi result valu within given rang support inform s3 file recent approach base cleavabl report peptid recalibr therebi determin exact concentr peptid standard suggest worth mention initi amount qprest determin similar method e normal toward well defin tag standard present studi sera six differ cat analyz make difficult draw conclus clinic use nevertheless cat acromegali expect higher igf healthi cat healthi human igf ii concentr higher igf also observ non acromegal cat present studi acromegal cat igf ii elev compar healthi cat remain three protein show high concentr human igf ii less gh depend igf concentr acromegal peopl shown increas decreas regul growth relat protein cat yet explor may facilit use ms wherebi mani compon igf system can identifi forese present mass spectrometri base method valuabl tool better understand complex system use prm protein can easili ad list protein quantifi suitabl peptid quantif identifi support informations1 tableshotgun screen three fraction cat serum obtain size exclus chromatographi result analysi fraction ii iii summar tabl s1a b c respect four target protein high light green data match peptid shown tabl obtain proteom discover use standard format pdf click addit data file s1 filecalcul paramet determin linear rang limit detect limit quantif first sheet show raw data area curv auc fragment appli record calibr curv follow four sheet show statist evalu igf igf ii igfbp igfbp respect skylin softwar appli extract auc fragment built tool data analysi microsoft excel use perform linear regress statist evalu xlsx click addit data file s2 filecalcul concentr seven differ cat sera peak area fragment use quantif shown protein concentr target protein calcul xlsx click addit data file s3 fileanalysi human control sampl control sampl prepar two differ analyst analyz duplic experi individu measur result valu well within specifi rang ng ml xlsx click addit data file', 'label individu viral protein fusion fluoresc molecul conjunct advanc fluoresc imag techniqu greatli expand possibl investig viru cell interact includ live cell imag approach studi dynam intracellular event well super resolut fluoresc microscopi method surmount diffract barrier light microscopi allow analysi fluoresc label structur resolut nm review see human immunodefici viru hiv deriv label fusion fluoresc protein fp structur polyprotein gag accessori protein vpr viral integras respect success employ analyz cell entri well particl assembl hiv live cell fluoresc microscopi e g review sub diffract microscopi employ proof principl studi display distribut mobil hiv gag molecul plasma membran viru produc cell fp becom invalu tool cell biolog virolog properti present disadvantag limit use live cell microscopi fp inferior mani modern synthet fluorophor respect quantum yield photost restrict time resolut durat observ live cell experi ii although continu increas rang fp differ spectral properti avail color rang limit particular blue far red rang fp display photophys properti render suitabl sub diffract microscopi method iii fluorophor fp display rel slow matur kinet consequ newli express fp molecul initi undetect fluoresc microscopi limit use puls chase experi iv fp obligatori multim may affect function cellular fusion partner v final experiment setup cell biolog often involv multi color approach use sever differenti label protein case fp fusion protein individu express construct clone character order obtain differ spectral variant protein interest genet encod non fluoresc label can specif stain use synthet fluoresc dye offer greater flexibl choic label well known exampl type motif six twelv amino acid long tetracystein tc tag attract due small size tc tag employ gener tag hiv deriv howev disadvantag system includ high degre intracellular background stain depend stain redox state tag limit select compat fluoresc dye therefor decid explor use call snap tag label hiv snap tag genet encod label slightli lower molecular mass fp kda deriv mammalian dna repair protein o6 alkylguanin dna alkyltransferas stabli transfer benzyl moieti o6 benzylguanin bg substrat activ site therebi perform self label reaction fluoresc label deriv bg offer substrat analog fp encod sequenc snap tag code sequenc can genet fuse code sequenc protein interest result fusion protein non fluoresc can label upon addit substrat choic avail bg coupl dye repres wide varieti synthet fluorophor good quantum yield photost reactiv snap tag larg independ natur attach fluoresc probe avail synthet dye coupl bg can principl use set describ gener character hiv deriv carri snap tag within main structur polyprotein gag hiv gag necessari suffici format releas viru like particl express cell hiv assembl process gag orchestr incorpor virion compon interact cellular factor requir particl releas fate gag replic cycl hiv studi varieti method review see e g howev elucid especi dynam interact host cellular protein will major interest snap tag hiv deriv hivsnap establish studi function respect viru cell fusion particl assembl allow viru replic tissu cultur gag snap specif stain viral cellular context hivsnap thu repres versatil tool studi hiv cell interact result discussionfor introduct snap tag hiv structur polyprotein gag made use fact gag modular protein consist individu fold subdomain separ flexibl linker region proteolyt process viral proteas pr specif site within linker region trigger morpholog rearrang matur gag subunit matrix ma capsid ca nucleocapsid nc p6 within virion essenti virion infect cryo electron microscopi shown within immatur virion gag molecul arrang parallel manner underneath viral membran region separ globular ma ca domain gag form layer low protein densiti previous demonstr foreign amino acid sequenc can insert within region without affect gag express assembl proteolyt matur small insert toler without affect viru replic tissu cultur exploit construct variou modifi hiv deriv us other base clone snap tag code sequenc codon amino acid ma outlin figur four c termin residu ma retain c termin snap order allow effici process downstream ma snap hiv pr hivsnap figur snap tag deriv gener context infecti hiv 1nl4 base provir plasmid yield pnlcsnap well context non replic compet deriv pchiv lack viral long termin repeat region encod hiv protein except nef pchivsnap addit construct hiv 1nl4 deriv carri snap tag ma ca flank two pr cleavag site pnlcisnap hivisnap figur case egfp label deriv analog construct pnlcegfp display robust replic tissu cultur introduct addit pr cleavag site upstream egfp domain report display nearli wild type wt replic kinet least mt t cell viru particl prepar ultracentrifug tissu cultur supernat 293t cell transfect pnlc4 pnlcsnap pnlcisnap respect analyz immunoblot hiv protein composit proteolyt process polyprotein well presenc snap tag fusion protein particl display expect viral protein composit modifi gag snap polyprotein effici process particl matur figur b data shown fusion protein ma snap kda reactiv immunostain antiserum rais hiv ma well anti snap antiserum shown present hivsnap particl wherea two separ band correspond ma kda snap kda detect immunoblot hivisnap sampl electron micrograph cell transfect either wt figur c snap tag provir plasmid figur d show viral bud profil well immatur matur virion cell transfect snap tag deriv display higher number earli bud structur similar result obtain egfp tag hiv deriv sinc moder reduc amount viru particl pellet supernat hiv wt pchivsnap transfect cell harvest h post transfect see figur black bar phenotyp may explain delay bud kinet result increas number bud structur detect steadi state repres still imag matur hivsnap particl found display wt morpholog figur d journal pone g001figur 1construct character hiv deriv carri snap tag within gag scheme hiv gag open read frame indic snap tag gene insert ma ca code region expand region display junction gag bold snap tag grey box amino acid sequenc separ short linker sequenc ital hivsnap hivisnap construct respect arrowhead indic cleavag site hiv pr b immunoblot analysi wt modifi virion particl releas supernat 293t cell transfect indic provir plasmid purifi ultracentrifug subject immunoblot analysi use indic antisera describ method posit molecular mass standard indic left kda c d morpholog hiv hivsnap virion 293t cell transfect pnlc4 c pnlcsnap d respect fix h post transfect embed em analysi describ method sampl analyz thin section electron microscopi journal pone g002figur 2replic capac snap tag hiv deriv influenc snap tag insert distinct step hiv replic 293t cell transfect pchiv pnlc4 hiv pchivsnap pnlcsnap hivsnap eqimolar mixtur plasmid hivsnap hiv pnlcisnap hivisnap respect virion harvest supernat h post transfect valu normal mean respect control white bar entri effici pchiv deriv particl purifi ultracentrifug sucros cushion measur jc53 cell use β lactamas virion fusion assay describ method mean valu standard deviat triplic sampl shown n d determin light grey bar infect r l u per ng ca pnlc4 deriv particl determin titrat viur supernat tzm bl report cell follow analysi luciferas activ describ method bar repres mean valu standard deviat independ experi black bar determin releas effici amount p24 ca releas supernat h post transfect measur quantit immunoblot divid sum p24 supernat cell lysat mean valu standard deviat three independ experi shown b replic capac hiv deriv equal amount viru ng p24 equival produc 293t cell transfect pnlc4 hiv open circl pnlcsnap hivsnap fill circl pnlcisnap hivisnap fill triangl pnlcegfp hivegfp fill squar respect use infect mt cell indic time point post infect amount ca releas supernat determin quantit dot blot analysi mean valu standard deviat six replic infect shown c retent snap tag sever round replic particl tissu cultur supernat infect mt cell day post transfect analyz immunoblot use indic antisera posit molecular mass standard indic left kda character function properti modifi viru fp label deriv hivegfp shown infecti tissu cultur infect significantli reduc compar wt hiv sustain multipl replic round tissu cultur co transfect cell equimolar mixtur pnlcegfp wt pnlc4 result product mix particl display wt singl round infect introduct foreign sequenc ma ca domain yield hiv deriv vari level infect rang wt infect complet lack particl product unpublish observ despit trend toward smaller insert gener favor observ direct correl molecular mass insert domain infect modifi viru studi compar hivsnap hivisnap wt viru well mix particl carri approxim equimolar amount gag gag snap respect respect effici individu replic step figur order determin effici cytoplasmat entri made use call beta lactamas virion fusion assay blam assay hiv cell fusion assay reli report virion carri beta lactamas blam cytoplasmat deliveri blam upon viru cell fusion monitor load target cell fluoresc substrat ccf chang fluoresc properti upon blam mediat cleavag report particl prepar tissu cultur supernat 293t cell co transfect plasmid pmm310 code vpr blam pchiv pchivsnap equimolar mixtur respect fusogen particl test incub jc53 cell equal amount viru follow ccf stain fluorimetr analysi describ method section found pchivsnap deriv particl hivsnap display compar fusion effici unlabel counterpart hiv mix virion hivsnap hiv respect figur white bar virion infect analyz incub tzm bl report cell particl prepar 293t cell transfect pnlc4 pnlcsnap mixtur plasmid pnlcisnap respect analysi hiv induc luciferas report activ h post infect reveal hivsnap hivisnap virion approxim fold reduc infect compar wt hiv subtl increas infect hivisnap virion compar hivsnap found non signific p determin student s t test full infect tzm bl cell howev restor mix particl figur gray bar sinc hivsnap impair viru cell fusion decreas infect indic defect replic step cytoplasmat entri viral gene express late stage viru replic analyz quantit ca releas supernat rel total amount gag express transfect cell figur black bar hivsnap display signific impair bulk particl releas decreas p determin student s t test observ hivisnap wt properti restor hivsnap upon co transfect equimolar amount wt plasmid order test replic capac modifi viru multipl round infect t cell line particl gener transfect 293t cell use pnlc4 pnlcsnap pnlcisnap respect use infect mt cell amount p24 ca releas tissu cultur supernat monitor day post infect figur b replic kinet hivsnap fill circl significantli delay compar wt hiv open circl compar level releas viru reach day post infect introduct addit pr cleavag site ma snap moieti hivisnap triangl result increas replic capac condit sinc observ signific function improv hivisnap compar hivsnap assay focus hivsnap character fact tag remain associ viral protein even proteolyt gag matur advantag mani experiment setup particular analys hiv entri contrast analog construct hivegfp replic detect level cell line fill squar hivsnap can employ studi viru cell interact infect cell immunoblot analys hivsnap tissu cultur supernat day post infect figur c reveal snap tag gag deriv indic modifi viru stabl sever round replic analys carri use modifi viru absenc snap substrat order test whether stain gag snap affect virion infect purifi hivsnap virion treat tmr star dmso respect test infect titrat tzm bl report cell describ method s1 stain effici analyz parallel confoc microscopi glass bound particl counterstain antiserum rais hiv ca found particl prepar give rise approxim doubl label virion moder impair singl round infect compar dmso control viru wild type hiv use neg control stain tmr star also display similar reduct infect upon tmr star treatment indic reduct due treatment procedur rather presenc ma snap tmr star figur s1 suitabl snap tag label specif detect intracellular hiv gag demonstr transfect hela cell pchivsnap follow stain transfect cell bg tmr star figur co transfect previous character hiv deriv pchivegfp allow effici detect gag use fluoresc microscopi techniqu employ investig snap tag stain specif intracellular local gag snap tmr star reactiv gag protein co local gag egfp viru express cell figur iii v indic gag snap show correct intracellular local gag snap molecul arrang gag assembl access stain procedur specif tmr star stain transfect cell demonstr lack signal non transfect cell figur white asterisk test applic tag physiolog context t cell line c8166 infect wt hiv hivsnap respect stain snap tag reactiv dye tmr star day post infect e sever round viru replic visual infect cell perform counterstain antiserum rais hiv ca unspecif stain tmr star detect cell infect wt hiv figur b contrast c8166 cell infect hivsnap virion display specif stain gag snap fluoresc snap substrat figur c stain absent cell reactiv ca antiserum figur c white asterisk stain pattern tmr star differ somewhat pattern reveal immunolabel tmr star label display higher number distinct punctuat signal plasma membran viru produc cell figur c compar left middl panel explain impair antibodi access epitop within ca assembl viral structur known affect detect intracellular gag assembl immunostain immunoprecipit approach contrast assembl gag snap appear access specif stain yield faith represent intracellular gag distribut conclud hivsnap variant suitabl live cell imag analys infect t cell journal pone g003figur 3specif intracellular stain snap tag gag protein intracellular detect snap tag gag protein transfect hela cell hela cell transfect equimolar mixtur pchivegfp pchivsnap label h post transfect use bg tmr star describ method nuclei stain hoechst figur show confoc imag mid section repres cell green channel red channel ii overlay green red blue channel iii scale bar µm pearson s coeffici green red channel equal imag iv repres enlarg section iii v fluoresc intens profil green red channel along white line shown iv b c intracellular detect snap tag gag protein infect c8166 t cell c8166 cell infect hiv b hivsnap c respect produc transfect 293t cell day post infect cell stain bg tmr star well immunofluoresc use antiserum rais hiv ca nuclei stain hoechst figur show confoc imag mid section immunofluoresc left panel tmr star middl panel overlay αp24 tmr star hoechst signal right panel scale bar µm white asterisk non infect cell presenc snap tag can label varieti synthet dye also make fusion protein amen visual super resolut fluoresc microscopi techniqu stimul emiss deplet sted microscopi stochast optic reconstruct microscopi storm allow local fluoresc molecul analysi label structur resolut well diffract limit given protein interest can specif label suitabl fluorophor genet encod snap tag conjunct appropri dye recent demonstr suitabl sted storm analys live cell hivsnap thu provid basi analysi sub viral structur live cell proof principl appli direct storm dstorm variat storm reli light induc revers photoswitch fluorophor visual purifi hivsnap particl figur c well membran hivsnap express a3 t cell figur d f tirf total intern reflect fluoresc mode shown figur c dstorm imag purifi virion resolv individu punctuat signal averag full width half maximum nm good agreement averag diamet hi virion nm determin cryo electron microscopi dstorm imag plasma membran hivsnap express t cell reveal individu bud site diamet around nm close adjac bud site resolv dstorm analysi figur e f journal pone g004figur 4visual hivsnap virion bud site super resolut tirf microscopi c high resolut microscopi stain hivsnap particl hivsnap particl purifi ultracentrifug supernat transfect 293t cell bound glass coverslip stain use snap surfac sum molecul tirf dstorm b fluoresc imag region interest shown white box indic particl magnifi c scale bar µm c cross section profil deriv dstorm imag individu hiv particl scale bar nm d f hiv bud site plasma membran hivsnap express t cell a3 cell nucleofect pchivsnap stain snap surfac imag describ materi method sum molecul tirf d dstorm e fluoresc imag cell shown f magnifi view box region dstorm imag shown d scale bar nm conclus consid snap tag base label strategi present use expans exist panel fluoresc hiv deriv versatil tool studi differ aspect viral life cycl microscop techniqu combin advantag genet label suitabl live cell analys sensit versatil stain use synthet fluoresc dye fact snap tag molecul can either stain variou fluoresc dye quench non fluoresc substrat allow applic sequenti label protocol puls chase approach may appli analysi intracellular gag traffick site synthesi direct imag studi gag traffick far hamper slow matur kinet fp impair visual newli synthes gag molecul tc tag gag deriv use circumv problem studi use label yield contradict result might explain non specif intracellular stain biarsen dye faster specif stain use hivsnap surmount shortcom therebi complement biochem analys gag distribut addit possibl chose differ color dye render hivsnap versatil tool multi color applic e g investig dynam interact hiv gag individu host cell factor furthermor snap tag viral protein can label synthet dye whose photochem properti tailor requir super resolut microscopi techniqu summari viru deriv describ open varieti possibl will allow detail investig hiv cell interact modern microscop techniqu materi methodsplasmid cell linesth snap tag code sequenc amplifi pcr pss26m covali primer introduc clai restrict site end ggcgcatcgatccgcccagcccaggcttgcc cagggatcgataggcggcatggacaaagactgcgaa respect result fragment subclon pbsmaj clai harbour uniqu clai restrict site posit nl4 sequenc result pbsmajsnap bsshii sphi fragment compris modifi ma sequenc transfer pchiv pnlc4 context obtain pchivsnap pnlcsnap respect construct pnlcisnap snap tag code sequenc amplifi pcr use forward revers primer introduc mlui xbai restrict site respect tgtacaaacgcgtatggacaaagactgc ttttggcttctagagcccagcccaggc result fragment insert pnlc igfp deriv pnlc4 addit hiv proteas cleavag site follow gfp introduc c termin ma insert bsshii sphi fragment plasmid hiv gag igfp obtain pnlcisnap 293t hela jc53 tzm bl cell grown dulbecco s modifi eagl s medium dmem glutamax invitrogen supplement u ml penicillin µg ml streptomycin fc c co2 c8166 mt4 a3 cell kept rpmi1640 glutamax supplement u ml penicillin µg ml streptomycin fc transfect carri use polyethyleneimin pei accord standard procedur 293t cell fugenehd roch accord manufactur s condit a3 t cell electropor cm cuvett invitrogen voltag capac µf volum µl serum free medium use gene pulser xcell system bio rad particl prepar immunoblot characterization293t cell transfect provir plasmid use pei h post transfect cell harvest lyse sd sampl buffer tissu cultur supernat preclear filtrat µm filter virion purifi ultracentrifug w w sucros cushion protein cell lysat pellet particl separ sd page acrylamid bisacrylamid acrylamid transfer nitrocellulos membran semi dri blot membran probe indic primari antisera bound antibodi detect quantit immunoblot use licor odyssey system well reagent protocol softwar provid manufactur analysi virion infectivitytzm bl indic cell seed well plate cell well infect one day seed use serial dilut filter tissu cultur supernat form 293t cell transfect pnlc pnlcsnap pnlcisnap respect h post infect luciferas activ measur infect cell determin use steadyglo assay system promega accord manufactur s instruct β lactamas virion fusion assayentri effici determin standard hiv fusion assay briefli viral particl prepar 293t cell co transfect indic hiv provir deriv pmm310 plasmid ratio µg particl concentr determin quantit immunoblot use antiserum rais hiv ca serial dilut viru use infect jc53 cell seed well one day prior infect follow incub c h cell wash co2 independ dmem invitrogen incub h room temperatur use ccf2 geneblaz invitrogen ltd paisley uk accord manufactur s protocol cell fix pfa pb fluoresc intens em nm nm ex nm determin multi well fluorimet tecan safir ratio fluoresc emiss nm emiss nm calcul normal correspond ratio obtain uninfect cell yield rel entri effici replic kinet hiv derivativeshiv hivsnap hivisnap produc transfect 293t cell plasmid pnlc4 pnlcsnap pnlcisnap respect amount p24 ca supernat determin quantit immunoblot supernat correspond ng p24 ca use infect mt cell sampl tissu cultur supernat collect everi day amount p24 supernat determin quantit dot blot procedur briefli µl supernat spot onto nitrocellulos membran use minifold devic whatman serial dilut purifi recombin hiv ca use standard membran dri block skim milk powder tb tween probe rabbit polyclon antiserum rais hiv ca signal detect quantit immunoblot use licor odyssey system well reagent protocol provid manufactur quantit use odyssey softwar intracellular stain gag snaphela cell seed coverslip h prior experi transfect fugene6 roch incub c h snap label cell incub µm snap cell tmr star new england biolab dmem min c wash incub fresh dmem min c allow diffus excess substrat cell fix paraformaldehyd pfa counterstain hoechst embed mowiol c8166 cell infect hivsnap hiv subject modifi protocol solut use condit differ step cell pellet rpm min follow fixat pfa cell adher fibronectin coat cover slip permeabil incub tritonx pb subject intracellular stain use rabbit polyclon serum rais hiv ca alexa488 goat anti rabbit antibodi invitrogen counterstain nuclei perform use hoechst secondari antibodi solut electron microscop analysi cell samples293t cell transfect pnlc4 pnlcsnap respect use fugen hd roch diagnost gmbh mannheim germani h post transfect cell fix process resin embed describ previous section examin zeiss em10 tem imag taken use gatan multiscan camera digit micrograph softwar dstorm analysi virion viru produc cellsparticl purifi supernat 293t cell transfect equimolar mixtur pchiv pchivsnap ultracentrifug sucros cushion particl adher fibronectin coat glass coverslip fix paraformaldehyd pb virus permeabil triton x second block bovin serum albumin bsa pb min stain µm snap surfac neb accord manufactur s instruct analysi hivexpress cell a3 cell electropor µg pchivsnap h post transfect cell transfer labtek well chamber coverglass fix paraformaldehyd pb min fix cell wash permeabil use triton x min block bsa solut min cell stain µm snap surfac accord manufactur s instruct dstorm imag record custom built microscop use experiment protocol describ earlier briefli multi line laser innova 70c coher usa coupl invert microscop ix71 olympu japan fluoresc signal detect use electron multipli charg coupl devic emccd ixon andor ireland appropri filter dichroic ahf germani photoswitch alexa fluor realiz oxygen free aqueou buffer mm mercaptoethylamin ad use two irradi wavelength nm kw cm2 activ nm kw cm2 read imag reconstruct perform use rapidstorm softwar packag dstorm imag shown consist individu superimpos frame sum molecul tirf imag reconstruct sum singl molecul fluoresc intens complet data set support informationfigur s1infect hivsnap virion tmr star stain hiv hivsnap particl purifi ultracentrifug supernat 293t cell transfect pnlc4 pnlcsnap respect incub µm tmr star solvent control dmso h room temperatur unbound dye remov gel filtrat western blot analysi hiv hivsnap particl stain tmr star dmso use indic antisera posit molecular mass standard indic left kda b stain specif effici determin confoc microscopi particl adher fibronectin coat glass coverslip tmr star stain particl fix pfa permeabil triton x block bovin serum albumin pb hiv ca detect immunostain use polyclon sheep anti ca serum alexa488 secondari antibodi repres confoc microscopi imag percentag signal indic channel depict c infect particl determin titrat stain black bar solvent treat white bar particl tzm bl indic cell describ method valu normal amount input viru determin quantit immunoblot analysi compar purifi ca protein standard mean valu standard deviat triplic titrat shown rlu rel light unit tif click addit data file method s1infect hivsnap particl stain doc click addit data file', 'mate partner violenc ipv women crisi post crisi popul import area public health research still nascent stage although data limit avail studi indic individu exposur arm conflict crise may exacerb ipv sever studi find quantit measur qualit perceiv posit associ exposur polit violenc women s vulner experienc ipv exampl cross section studi palestin found marri women partner expos polit violenc significantli like experi physic sexual ipv compar women whose partner expos polit violenc qualit studi caus ipv post conflict sierra leon liberia women believ men particip wit violenc conflict possibl risk factor ipv perpetr prior research posit increas post crisi ipv like result complex interact factor includ limit increas commun violenc shift gender role econom stress displac studi frequenc risk factor ipv crisi post crisi set start emerg littl inform crisi affect women men conceptu ipv experi impact day day live understand need provid import insight cultur appropri tailor ipv prevent respons program côte d ivoir emerg period crisi instabl mid s recent experienc new wave polit violenc displac contest presidenti elect intens fight ensu follow elect member polit parti commit human right abus crime includ murder rape polit persecut span six month least civilian report kill thousand intern displac mani injur wit violenc major case intern displac peopl idp move abidjan live famili previou research popul present studi found unemploy food insecur hous instabl lack social network common concern idp prior commun base research rural côte d ivoir also document high preval ipv among rural women survey women report experienc lifetim ipv past year estim rang current studi make import contribut measur frequenc describ experi ipv urban ivorian popul experienc arm conflict widespread elect relat violenc perspect women men solicit includ descript multipl form ipv experienc women particularli relat health everyday activ shame studi add small grow bodi work ipv post crisi situat materi methodsthi studi sequenti mix method studi first step administ cross section survey urban crisi affect women next focu group discuss conduct women men increas understand experi women describ survey data collect quantit surveyin juli eighti women systemat sampl household abobo neighborhood abidjan côte d ivoir complet one time survey econom autonomi decis make violenc reproduct health post elect crisi survey undertaken part pilot activ endlin survey random control trial occur rural villag abobo neighborhood select survey due concentr crisi relat violenc dens popul low socio econom statu ethnic divers includ idp four abobo s quartier randomli select particip survey research team first met quartier s leader obtain permiss conduct survey household systemat sampl local train ivorian french speak enumer elig women age older invit particip one hundr women approach consent particip due lack time n partner disapprov n anoth reason n yield final sampl particip languag match train femal research assist administ paper base survey concern women s experi differ form ipv socio demograph characterist abobo juli survey assess gender base violenc côte d ivoir adapt three previou studi multi countri studi women s health domest violenc london school hygien tropic medicin violenc health among women asylum seeker hiv ipv prevent trial uganda instrument also contain addit item e g household decis make exposur conflict gaug facet women s live descript statist use examin preval ipv particip socio demograph characterist focu group discussionsten focu group conduct may june n women n men focu group particip identifi commun leader abobo neighborhood collabor intern rescu committe irc commun partner irc intern humanitarian organ establish histori côte d ivoir commun member age invit seri meet irc present purpos studi meet result format six focu group non idp women non idp men idp women idp men idp women idp men elig criteria focu group includ least year old french speak partner interest join focu group discuss four addit gender stratifi focu group form women particip urban save loan associ usla irc group save program adjam treichvil neighborhood share socioeconom popul densiti characterist abobo focu group seven ten compos usla women usla men usla women usla men usla group facilit separ see program particip differ perspect ipv contribut factor solut reduc ipv urban set compar particip two ivorian facilit led group two note taker present interview guid includ semi structur question free list exercis pair wise rank activ explor follow women famili commun impact elect relat violenc b investig women men understand ipv relat shame health impact everyday life free list produc inventori list offer insight salienc item among respond pair wise rank particip ask compar two differ form ipv e g physic ipv econom ipv import two discuss term shame health impact everyday activ methodolog use stimul convers specif form ipv facilit guid interview particip free list pair wise rank process goal pair wise rank necessarili reach consensu among particip rather methodolog tool explor percept thought process regard impact differ form ipv focu group last approxim two half hour focu group discuss record use digit audio record record transcrib verbatim french nativ ivorian french speaker translat english profession translat train bilingu ivorian research compar english translat french transcript confirm accuraci clarifi term specif region atla ti softwar use organ code transcript ground theori approach use data analysi ground theori emphas induct open end approach toward data analysi encourag elimin preconceiv idea shift gener list emerg theme interview transcript code english two research l g s s descript statement creat reflect emerg theme discrep code discuss princip investig j g k f code organ theme across interview iter process review princip investig code team data collect focu group note taker care record free list pair wise rank result free list respons record paper rank result enter matrix survey focu group particip provid sign inform consent prior particip studi receiv ethic approv institut review board yale univers georg mason univers review ivorian nation ethic review board resultsparticip characteristicsa total women complet survey n report male intim partner within last year approxim n partner women polygam marriag idp statu collect part quantit survey advis irc order minim feel stigma among idp quantit data collect conduct close time elect violenc similar survey sampl focu group particip larg partner n idp n seventi six percent focu group respond employ n three student frequenc ipv quantit resultshalf women partner non partner survey sampl report experienc emot physic sexual ipv past year multipl type violenc emot ipv common follow sexual ipv physic ipv nearli one three women report experienc past year physic sexual ipv among partner women push shove kick drag slap someth thrown hit someth common form physic ipv forc sex result threat intimid physic forc sex common type sexual ipv feel frighten humili common form emot ipv among partner women percept ipv qualit resultsdur focu group women men first creat list problem discrimin experi face crisi affect women afterward creat matric discuss differ form ipv relat feel shame overal health abil perform everyday activ result free list activ pair wise rank discuss present activ particip provid time discuss explain provid exampl choic support quot discuss present follow section although consider overlap exist women men gender differ highlight relev free list resultsth free list prompt focu group particip creat list gener problem type ipv violenc discrimin experienc crisi affect women côte d ivoir result gender present tabl journal pone t001tabl 1free list result focu group interview gender n question type problem women affect elect relat violenc face commun totalwomenmenn n n financi problems16 unemploy lost business11 mental health repercuss trauma11 respons manag household10 death famili member6 forc prostitut transact sex5 loss materi goods5 sexual violenc rape non ipv food insecurity4 physic health repercussions3 hous insecurity3 0abandon partner separ divorce3 poor live conditions2 traumat children2 partner unemploy lost business1 0displacement1 physic intim partner violenc ipv 0emot financi ipv1 0question type violenc discrimin crisi affect women usual experi totalwomenmenn n n physic ipv13 econom ipv13 argument partner11 sexual ipv10 emot ipv8 discrimin commun members8 partner control behavior4 0neglect partner3 0discrimin famili members3 discrimin house2 0infidelity2 gener problem face crisi affect women wide rang although financi concern frequent mention problem women men focu group particip follow financi problem unemploy women like name increas respons manag household mental health problem trauma common problem men identifi similar concern crisi affect women although like identifi sexual violenc non intim partner problem women men compar women smaller number women mention hous insecur partner s unemploy physic ipv emot ipv problem face crisi affect women respect men mention area facilit ask particip describ type violenc discrimin crisi affect women usual experi physic econom sexual emot ipv mention focu group women men argument partner discrimin experienc commun member often form name call gossip social exclus also cite problem women men women men mention differ form ipv problem women except sexual ipv mention approxim women men control neglect partner face discrimin household issu identifi women men pair wise rank discuss resultsin pair wise rank activ focu group particip ask compar contrast differ form ipv relat shame health everyday activ exampl facilit prompt group say now go compar type violenc ll tell us shame type woman man beat wife man insult wife will shame situat women question repeat compar type ipv three domain shame health everyday activ result discuss theme ipv shamefocu group particip ask compar type ipv relat feel shame gener women consid emot violenc shame even compar physic sexual ipv exampl ask compar shame associ emot ipv versu sexual ipv one woman comment think insult shame although forc rape pain well insult will happen front peopl don t want sex will will pain batter anyth sexual issu insult s alway thing s stuck follow everywher femal trader quot illustr emot ipv perceiv shame women also shame close tie social stigma felt depend ipv perpetr public privat broad consensu ipv perpetr public shame result social stigma women express concern commun member may gossip lose respect use knowledg ipv way humili insult women therefor decid whether someth shame highli depend wit awar abus exampl insult woman public describ much shame insult woman privat concern highlight follow quot know peopl know happen household keep respect realiz re regularli batter husband lose respect show longer consider concern other eye shame us re batter front femal hairdress idp furthermor particip resid citi presum anonym due larger popul howev often live close cramp area sens privaci neighbor hear wit see result violenc commonli mention concern women idp urban environ lack privaci contrast experi rural region exampl one femal idp rais issu shame neighbor mock result ipv anoth discuss felt less social support differ experi move abidjan although urban area live common courtyard hous kind hous common courtyard can t realli privat life hous close courtyard common everybodi will hear s happen household husband batter time everybodi will know ll longer respect neighbor even children will disrespect s concern other eye femal hairdress idp woman issu coupl nobodi help neighbor just mock think lack social cohes may explain violenc urban coupl compar rural one femal unemploy idp less consensu among men regard shame emot ipv women men view physic econom abus similarli shame women comparison form violenc exampl physic violenc shame emot violenc emerg three five men s focu group said earlier batter wife put littl detail face goe feel asham detail still shame disappear detail disappear eh swell will shame bring male artist non idp quot focus relationship shame physic violenc similar women element public shame import physic violenc seen shame other detect woman beaten shame appear result actual abus abus partner rather result evid abus can seen other summari result pair wise rank reveal women consid emot ipv particularli form insult shame consensu seen among men s group howev ipv identifi other regardless specif form perceiv shame result social stigmat case addit abus non intim partner e neighbor urban live circumst includ crowd live close built home appear exacerb shame public ipv ipv healthnext particip ask compar describ differ form ipv impact health crisi affect women health defin broadli inclus physic mental health women men identifi physic ipv follow sexual ipv neg impact health women batter pain six teeth husband batter lost almost teeth femal trader idp woman might traumat sexual ipv exampl night fall begin anxiou feel uneasi alreadi worri will happen panic might caus sever diseas stress ulcer diabet will wast slowli femal trader idp discuss becam clear women perceiv relationship differ form ipv health impact distinct exampl physic sexual ipv often describ simultan co occur within episod thu make difficult assess harm health surpris sexual abus often involv threat use physic violenc descript simultan co occur ipv relat health impact shown men quit violent can beat sex women disfigur husband beat ask caus sex will brutal will beat femal trader non ipd lot thing involv rape hit blow head butt whole caus open leg laughter whisper can kill male electr engin non idp someon forc women sex will brutal will gentl will brutal women will suffer pain will throw leg apart s tiresom will necessarili affect will abl anyth morn femal housewif non idp focu group particip provid addit exampl interplay differ kind violenc within intim partner relationship exampl econom ipv often led physic ipv result deleteri physic emot health impact post crisi côte d ivoir econom opportun scarc case women becom financi provid famili see tabl women welcom opportun control resourc relationship also describ perceiv threat partner among men perceiv loss control tradit gender respons discuss underli caus form ipv ipv everyday activitiesin addit ipv specif physic mental health repercuss women ipv also impact abil perform everyday activ includ household chore work famili task similar percept differ form ipv impact health physic sexual form ipv view disrupt complet everyday activ compar econom emot ipv ask compar econom ipv emot ipv four five femal focu group identifi emot ipv disrupt everyday activ contrast comparison four five men s focu group identifi econom ipv disrupt women suggest women men view repercuss emot econom ipv differ shame health particip describ situat form ipv impact daili activ oblig women quot woman describ emot ipv can disrupt daili activ insult hurt realli hurt man will insult way wrong word oblig keep can t tell anybodi keep think word often start attend activ rememb whole word use call longer strength continu get sad re dishearten longer strength continu wonder husband use ugli word good hurt prevent activ femal dyer non idp econom ipv commonli form partner take money wive limit women complet daili task prevent women purchas item leav hous snatch money econom ipv without money busi insult won t effect work femal trader idp five women s focu group thought physic ipv disrupt econom ipv howev two men s focu group unabl reach consensu regard disrupt form ipv three group identifi physic ipv disrupt daili activ econom ipv forc sex will exhaust anyth els forc move will stay home will tire femal trader non idp discussionapproxim one third women studi report past year physic sexual ipv slightli half report physic sexual emot ipv find consist global preval ipv focu group discuss reveal physic sexual emot ipv addit less recogn form violenc women econom abus discrimin commun famili member common problem face crisi affect women shame social stigma play import role ipv perceiv experienc women studi shame social stigma often import factor women discuss harm type ipv public abus almost univers view harm health shame disrupt everyday activ non public ipv previou qualit research rural men côte d ivoir men report eros tradit gender norm conjunct financi stress arm conflict challeng sens masculin recent multi countri studi among displac popul displac believ increas ipv result remov men tradit role head household financi provid result women contribut financi well famili women gain financi household respons degre empower increas tension observ partner turn increas risk ipv within previou studi women s percept chang social gender role influenc ipv post crisi mix women believ empower increas independ result crisi reduc ipv perpetr other cite chang gender role respons post crisi risk factor increas ipv howev present studi chang gender role commonli discuss catalyz ipv protect violenc abus partner although sexual violenc conflict set often receiv focu organ media donor found ipv result shame stigma particularli emot ipv also frequent cite concern crisi affect women shame stigma common theme focu group ipv perpetr public public knowledg perceiv shame regardless type conflict affect women focu group conduct democrat republ congo describ similar phenomenon women specif ask experi repercuss relat sexual violenc congoles war report commun gossip ridicul particularli hurt case shame result sexual violenc equal concern attack alway explicitli discuss focu group s import consid broader structur inequ women regularli can influenc perpetu experi ipv seen abidjan social norm can also play role women focu group experienc ipv found littl support surround commun yet instead blame violenc perpetr sort public shame reinforc ipv legitim mean control limit women s abil seek help reinforc women s perceiv actual lower social statu len mind can truli understand natur ipv abidjan identifi effect way prevent studi result import implic practition research practition critic recogn interplay differ kind violenc within intim partner relationship result indic like woman may experienc multipl form ipv furthermor econom emot ipv may less visibl physic ipv respons servic intervent need work holist around women s need experi design address aspect violenc note focu group men women may differ percept ipv consequ serious thu discrep address within program seek engag men women separ programmat intervent also take account barrier consequ disclosur ipv survivor includ role stigma shame decis disclos ipv experi attent paid creat environ women feel safe support disclos strengthen relationship women increas peer support focu confidenti solidar import recogn less seriou form ipv make sure women feel comfort disclos experi without jeopard safeti studi util free list pair wise rank allow particip identifi priorit issu relev futur gbv research may consid util qualit method allow facilit structur convers sensit topic provid insight percept frequenc sever relev ipv discrimin problem face crisi affect women research regard sexual physic violenc exacerb crisi situat still necessari futur studi also includ investig addit form ipv discrimin given relationship poor health outcom disrupt daili activ limit must acknowledg sampl quantit survey focu group small repres therefor find gener two research perform qualit analysi independ howev pair wise rank result analyz quantit softwar research stigmat behavior ipv experi may report final one first time methodolog use examin peopl perceiv differ form ipv thu addit research need summari studi highlight high frequenc past year ipv provid import insight women men perceiv differ form ipv post crisi urban set violenc experienc women includ physic sexual emot ipv well econom ipv commun discrimin argument partner lack financi resourc unemploy common problem among crisi affect women describ underli sourc ipv research also highlight women often experi differ form ipv concurr final women men report shame stigma play larg role women experi repercuss ipv public episod ipv almost alway seen detriment privat episod ipv result underscor need increas social support mechan women reduc shame stigma isol associ experi creation safe support space women talk challeng social norm may import first step reduc commun shame secreci often surround ipv safe space along broader societ outreach includ challeng men s social posit creat opportun increas econom resourc can turn potenti decreas frequenc ipv deleteri impact woman s well support informations1 surveyintim partner violenc questionnair juli docx click addit data file', 'hard imagin planet look like million year ago green alga first colon terrestri habitat plant now blanket highest alpin peak lowest desert tropic rainforest arctic expans even aquat marin environ microfossil fragment plant tissu middl ordovician mya reveal evid first plant colon pioneer speci green algal progenitor long sinc disappear descend earli pioneer widespread howev beg question extant green algal group closest live rel land plant despit decad molecular phylogenet research land plant green alga question far settl land plant lp embryophyt monophylet group nest within charophyt group fresh water green alga togeth charophyt embryophyt constitut monophylet streptophyta green algal lineag chlorophyta contain divers assemblag marin fresh water green alga nearli decad ago karol et al conclud four gene three genom analysi charophyt charal constitut closest live rel land plant anoth combin data analysi support topolog time appear settl matter past centuri charal sister relationship use wide biolog textbook morpholog standpoint relationship tell good stori charophyt lineag diverg bodi plan grow increasingli complex unicellular mesostigmatal sarcinoid packet chlorokybal un branch filament klebsormidial branch filament zygnematal parenchemat tissu coleochaetal final macrophyt charal bodi plan evolv earli land colon equip complex tissu allow life water similarli sexual reproduct evolv isogami ancestr lineag oogami deriv charophyt lineag spite morpholog support charal sister land plant data conflict interpret plastid gene phylogeni provid support zygnematal sister land plant addit new data base nuclear gene support altern topolog zygnematal conjug sexual green alga filament unicellular flagel form one explan incongru topolog taxon sampl four gene topolog charal lp much broader taxon sampl algal taxa reconstruct support zygnematal lp six charophyt one studi broader taxon sampl algal taxa put zygnematal sister land plant much less support relationship second altern topolog also emerg coleochaet lp molecular data support relationship deriv exclus nuclear ribosom protein gene addit charact plasmodesmata nad5 intron support topolog coleochaetal order reconstruct monophylet phylogeni caus concern overal topolog address uncertainti field sought comprehens genom scale analysi use deep sampl mani gene drawn seven speci distribut across major charophyt lineag charal coleochaetal zygnematal klebsormidial chlorokybal addit includ publish sanger sequenc mesostigma virid est librari analyz alongsid hous transcriptom data identifi set ortholog common across green lineag chlorophyta streptophyta use unbias approach priori gene select yield larg set nuclear encod protein gene use reconstruct phylogeni identifi sister lineag land plant resultsour taxon sampl includ total taxa eight charophyt four land plant two chlorophyt five charophyt newli collect transcriptom tabl sanger sequenc read per taxon gs flx titanium sequenc read per taxon gather assembl raw read contig repres mrna organ time collect contig put code region predict estscan refer unigen number rang unigen per taxon journal pone t001tabl 1primari sequenc data summari cluster result reads5 sanger reads454 clustering454 sanger clusteringunigeneschaetosphaeridium globosumnumb reads884 490averag length bp 562949513656515chlorokybu atmophyticusnumb reads444 607averag length bp 513950726903904klebsormidium flaccidumnumb reads994 881averag length bp 538946629849731penium margaritaceumnumb reads1 880averag length bp 527943571811638nitella hyalinanumb reads949 106averag length bp 547955544682492unigen contig put code region inparanoid tc approach find core ortholog yield put ortholog group filter phylogeni reduc core otholog fig b hamstr identifi hit charophyt core ortholog filter good charophyt taxon represent remov gene amino acid composit bia ortholog gene remain fig c gene annot associ data tabl s1 journal pone g001figur 1ortholog identif method diagram outlin step use identifi ortholog gene phylogenet analysi unresolv phylogenet scheme relat chlorophyt charophyt embryophyt list six taxa fulli sequenc genom use core ortholog determin b core ortholog predict previou six taxa c charophyt orthog predict core ortholog use search protein eight charophyt transcriptom filter good taxon sampl remov ortholog signific amino acid bia result align protein concaten onto one larg multigen data matrix phylogenet analysi use ortholog gene reconstruct evolutionari histori streptophyt two outgroup chlorophyt first concaten protein product gene total amino acid miss gap charact trim poorli align region dataset condens amino acid miss gap charact averag gene present taxa six eight charophyt tabl represent individu gene vari among taxa except mesostigma contain gene presum markedli smaller size dataset two differ phylogenet analys perform trim align result strongli support topolog fig journal pone g002figur 2phylogenet relationship viridiplanta taxa determin concaten protein phylogenet analys summar bi cat poisson model consensu tree branch support valu bi ml analys ml bootstrap bayesian posterior probabl journal pone t002tabl 2summari miss data charophyt taxonnumb genesperc geneschlorokybu atmophyticus160100chaetosphaeridium globosum10565 625coleochaet sp 75klebsormidium flaccidum160100mesostigma viride1811 25nitella hyalina160100penium margaritaceum14288 75spirogyra pratensis10968 125gene present charophyt taxon multigen align total ml bi analys concaten gene dataset recov relationship zygnematal sister land plant strong statist support ml pp coleochaetal sister zygnematal lp clade ml pp charal diverg earlier ml pp follow klebsormidium ml pp final chlorokybal mesostigmatal moder support sister one anoth ml pp togeth compris earliest diverg lineag streptophyt ml pp addit branch order charophyt lineag includ two taxa per order zygnematal coleochaetal recov monophylet lend support classic recogn order larg concaten studi type logic concern subset gene might support altern topolog part ignor multi gene phylogenet analys given propens plant phylogeni gene tree speci tree conflict address issu directli statist test data incongru use program concaterpillar given multi gene dataset analysi use likelihood ratio test identifi compat partit program group gene set incongru leigh et al defin gene phylogenet incompat either due truli differ evolutionari histori systemat error fifteen set rang size gene fig s1 identifi total set gene none partit place charal sister land plant surprisingli largest set gene support zygnematal lp relationship also occur across four addit set total gene s1 d s1 h s1 k s1 l set differ placement mesostigma basal charophyt one noteworthi minor partit recov coleochaetal lp topolog fig s1 c two other coleochaet lp chaetospheridium branch earlier fig s1 j s1 o ensur toss phylogenet inform charact elimin gene amino acid composit bia perform similar phylogenet analys concaten gene set result ml topolog almost exactli bootstrap support everi bipartit except chlorokybu mesostigma lineag support recov howev concaterpil analys larger gene set recov interest gene set one recov set contain gene support nitella lp topolog gene amino acid composit bia fairli well distribut across variou incongru set eight land nitella lp set set topolog recov subsequ gene concaterpil analysi discussionthi studi includ charophyt lineag provid robust well support result lp zygnematal sister lineag believ result warrant seriou reconsider charophyt evolut given phylogenom approach studi confirm plastid encod analys turmel et al recent nuclear genom studi wodniok et al studi use target gene approach reconstruct altern topolog none broad unbias nuclear genom sampl use current studi two phylogenet studi publish past year use next gener sequenc data address similar question pose manuscript howev data collect analyz studi almost complet non overlap consequ three independ analys provid divers perspect difficult deep evolutionari relationship finet et al focus ribosom gene charact select priori transcriptom collect studi despit fact present studi finet et al drew transcriptom dataset five gene overlap two studi core ortholog select final dataset thu analys almost complet independ tree topolog differ assign coleochaet sister lineag land plant addit noteworthi like ribosom protein tree ribosom rna gene tree reconstruct monophylet coleochaetal coleochaetal fact monophylet indic morpholog organellar data suggest form molecular coevolut may underli appar conflict noteworthi studi charophyt phylogenet came wodniok et al also broad transcriptom analysi like finet et al studi make use priori set select gene draw smaller number charophyt taxa six fewer align charact amino acid studi directli compar wodniok et al tree topolog congruent lower branch support charophyt node analysi report base filtrat roughli charact select evid ortholog combin result dataset charact strongli support tree topolog ultim set analysi apart howev priori gene select thu addit intrins phylogenet interest demonstr power new approach data select leverag use high throughput sequenc data howev given genom scale data collect taxon sampl limit may sourc error without addit transcriptom directli test issu long branch attract much less factor amino acid data use appropri model evolut short intern branch shown sourc phylogenet inconsist much harder issu address two analys suggest taxon sampl might confound issu studi turmel et al rrna plastid phylogeni twice taxon sampl recov zygnematal lp relationship use nucleotid base analysi charal lp relationship still emerg reduc karol et al dataset reanalyz approxim taxon sampl second line evid provid tenuou support best worth report due similar taxon spread well support land plant zygnematal topolog use larg suit gene requir rethink charact evolut charophyt lineag lead land colon previou hypothes increas morpholog complex congruent result studi howev multipl gain loss multicellular across green alga well document reduct charact zygnematal zygnematal includ filament unicellular organ unicellular state may well deriv condit branch filament ancestor just flagel stage lost order context stretch imagin charact reduct sister lineag land plant fig result loss homolog charact potenti share common ancestor multicellular complex charal coleochaetal appear independ deriv common branch filament ancestor one like oogam reproduct charact probabl present common ancestor four advanc lineag idea suggest previou investig model howev parenchyma like organ axial growth protonema charal exampl parallel evolut multipl zygot product coleochaet journal pone g003figur 3hypothesi charact evolut charophyt earliest branch streptophyt mesostigma chlorokybu unicellular flagel isogam multicellular form unbranch filament evolv common ancestor remain streptophyt repres klebsormidial recent common ancestor charal coleochaetal zygnematal lp like alga plant like cell divis phragmoplast branch filament oogam sexual reproduct charal went independ evolv complex macrophyt form coleochaetal independ acquir parenchymat tissu matern retain zygot howev zygnematal went rout reduct loss flagel cell reproduct via conjug loss multicelluar desmid loss phragmoplast conclus research lend strong support notion closest live green algal lineag land plant plant like stonewort charal previous thought speci rich assemblag fresh water filament unicellular organ better known pond scum materi methodsalg samplingal seven transcriptom similarli process see timm delwich detail method spirogyra pratensi utex coleochaet sp cfd summari chaetosphaeridium globosum sag penium margaritaceum skd2004_cl18 cultur avail david domozych skidmor colleg saratoga spring ny klebsormidium flaccidum utex chlorokybu atmophyticu utex 2591were grown appropri cultur media c ld photoperiod photon flux µmol s m nitella hyalina kgk0190 cultur avail kenneth karol new york botan garden bronx ny cultur fresh water aquarium room temperatur cultur harvest log phase growth varieti condit maxim divers transcript interv pm pm pm sit dark enclosur hour expos minut c algal cultur pellet 4000rpm nitella requir centrifug drop liquid nitrogen store c rna extract rna isolationfrozen tissu ground cryogen temperatur use spex freezer mill spex certi prep metuchen nj ground cell ad tri reagent molecular research center inc cincinnati oh manufactur s protocol follow extra chloroform extract addit licl precipit requir elimin polysaccharid genom dna contamin isol nucleic acid concentr od ratio quantifi nanodrop thermo scientif nanodroptm spectrophotomet wilmington de qualiti rna determin run µg total rna agaros mop formaldehyd gel appli biosystem ambion austin tx stain ethidium bromid examin rrna band pattern high qualiti clean rna pool mg total rna reach cdna construct dna sequencingtot rna mg ship dri ice agencourt bioscienc corpor beverli ma poli rna total rna isol convert doubl strand cdna size fraction kb clone direct pexpress vector grown t1 phage resist e coli subsequ dna sequenc includ prime sanger read sequenc technolog summari taxon sanger read plu full plate gs flx titanium sequenc gener see tabl exact number sanger sequenc dna clone purifi use agencourt s proprietari solid phase revers immobil spri system purifi dna sequenc use abi dye termin chemistri run abi appli biosystem inc foster citi ca machin addit includ publish sanger sequenc one addit taxon mesostigma virid sequenc ug isol dna nebul mean size rang bp follow size select fragment bp column exclus ampur agencourt bioscienc danver ma isol adapt ligat onto fragment select use librari captur bead singl strand fragment isol follow standard librari dilut librari amplifi onto dna captur bead emuls pcr empcr dna captur bead collect sequenc primer anneal thermocycl bead genom place picotitr plate sequenc roch gs flx instrument analyz base call softwar use default paramet transcriptom cluster methodth cluster taxon perform two step process first read cluster use mira vs second raw sanger read combin contig respect qualiti score process est2uni pipelin use varieti method remov low qualiti sequenc vector contamin low complex region cluster clean read cap3 use bp plu percent ident overlap estscan predict protein code region contig singleton use arabidopsi thaliana score matrix cluster process result set predict protein unigen taxon use downstream analys ortholog predict use extend hamstr approach fig hamstr approach ortholog predict use well curat set gene core ortholog identifi put ortholog est librari core ortholog hamstr search set unigen identifi set put ortholog present curat set ortholog exist entir green lineag set build six fulli sequenc genom chosen construct core ortholog four embryophyt two chlorophyt fig arabidopsi thaliana uniprot v populu trichocarpa jgi v oryza sativa plantbiolog v physcomitrella paten jgi v ostreococcu tauri jgi v chlamydomona reinhardtii jgi v phylogenet posit core ortholog taxa ideal purpos unless gene loss ortholog present embryophyt chlorophyt also present charophyt protein sequenc six genom use infer set core ortholog use modifi inparanoid approach inparanoid tc genom duplic embryophyt can caus paralog issu use phylogenet filter confirm true ortholog fig b briefli align put ortholog group use muscl trim align trimal gt w st reconstruct maximum likelihood ml phylogeni use raxml f m protgammawag use hous perl script run paup filter command identifi ml topolog consist well known phylogenet relationship ortholog pass filter consid core ortholog fig b viridiplanta core ortholog use input program hamstr instead identifi set ortholog transcriptom modifi hamstr program extract top hit present singl put ortholog eight transcriptom modif allow us submit top hit directli phylogenet analysi eight hamstr analys preform align made use muscl gather set core ortholog least one match charophyt fig c ortholog collect phylogenet purpos filter good taxon sampl least one charophyt major charophyt lineag chlorokybu klebsormidium nitella coleochaet chaetosphaeridium penium spirogyra fig c lastli gene span diverg taxa one billion year diverg time chang amino acid composit heterogen time issu want minim spirit use tree puzzl identifi ortholog signific amino acid bia assumpt phylogenet analys assum charact composit chang time remov gene signific amino acid bia elimin possibl sourc systemat error last filter step produc set align ortholog gene good taxon sampl amino acid composit bia fig c concaten onto one larg multi gene data matrix detail follow section reconstruct multi gene phylogenyw align amino acid unigen use muscl default paramet concaten use hous perl script trim poorli align region use trimal gt w st estim model evolut ml analysi use protest2 ran phylogenet analys multi gene dataset maximum likelihood ml lg g f model use raxml bayesian infer bi cat poisson model use phylobay bi analysi allow us test effect appli site heterogen model evolut cat multi gene amino acid data matrix measur phylogenet stabil bootstrap perform ml analysi posterior probabl pp infer bi analysi data accessth individu read transcriptom deposit genbank http www ncbi nlm nih gov sanger read locat dbest follow access number chlorokybu atmophyticu genbank ho407395 ho431109 chaetosphaeridium globosum genbank ho348296 ho407394 klebsormidium flaccidum genbank ho431110 ho486407 nitella hyalina genbank ho486408 ho574687 penium margaritaceum genbank ho574688 ho651665 sequenc sequenc read archiv sra c atmophyticu genbank srx025846 c globosum genbank srx025844 k flaccidum genbank srx025847 n hyalina genbank srx025843 p margaritaceum genbank srx025845 cluster sanger read deposit transcriptom shotgun assembl sequenc databas tsa c atmophyticu genbank jo192127 jo204622 c globosum genbank jo157958 jo182157 coleochaet sp genbank jo233843 jo252228 k flaccidum genbank jo252229 jo277141 n hyalina genbank jo277142 jo317756 spirogyra pratensi genbank jo182540 jo192126 p margaritaceum genbank jo204623 jo233842 trim align ml tree bi consensu tree upload treebas access follow url http purl org phylo treebas phylow studi tb2 s10897 support informationfigur s1concaterpillar ml tree deriv compat partit multigen align set number determin concaterpillar list figur descend size tif click addit data file tabl s1tab delimit text file contain annot summari data ortholog use phylogenet analysi txt click addit data file']"
     ]
    }
   ],
   "source": [
    "#documents = [doc for doc in TaggedLineDocument('/volume/processed_docs.txt')]\n",
    "documents = [doc for doc in TaggedLineDocument(bods_sm)]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "model = Doc2Vec(documents, size=200, window=5, min_count=5,workers=15, iter=10)\n",
    "\n",
    "np.save('models/body_features-w2v-200.npy',model.docvecs.doctag_syn0)\n",
    "model.save('models/body_features-w2v-200.doc2vec')"
   ]
  }
 ],
 "metadata": {
  "anaconda-cloud": {},
  "kernel_info": {
   "name": "python3"
  },
  "kernelspec": {
   "display_name": "Python [Root]",
   "language": "python",
   "name": "Python [Root]"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.5.2"
  },
  "notify_time": "30",
  "nteract": {
   "version": "0.6.2"
  },
  "varInspector": {
   "cols": {
    "lenName": 16,
    "lenType": 16,
    "lenVar": 40
   },
   "kernels_config": {
    "python": {
     "delete_cmd_postfix": "",
     "delete_cmd_prefix": "del ",
     "library": "var_list.py",
     "varRefreshCmd": "print(var_dic_list())"
    },
    "r": {
     "delete_cmd_postfix": ") ",
     "delete_cmd_prefix": "rm(",
     "library": "var_list.r",
     "varRefreshCmd": "cat(var_dic_list()) "
    }
   },
   "position": {
    "height": "518px",
    "left": "775px",
    "right": "31px",
    "top": "120px",
    "width": "339px"
   },
   "types_to_exclude": [
    "module",
    "function",
    "builtin_function_or_method",
    "instance",
    "_Feature"
   ],
   "window_display": false
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
